{"matching_results": 21116, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1600, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1274}, {"key": "negative", "matching_results": 325}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "freelancer.com.co", "matching_results": 840, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 776}, {"key": "negative", "matching_results": 61}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "wkrb13.com", "matching_results": 688, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 535}, {"key": "negative", "matching_results": 153}]}]}, {"key": "watchlistnews.com", "matching_results": 650, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 493}, {"key": "negative", "matching_results": 157}]}]}, {"key": "dailypolitical.com", "matching_results": 638, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 519}, {"key": "negative", "matching_results": 119}]}]}, {"key": "tickerreport.com", "matching_results": 622, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 522}, {"key": "negative", "matching_results": 99}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 573, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 445}, {"key": "negative", "matching_results": 128}]}]}, {"key": "thelincolnianonline.com", "matching_results": 568, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 427}, {"key": "negative", "matching_results": 140}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 384, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 282}, {"key": "negative", "matching_results": 102}]}]}, {"key": "openpr.com", "matching_results": 381, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 333}, {"key": "negative", "matching_results": 48}]}]}]}], "results": [{"id": "SvKGsiwsTe03NVzEJtuHXWRWTYeLgcYgWyVx2VfjvLqktOWGax1daj1JPEFYWy-v", "result_metadata": {"score": 36.002182}, "author": "Ankush Nikam", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Carcinoma HCC Treatment Market", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Cancer", "relevance": 0.9072, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}], "categories": [{"score": 0.855163, "label": "/health and fitness/disease/cancer"}, {"score": 0.715997, "label": "/health and fitness/therapy"}, {"score": 0.637131, "label": "/health and fitness/weight loss"}], "relations": [], "keywords": [{"text": "Hepatocellular Carcinoma HCC Treatment Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.99193, "count": 1}, {"text": "Meteoric Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.00807, "count": 1}]}, "crawl_date": "2018-11-18T20:17:46Z", "url": "https://www.findmarketresearch.org/2018/08/hepatocellular-carcinoma-hcc-treatment-market-to-incur-meteoric-growth-during-2016-2026/", "host": "findmarketresearch.org", "text": "Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-08-03T16:34:00+05:00", "enriched_text": {"entities": [{"count": 19, "sentiment": {"score": -0.422037, "label": "negative"}, "text": "Hepatocellular carcinoma", "relevance": 0.896845, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 11, "sentiment": {"score": -0.765735, "label": "negative"}, "text": "HCC", "relevance": 0.278833, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver disease", "relevance": 0.0824919, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}}, {"count": 1, "sentiment": {"score": -0.525162, "label": "negative"}, "text": "biliary cirrhosis", "relevance": 0.0734095, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Primary biliary cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Primary_biliary_cirrhosis"}}, {"count": 1, "sentiment": {"score": -0.223199, "label": "negative"}, "text": "cirrhosis", "relevance": 0.0732094, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 2, "sentiment": {"score": -0.569662, "label": "negative"}, "text": "principal", "relevance": 0.072792, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.209731, "label": "negative"}, "text": "HCV", "relevance": 0.0725618, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseCause", "RiskFactor"], "name": "Virus", "dbpedia_resource": "http://dbpedia.org/resource/Virus"}}, {"count": 2, "sentiment": {"score": -0.305367, "label": "negative"}, "text": "North America", "relevance": 0.0711864, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.0710664, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.20346, "label": "negative"}, "text": "HCV", "relevance": 0.0676277, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.0656916, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.062877, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": -0.46489, "label": "negative"}, "text": "Novartis Pharmaceuticals", "relevance": 0.0615965, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva pharmaceutical Industries Ltd.", "relevance": 0.0608747, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": -0.709974, "label": "negative"}, "text": "U.S.", "relevance": 0.0601681, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.0599734, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.0577306, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": -0.295954, "label": "negative"}, "text": "Middle East", "relevance": 0.0569611, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Pvt", "relevance": 0.0560516, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgen Corporation", "relevance": 0.0555259, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.535509, "label": "negative"}, "text": "metabolic syndrome", "relevance": 0.0546292, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Metabolic syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}}, {"count": 1, "sentiment": {"score": 0.267702, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.0534293, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": -0.833957, "label": "negative"}, "text": "Asia", "relevance": 0.0531824, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.052686, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0.263121, "label": "positive"}, "text": "Western Europe", "relevance": 0.0518763, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": -0.833957, "label": "negative"}, "text": "Africa", "relevance": 0.0501496, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0488203, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.333167, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.046901, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.0465452, "type": "Company"}], "sentiment": {"document": {"score": -0.590933, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Hepatocellular carcinoma (HCC)", "keywords": [{"text": "Hepatocellular carcinoma"}, {"text": "HCC"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": "Hepatocellular carcinoma (HCC) is also known as malignant hepatoma.", "object": {"text": "also known as malignant hepatoma", "keywords": [{"text": "malignant hepatoma"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Hepatocellular carcinoma (HCC)", "keywords": [{"text": "Hepatocellular carcinoma"}, {"text": "HCC"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": "Hepatocellular carcinoma (HCC) is also known as malignant hepatoma.", "object": {"text": "as malignant hepatoma", "keywords": [{"text": "malignant hepatoma"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "is also known", "normalized": "be also know"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "object": {"text": "the major malignancy of the liver", "keywords": [{"text": "major malignancy"}, {"text": "liver"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The cells of origin of HCC", "keywords": [{"text": "HCC"}, {"text": "cells"}, {"text": "origin"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation.", "object": {"text": "the hepatic stem cells", "keywords": [{"text": "hepatic stem cells"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The hepatic tumors", "keywords": [{"text": "hepatic tumors"}]}, "sentence": " The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases.", "object": {"text": "with local expansion", "keywords": [{"text": "local expansion"}]}, "action": {"verb": {"text": "proliferate", "tense": "present"}, "text": "proliferates", "normalized": "proliferate"}}, {"subject": {"text": "The uncommon hepatocellular carcinoma", "keywords": [{"text": "uncommon hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate HCC is currently expected to be the third leading cause of death worldwide.", "object": {"text": "anticipated to witness rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The uncommon hepatocellular carcinoma", "keywords": [{"text": "uncommon hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate HCC is currently expected to be the third leading cause of death worldwide.", "object": {"text": "rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is anticipated to witness", "normalized": "be anticipate to witness"}}, {"subject": {"text": "incidence rate HCC", "keywords": [{"text": "incidence rate"}, {"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate HCC is currently expected to be the third leading cause of death worldwide.", "action": {"verb": {"text": "expect", "tense": "past"}, "text": "expected", "normalized": "expect"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In the past, HCC generally occurred at an advanced stage of decompensated liver disease or cirrhosis.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "HCC", "keywords": [{"text": "HCC"}], "entities": [{"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In the past, HCC generally occurred at an advanced stage of decompensated liver disease or cirrhosis.", "object": {"text": "liver disease or cirrhosis", "keywords": [{"text": "liver disease"}, {"text": "cirrhosis"}], "entities": [{"type": "HealthCondition", "text": "liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Disease"], "name": "Liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}}]}, "action": {"verb": {"text": "decompensated", "tense": "past"}, "text": "decompensated", "normalized": "decompensated"}}, {"subject": {"text": "The technological advancements and the routine liver function tests", "keywords": [{"text": "routine liver function"}, {"text": "technological advancements"}]}, "sentence": " The technological advancements and the routine liver function tests are now resulting in the early detection of hepatocellular carcinoma.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "incidences of hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "incidences"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The increase in incidences of hepatocellular carcinoma associated with hepatitis C virus are expected to grow the hepatocellular carcinoma treatment market The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015.", "object": {"text": "with hepatitis C virus", "keywords": [{"text": "hepatitis C virus"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "hepatitis C virus", "keywords": [{"text": "hepatitis C virus"}]}, "sentence": " The increase in incidences of hepatocellular carcinoma associated with hepatitis C virus are expected to grow the hepatocellular carcinoma treatment market The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015.", "object": {"text": "the hepatocellular carcinoma treatment market The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015", "keywords": [{"text": "intrahepatic bile duct"}, {"text": "hepatocellular carcinoma treatment"}, {"text": "incidence rate"}, {"text": "hepatic cancer"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "are expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "The risk factors", "keywords": [{"text": "risk factors"}]}, "sentence": " The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury.", "object": {"text": "with hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The risk factors associated with hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "risk factors"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury.", "object": {"text": "Hepatitis B virus", "keywords": [{"text": "Hepatitis B virus"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "cost effective treatment procedures", "keywords": [{"text": "cost effective treatment"}, {"text": "procedures"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "to keep up the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "predict", "tense": "past"}, "text": "predicted", "normalized": "predict"}}, {"subject": {"text": "few other factors", "keywords": [{"text": "factors"}]}, "sentence": " The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "up the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "keep", "tense": "future"}, "text": "predicted to keep", "normalized": "predict to keep"}}, {"subject": {"text": "side effects", "keywords": [{"text": "effects"}]}, "sentence": " However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "with the chemotherapy", "keywords": [{"text": "chemotherapy"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "high cost of treatment", "keywords": [{"text": "high cost"}, {"text": "treatment"}]}, "sentence": " However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.", "object": {"text": "some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "major restraints"}, {"text": "treatment market"}, {"text": "growth"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the global hepatocellular carcinoma (HCC) treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Based on application, the global hepatocellular carcinoma (HCC) treatment market is segmented into: Brachytherapy, Chemotherapy, Local Ablation Therapy; Based on end user type, the global hepatocellular carcinoma (HCC) treatment market is segmented into: Hospitals, Clinics, Cancer rehabilitation centers", "object": {"text": "segmented into: Hospitals, Clinics, Cancer rehabilitation centers", "keywords": [{"text": "Cancer rehabilitation centers"}, {"text": "Hospitals"}, {"text": "Clinics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Inventions in technologies for cancer treatment procedures", "keywords": [{"text": "cancer treatment procedures"}, {"text": "Inventions"}]}, "sentence": " Inventions in technologies for cancer treatment procedures are expected to launch into the market in the forecast period.", "object": {"text": "into the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "launch", "tense": "future"}, "text": "are expected to launch", "normalized": "be expect to launch"}}, {"subject": {"text": "Monoclonal antibodies and other immunological treatments", "keywords": [{"text": "Monoclonal antibodies"}, {"text": "immunological treatments"}]}, "sentence": " Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy.", "object": {"text": "generally known"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Monoclonal antibodies and other immunological treatments", "keywords": [{"text": "Monoclonal antibodies"}, {"text": "immunological treatments"}]}, "sentence": " Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy.", "object": {"text": "for their lesser side effects and better efficacy", "keywords": [{"text": "better efficacy"}, {"text": "lesser side effects"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are generally known", "normalized": "be generally know"}}, {"subject": {"text": "the global Hepatocellular Carcinoma (HCC) treatment market", "keywords": [{"text": "global Hepatocellular Carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "classified into regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global Hepatocellular Carcinoma (HCC) treatment market", "keywords": [{"text": "global Hepatocellular Carcinoma"}, {"text": "HCC"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "Africa.Hepatitis B virus"}, {"text": "Middle East"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "Africa.Hepatitis B virus"}, {"text": "Middle East"}, {"text": "HBV"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "action": {"verb": {"text": "find", "tense": "past"}, "text": "are found to be", "normalized": "be find to be"}}, {"subject": {"text": "HBV) infection and hepatitis C virus (HCV) infections", "keywords": [{"text": "hepatitis C virus"}, {"text": "HBV"}, {"text": "HCV"}, {"text": "infection"}], "entities": [{"type": "HealthCondition", "text": "HCV", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "DiseaseCause"], "name": "Hepatitis C virus", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}}]}, "sentence": " Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "object": {"text": "the most significant cause of hepatocellular carcinoma", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "significant cause"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are found to be", "normalized": "be find to be"}}, {"subject": {"text": "Chronic HBV infection", "keywords": [{"text": "Chronic HBV infection"}]}, "sentence": " Chronic HBV infection is the principal cause of hepatocellular carcinoma in Asia and Africa.", "object": {"text": "the principal cause of hepatocellular carcinoma in Asia and Africa", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "principal cause"}, {"text": "Asia"}, {"text": "Africa"}], "entities": [{"type": "JobTitle", "text": "principal"}, {"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "HCV infection", "keywords": [{"text": "HCV infection"}]}, "sentence": " HCV infection is the principal cause of hepatocellular carcinoma in North America, Europe, and Japan.", "object": {"text": "the principal cause of hepatocellular carcinoma in North America, Europe, and Japan", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "principal cause"}, {"text": "North America"}, {"text": "Europe"}], "entities": [{"type": "JobTitle", "text": "principal"}, {"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global hepatocellular carcinoma treatment market", "keywords": [{"text": "global hepatocellular carcinoma"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " The global hepatocellular carcinoma treatment market is expected to grow in future due to increasing investment by multinational companies in the cancer research.", "object": {"text": "in future"}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "Bayer AG", "keywords": [{"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}]}, "sentence": " Bayer AG is one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs.", "object": {"text": "one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "treatment drugs"}, {"text": "HCC"}, {"text": "provider"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"type": "Location", "text": "HCC", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Some of the key players in hepatocellular carcinoma treatment market", "keywords": [{"text": "hepatocellular carcinoma treatment"}, {"text": "key players"}], "entities": [{"type": "HealthCondition", "text": "Hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt.", "object": {"text": "Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Novartis Pharmaceuticals"}, {"text": "Johnson Pvt"}, {"text": "Merck"}], "entities": [{"type": "Company", "text": "Novartis Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Johnson & Johnson Pvt"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the antiviral and oncology", "keywords": [{"text": "oncology"}]}, "sentence": " These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "object": {"text": "unmet medical needs", "keywords": [{"text": "unmet medical needs"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.943349, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Liver", "relevance": 0.875709, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Hepatitis C", "relevance": 0.872975, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Cancer", "relevance": 0.842927, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Hepatitis B", "relevance": 0.824218, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Hepatology", "relevance": 0.789122, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Hepatitis", "relevance": 0.668059, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Hepatocellular carcinoma", "relevance": 0.594417, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Bilirubin", "relevance": 0.543504, "dbpedia_resource": "http://dbpedia.org/resource/Bilirubin"}, {"text": "Oncology", "relevance": 0.446387, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Liver disease", "relevance": 0.419256, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Liver function tests", "relevance": 0.402136, "dbpedia_resource": "http://dbpedia.org/resource/Liver_function_tests"}, {"text": "Primary sclerosing cholangitis", "relevance": 0.38254, "dbpedia_resource": "http://dbpedia.org/resource/Primary_sclerosing_cholangitis"}, {"text": "Liver biopsy", "relevance": 0.373877, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Bile duct", "relevance": 0.36545, "dbpedia_resource": "http://dbpedia.org/resource/Bile_duct"}, {"text": "Hepatitis B virus", "relevance": 0.36501, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B_virus"}, {"text": "Bristol-Myers Squibb", "relevance": 0.362959, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Liver transplantation", "relevance": 0.341714, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Hepatitis A", "relevance": 0.335761, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_A"}, {"text": "Interferon", "relevance": 0.330532, "dbpedia_resource": "http://dbpedia.org/resource/Interferon"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.328791, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Chemotherapy", "relevance": 0.325913, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Gastroenterology", "relevance": 0.313231, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Immune system", "relevance": 0.304681, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Alanine transaminase", "relevance": 0.290774, "dbpedia_resource": "http://dbpedia.org/resource/Alanine_transaminase"}, {"text": "Cholangiocarcinoma", "relevance": 0.289338, "dbpedia_resource": "http://dbpedia.org/resource/Cholangiocarcinoma"}, {"text": "Bile", "relevance": 0.282695, "dbpedia_resource": "http://dbpedia.org/resource/Bile"}, {"text": "Jade Ribbon Campaign", "relevance": 0.257922, "dbpedia_resource": "http://dbpedia.org/resource/Jade_Ribbon_Campaign"}, {"text": "Hepatitis C virus", "relevance": 0.256839, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C_virus"}, {"text": "Paclitaxel", "relevance": 0.250443, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Hepatic encephalopathy", "relevance": 0.245856, "dbpedia_resource": "http://dbpedia.org/resource/Hepatic_encephalopathy"}, {"text": "Alcoholic liver disease", "relevance": 0.245134, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholic_liver_disease"}, {"text": "Hepatic portal vein", "relevance": 0.236934, "dbpedia_resource": "http://dbpedia.org/resource/Hepatic_portal_vein"}, {"text": "Alcoholism", "relevance": 0.234947, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholism"}, {"text": "North America", "relevance": 0.234855, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Jaundice", "relevance": 0.233927, "dbpedia_resource": "http://dbpedia.org/resource/Jaundice"}, {"text": "Cholestasis", "relevance": 0.233513, "dbpedia_resource": "http://dbpedia.org/resource/Cholestasis"}, {"text": "Generic drug", "relevance": 0.232405, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Blood transfusion", "relevance": 0.230456, "dbpedia_resource": "http://dbpedia.org/resource/Blood_transfusion"}, {"text": "Primary biliary cirrhosis", "relevance": 0.228548, "dbpedia_resource": "http://dbpedia.org/resource/Primary_biliary_cirrhosis"}, {"text": "Clopidogrel", "relevance": 0.225152, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Wilson's disease", "relevance": 0.215544, "dbpedia_resource": "http://dbpedia.org/resource/Wilson's_disease"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.214842, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Breast cancer", "relevance": 0.214656, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Epidemiology", "relevance": 0.21444, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Gastrointestinal cancer", "relevance": 0.209597, "dbpedia_resource": "http://dbpedia.org/resource/Gastrointestinal_cancer"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.205979, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Carcinoma", "relevance": 0.204477, "dbpedia_resource": "http://dbpedia.org/resource/Carcinoma"}, {"text": "Liver cancer", "relevance": 0.20369, "dbpedia_resource": "http://dbpedia.org/resource/Liver_cancer"}, {"text": "Gallbladder", "relevance": 0.202957, "dbpedia_resource": "http://dbpedia.org/resource/Gallbladder"}], "categories": [{"score": 0.951224, "label": "/health and fitness/disease"}, {"score": 0.901412, "label": "/health and fitness/disease/cancer"}, {"score": 0.877999, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "score": 0.891192, "arguments": [{"text": "patients", "location": [141, 149], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic liver diseases", "location": [155, 177], "entities": [{"type": "HealthCondition", "text": "chronic liver diseases"}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.431826, "arguments": [{"text": "companies", "location": [3695, 3704], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Pfizer Inc.", "location": [3641, 3652], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.790481, "arguments": [{"text": "companies", "location": [3695, 3704], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda Pharmaceutical Co. Ltd.", "location": [3658, 3688], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis.", "score": 0.872374, "arguments": [{"text": "patients", "location": [141, 149], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cirrhosis", "location": [182, 191], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "agentOf", "sentence": "The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation.", "score": 0.465097, "arguments": [{"text": "HCC", "location": [216, 219], "entities": [{"type": "Organization", "text": "HCC"}]}, {"text": "investigation", "location": [285, 298], "entities": [{"type": "EventLegal", "text": "investigation"}]}]}, {"type": "populationOf", "sentence": "The increase in incidences of hepatocellular carcinoma associated with hepatitis C virus are expected to grow the hepatocellular carcinoma treatment market The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015.", "score": 0.352493, "arguments": [{"text": "39,230", "location": [1079, 1085], "entities": [{"type": "Cardinal", "text": "39,230"}]}, {"text": "U.S.", "location": [1056, 1060], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa.Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.", "score": 0.670053, "arguments": [{"text": "APEJ", "location": [2752, 2756], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}, {"text": "Japan", "location": [2758, 2763], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.811736, "arguments": [{"text": "Some", "location": [3382, 3386], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [3398, 3405], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.423466, "arguments": [{"text": "companies", "location": [3695, 3704], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Celgen Corporation", "location": [3572, 3590], "entities": [{"type": "Organization", "text": "Celgen Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.505414, "arguments": [{"text": "companies", "location": [3695, 3704], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Amgen Inc.", "location": [3592, 3602], "entities": [{"type": "Organization", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.", "score": 0.482026, "arguments": [{"text": "companies", "location": [3695, 3704], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Teva pharmaceutical Industries Ltd.", "location": [3604, 3639], "entities": [{"type": "Organization", "text": "Teva pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Hepatocellular carcinoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.827996, "count": 1}, {"text": "hepatocellular carcinoma treatment market", "sentiment": {"score": -0.789253, "label": "negative"}, "relevance": 0.749932, "count": 2}, {"text": "hepatitis C virus", "sentiment": {"score": -0.860088, "label": "negative"}, "relevance": 0.659899, "count": 3}, {"text": "uncommon hepatocellular carcinoma", "sentiment": {"score": -0.84626, "label": "negative"}, "relevance": 0.646644, "count": 1}, {"text": "technological advancements", "sentiment": {"score": 0.749622, "label": "positive"}, "relevance": 0.631904, "count": 1}, {"text": "effective treatment procedures", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.597317, "count": 1}, {"text": "Hepatitis B virus", "sentiment": {"score": -0.892406, "label": "negative"}, "relevance": 0.588935, "count": 2}, {"text": "early detection of hepatocellular carcinoma", "sentiment": {"score": -0.266423, "mixed": "1", "label": "negative"}, "relevance": 0.584593, "count": 1}, {"text": "increasing investment of pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57864, "count": 1}, {"text": "Monoclonal antibodies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567457, "count": 1}, {"text": "cells of origin of HCC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565311, "count": 1}, {"text": "hepatocellular carcinoma", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.565107, "count": 1}, {"text": "hepatic stem cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562147, "count": 1}, {"text": "risk factors", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.561829, "count": 1}, {"text": "North America", "sentiment": {"score": -0.672214, "label": "negative"}, "relevance": 0.560543, "count": 2}, {"text": "incidences of hepatocellular carcinoma", "sentiment": {"score": -0.789253, "label": "negative"}, "relevance": 0.556067, "count": 1}, {"text": "infection", "sentiment": {"score": -0.893432, "label": "negative"}, "relevance": 0.55593, "count": 3}, {"text": "Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554848, "count": 1}, {"text": "Western Europe", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.553137, "count": 1}, {"text": "multinational companies", "sentiment": {"score": -0.342438, "label": "negative"}, "relevance": 0.55121, "count": 1}, {"text": "incidence rate HCC", "sentiment": {"score": -0.84626, "label": "negative"}, "relevance": 0.548457, "count": 1}, {"text": "HCC", "sentiment": {"score": -0.772834, "label": "negative"}, "relevance": 0.544732, "count": 8}, {"text": "advancement", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.543971, "count": 1}, {"text": "Middle East", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.536496, "count": 1}, {"text": "priority areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536012, "count": 1}, {"text": "Latin America", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.53554, "count": 1}, {"text": "Eastern Europe", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.534347, "count": 1}, {"text": "Chemotherapy", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.534041, "count": 1}, {"text": "chemotherapy", "sentiment": {"score": -0.824227, "label": "negative"}, "relevance": 0.534041, "count": 1}, {"text": "HBV", "sentiment": {"score": -0.892406, "label": "negative"}, "relevance": 0.532021, "count": 2}, {"text": "high cost of treatment", "sentiment": {"score": -0.824227, "label": "negative"}, "relevance": 0.531841, "count": 1}, {"text": "technologies", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.530393, "count": 1}, {"text": "technology", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.530393, "count": 1}, {"text": "major malignancy of the liver", "sentiment": {"score": -0.806673, "label": "negative"}, "relevance": 0.530151, "count": 1}, {"text": "metabolic syndrome", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.529482, "count": 1}, {"text": "cost", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.529145, "count": 1}, {"text": "HCV", "sentiment": {"score": -0.892406, "label": "negative"}, "relevance": 0.529007, "count": 2}, {"text": "infections", "sentiment": {"score": -0.889303, "label": "negative"}, "relevance": 0.528053, "count": 1}, {"text": "factors", "sentiment": {"score": 0.943036, "label": "positive"}, "relevance": 0.526415, "count": 1}, {"text": "pharmaceutical Industries Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52538, "count": 1}, {"text": "investment", "sentiment": {"score": -0.342438, "label": "negative"}, "relevance": 0.524464, "count": 1}, {"text": "advanced stage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524274, "count": 1}, {"text": "market", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.523745, "count": 1}, {"text": "Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521958, "count": 1}, {"text": "Teva", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52137, "count": 1}, {"text": "biliary cirrhosis", "sentiment": {"score": -0.895473, "label": "negative"}, "relevance": 0.519436, "count": 1}, {"text": "Brachytherapy", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.519249, "count": 1}, {"text": "Celgen Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519034, "count": 1}, {"text": "application", "sentiment": {"score": -0.674131, "label": "negative"}, "relevance": 0.518692, "count": 1}, {"text": "liver disease", "sentiment": {"score": 0.749622, "label": "positive"}, "relevance": 0.518254, "count": 1}]}, "extracted_metadata": {"sha1": "8dbdfd1e6e08673bad26430626fdc7b19c356958", "filename": "1542572266373.zip-b036ef03970df81e7b2d524b0f9cf793.xml", "file_type": "json"}, "external_links": ["http://www.futuremarketinsights.com/reports/hepatocellular-carcinoma-hcc-treatment-market", "http://www.futuremarketinsights.com/reports/sample/rep-gb-1370"], "title": "Hepatocellular Carcinoma HCC Treatment Market to Incur Meteoric Growth During 2016-2026", "forum_title": "Research Insights | Find Market Research - Part 27"}, {"id": "8N5kV7mgQepPBmJk2oaiNEkKYIIMhcOcgQy-AqQc6h502sWDqRNLK-ME6zOOTrtQ", "result_metadata": {"score": 35.103363}, "author": "Bloomberg News", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Debt", "relevance": 0.860354, "dbpedia_resource": "http://dbpedia.org/resource/Debt"}], "categories": [{"score": 0.812725, "label": "/finance/investing/day trading"}, {"score": 0.792205, "label": "/finance/financial news"}, {"score": 0.786041, "label": "/real estate/buying and selling homes"}], "relations": [], "keywords": [{"text": "European Credit Markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.975144, "count": 1}, {"text": "Week", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.815614, "count": 1}]}, "crawl_date": "2018-11-19T11:13:29Z", "url": "https://www.bnn.ca/what-to-watch-in-european-credit-markets-this-week-1.1170213", "host": "bnn.ca", "text": "The other obvious prospect for this week is a sustainability bond from Co-Operative Group Ltd.", "main_image_url": "https://www.bnnbloomberg.ca/polopoly_fs/1.1170214!/fileimage/httpImage/image.png_gen/derivatives/landscape_620/bc-what-to-watch-in-european-credit-markets-this-week.png", "country": "CA", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T00:00:00-06:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.442703, "label": "negative"}, "text": "Italy", "relevance": 0.727835, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Deputy Prime Minister Luigi Di Maio", "relevance": 0.572775, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.910805, "label": "negative"}, "text": "U.S.", "relevance": 0.556024, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.636311, "label": "negative"}, "text": "Brexit turbulence", "relevance": 0.545565, "type": "GeographicFeature"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Stryker Corp", "relevance": 0.53095, "type": "Company", "disambiguation": {"subtype": [], "name": "Stryker Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Stryker_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bloomberg", "relevance": 0.527573, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.700035, "label": "positive"}, "text": "Co-Operative Group Ltd", "relevance": 0.487622, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.481041, "label": "positive"}, "text": "Europe", "relevance": 0.469317, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": -0.426915, "label": "negative"}, "text": "PizzaExpress Ltd", "relevance": 0.46846, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.396077, "label": "negative"}, "text": "U.K.", "relevance": 0.466979, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": -0.308529, "label": "negative"}, "text": "Theresa", "relevance": 0.466845, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hannah Benjamin", "relevance": 0.463375, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Commission", "relevance": 0.461824, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tom Freke", "relevance": 0.461529, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Emma Haslett", "relevance": 0.457814, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Yankees", "relevance": 0.457261, "type": "Organization", "disambiguation": {"subtype": ["SportsTeam", "ProfessionalSportsTeam"], "name": "New York Yankees", "dbpedia_resource": "http://dbpedia.org/resource/New_York_Yankees"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "reporter", "relevance": 0.446598, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.423574, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Volkswagen International Finance NV", "relevance": 0.408992, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.396202, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hbenjamin1@bloomberg.net", "relevance": 0.396202, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ehaslett@bloomberg.net", "relevance": 0.396202, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$22.9 billion", "relevance": 0.396202, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.4 percent", "relevance": 0.396202, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five weeks", "relevance": 0.396202, "type": "Quantity"}], "sentiment": {"document": {"score": -0.781107, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "what we will be watching this week"}, "sentence": " Here\u2019s what we will be watching this week:", "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "we"}, "sentence": " Here\u2019s what we will be watching this week:", "action": {"verb": {"text": "watch", "tense": "future"}, "text": "will be watching", "normalized": "will be watch"}}, {"subject": {"text": "The drama", "keywords": [{"text": "drama"}]}, "sentence": " The drama playing out at Westminster will likely shape market tone this week.", "action": {"verb": {"text": "play", "tense": "present"}, "text": "playing", "normalized": "play"}}, {"subject": {"text": "The drama playing out at Westminster", "keywords": [{"text": "Westminster"}, {"text": "drama"}]}, "sentence": " The drama playing out at Westminster will likely shape market tone this week.", "object": {"text": "market tone", "keywords": [{"text": "market tone"}]}, "action": {"verb": {"text": "shape", "tense": "future"}, "text": "will likely shape", "normalized": "will likely shape"}}, {"subject": {"text": "Theresa", "entities": [{"type": "Person", "text": "Theresa"}]}, "sentence": " Today, Theresa May is due to defend her Brexit deal in front of business.", "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Theresa", "entities": [{"type": "Person", "text": "Theresa"}]}, "sentence": " Today, Theresa May is due to defend her Brexit deal in front of business.", "object": {"text": "her Brexit deal", "keywords": [{"text": "Brexit deal"}], "entities": []}, "action": {"verb": {"text": "defend", "tense": "future"}, "text": "to defend", "normalized": "to defend"}}, {"subject": {"text": "More cabinet resignations", "keywords": [{"text": "cabinet resignations"}]}, "sentence": " More cabinet resignations could signal further weakness, and there remains the possibility of a no confidence vote.", "object": {"text": "further weakness", "keywords": [{"text": "weakness"}]}, "action": {"verb": {"text": "signal", "tense": "future"}, "text": "could signal", "normalized": "could signal"}}, {"subject": {"text": "U.K. banks", "keywords": [{"text": "U.K. banks"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}]}, "sentence": " U.K. banks in particular took a hit last week as rumors swirled.", "object": {"text": "a hit", "keywords": [{"text": "hit"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "Such uncertainty", "keywords": [{"text": "uncertainty"}]}, "sentence": " Such uncertainty is likely to weigh against risk taking in the markets, and constrain the flow of bond sales.", "object": {"text": "likely to weigh against risk taking in the markets", "keywords": [{"text": "risk taking"}, {"text": "markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Christmas", "keywords": [{"text": "Christmas"}], "entities": []}, "sentence": " Christmas is coming", "object": {"text": "coming"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Euro credit", "keywords": [{"text": "Euro credit"}]}, "sentence": " Euro credit has generally shrugged off Brexit turbulence so far, but with five weeks to go before the festive period and Thanksgiving due to curb issuance this week, some borrowers may choose to pull up the shutters for the rest of the year.", "object": {"text": "off Brexit turbulence", "keywords": [{"text": "Brexit turbulence"}], "entities": [{"type": "GeographicFeature", "text": "Brexit turbulence"}]}, "action": {"verb": {"text": "shrug", "tense": "past"}, "text": "has generally shrugged", "normalized": "have generally shrug"}}, {"subject": {"text": "issuance", "keywords": [{"text": "issuance"}]}, "sentence": " Euro credit has generally shrugged off Brexit turbulence so far, but with five weeks to go before the festive period and Thanksgiving due to curb issuance this week, some borrowers may choose to pull up the shutters for the rest of the year.", "action": {"verb": {"text": "curb", "tense": "future"}, "text": "to curb", "normalized": "to curb"}}, {"subject": {"text": "some borrowers", "keywords": [{"text": "borrowers"}]}, "sentence": " Euro credit has generally shrugged off Brexit turbulence so far, but with five weeks to go before the festive period and Thanksgiving due to curb issuance this week, some borrowers may choose to pull up the shutters for the rest of the year.", "object": {"text": "to pull up the shutters", "keywords": [{"text": "shutters"}]}, "action": {"verb": {"text": "choose", "tense": "future"}, "text": "choose", "normalized": "choose"}}, {"subject": {"text": "some borrowers", "keywords": [{"text": "borrowers"}]}, "sentence": " Euro credit has generally shrugged off Brexit turbulence so far, but with five weeks to go before the festive period and Thanksgiving due to curb issuance this week, some borrowers may choose to pull up the shutters for the rest of the year.", "object": {"text": "the shutters", "keywords": [{"text": "shutters"}]}, "action": {"verb": {"text": "pull", "tense": "future"}, "text": "may choose to pull", "normalized": "may choose to pull"}}, {"subject": {"text": "closely-watched purchasing managers\u2019 indexes on Friday", "keywords": [{"text": "closely-watched purchasing managers"}, {"text": "indexes"}, {"text": "Friday"}]}, "sentence": " Economic data this week, which includes closely-watched purchasing managers\u2019 indexes on Friday, will be monitored closely.", "object": {"text": "Economic data this week", "keywords": [{"text": "Economic data"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Respondents to our weekly issuance survey", "keywords": [{"text": "weekly issuance survey"}, {"text": "Respondents"}]}, "sentence": " Respondents to our weekly issuance survey suggest volumes are unlikely to exceed 20 billion euros ($22.9 billion).", "object": {"text": "volumes are unlikely to exceed 20 billion euros ($22.9 billion)", "keywords": [{"text": "euros"}, {"text": "volumes"}], "entities": [{"type": "Quantity", "text": "$22.9 billion"}]}, "action": {"verb": {"text": "suggest", "tense": "present"}, "text": "suggest", "normalized": "suggest"}}, {"subject": {"text": "volumes", "keywords": [{"text": "volumes"}]}, "sentence": " Respondents to our weekly issuance survey suggest volumes are unlikely to exceed 20 billion euros ($22.9 billion).", "object": {"text": "20 billion euros ($22.9 billion)", "keywords": [{"text": "euros"}], "entities": [{"type": "Quantity", "text": "$22.9 billion"}]}, "action": {"verb": {"text": "exceed", "tense": "future"}, "text": "to exceed", "normalized": "to exceed"}}, {"subject": {"text": "jumbo"}, "sentence": " ... but jumbo is still where it\u2019s at", "object": {"text": "still where it\u2019s at"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "U.S. surgical equipment maker Stryker Corp", "keywords": [{"text": "equipment maker Stryker"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Stryker Corp", "disambiguation": {"subtype": ["Company"], "name": "Stryker Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Stryker_Corporation"}}]}, "sentence": " U.S. surgical equipment maker Stryker Corp may be in the market with a significant-sized bond sale this week, just days after Takeda Pharmaceutical Co Ltd and Volkswagen International Finance NV became two of the year\u2019s biggest issuers, though at a price.", "object": {"text": "in the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "may be", "normalized": "may be"}}, {"subject": {"text": "Takeda Pharmaceutical Co Ltd and Volkswagen International Finance NV", "keywords": [{"text": "Volkswagen International Finance"}, {"text": "Takeda Pharmaceutical"}, {"text": "NV"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "Company", "text": "Volkswagen International Finance NV"}]}, "sentence": " U.S. surgical equipment maker Stryker Corp may be in the market with a significant-sized bond sale this week, just days after Takeda Pharmaceutical Co Ltd and Volkswagen International Finance NV became two of the year\u2019s biggest issuers, though at a price.", "object": {"text": "two of the year\u2019s biggest issuers", "keywords": [{"text": "biggest issuers"}]}, "action": {"verb": {"text": "become", "tense": "past"}, "text": "became", "normalized": "become"}}, {"subject": {"text": "it"}, "sentence": " If the deal goes ahead it will follow a spate of euro-denominated sales by U.S.-based borrowers: October was the first month since July in which so-called \u2018reverse Yankees\u2019 racked up more than 5 billion euros of borrowing.", "object": {"text": "a spate of euro-denominated sales", "keywords": [{"text": "spate"}, {"text": "euro-denominated sales"}]}, "action": {"verb": {"text": "follow", "tense": "future"}, "text": "will follow", "normalized": "will follow"}}, {"subject": {"text": "so-called \u2018reverse Yankees\u2019", "keywords": [{"text": "so-called \u2018reverse Yankees"}], "entities": [{"type": "Organization", "text": "Yankees", "disambiguation": {"subtype": ["SportsTeam", "ProfessionalSportsTeam"], "name": "New York Yankees", "dbpedia_resource": "http://dbpedia.org/resource/New_York_Yankees"}}]}, "sentence": " If the deal goes ahead it will follow a spate of euro-denominated sales by U.S.-based borrowers: October was the first month since July in which so-called \u2018reverse Yankees\u2019 racked up more than 5 billion euros of borrowing.", "object": {"text": "more than 5 billion euros of borrowing", "keywords": [{"text": "euros"}]}, "action": {"verb": {"text": "rack", "tense": "past"}, "text": "racked", "normalized": "rack"}}, {"subject": {"text": "Europe\u2019s high-yield issuers", "keywords": [{"text": "high-yield issuers"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Earnings season for Europe\u2019s high-yield issuers helped generate some negative surprises, leading to a string of sudden drops in bond prices.", "object": {"text": "generate some negative surprises", "keywords": [{"text": "negative surprises"}]}, "action": {"verb": {"text": "help", "tense": "past"}, "text": "helped", "normalized": "help"}}, {"subject": {"text": "Earnings season for Europe\u2019s high-yield issuers", "keywords": [{"text": "high-yield issuers"}, {"text": "Earnings season"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Earnings season for Europe\u2019s high-yield issuers helped generate some negative surprises, leading to a string of sudden drops in bond prices.", "object": {"text": "some negative surprises", "keywords": [{"text": "negative surprises"}]}, "action": {"verb": {"text": "generate", "tense": "present"}, "text": "helped generate", "normalized": "help generate"}}, {"subject": {"text": "A sense of fragility and nervousness across the European and U.S. credit markets", "keywords": [{"text": "U.S. credit markets"}, {"text": "nervousness"}, {"text": "fragility"}, {"text": "sense"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " A sense of fragility and nervousness across the European and U.S. credit markets seems to be triggering these crashes.", "object": {"text": "triggering these crashes", "keywords": [{"text": "crashes"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "A sense of fragility and nervousness across the European and U.S. credit markets", "keywords": [{"text": "U.S. credit markets"}, {"text": "nervousness"}, {"text": "fragility"}, {"text": "sense"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " A sense of fragility and nervousness across the European and U.S. credit markets seems to be triggering these crashes.", "object": {"text": "these crashes", "keywords": [{"text": "crashes"}]}, "action": {"verb": {"text": "trigger", "tense": "present"}, "text": "seems to be triggering", "normalized": "seem to be trigger"}}, {"subject": {"text": "Investors", "keywords": [{"text": "Investors"}]}, "sentence": " Investors are selling out of names fast if they suspect worse is to come.", "object": {"text": "selling out of names fast", "keywords": [{"text": "names"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "they"}, "sentence": " Investors are selling out of names fast if they suspect worse is to come.", "object": {"text": "worse is to come"}, "action": {"verb": {"text": "suspect", "tense": "present"}, "text": "suspect", "normalized": "suspect"}}, {"subject": {"text": "Vallourec SA bond prices", "keywords": [{"text": "Vallourec SA bond"}]}, "sentence": " Vallourec SA bond prices dropped on Friday, and today it seems PizzaExpress Ltd bonds are in focus.", "action": {"verb": {"text": "drop", "tense": "past"}, "text": "dropped", "normalized": "drop"}}, {"subject": {"text": "Italy", "entities": [{"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Italy isn\u2019t going away", "object": {"text": "n\u2019t going away"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " The European Commission is due to issue its opinions on member states\u2019 draft budgets on Wednesday.", "object": {"text": "its opinions", "keywords": [{"text": "opinions"}]}, "action": {"verb": {"text": "issue", "tense": "future"}, "text": "to issue", "normalized": "to issue"}}, {"subject": {"text": "Italy", "entities": [{"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Yesterday Italy\u2019s Deputy Prime Minister Luigi Di Maio insisted the country will maintain the \"big reforms\" of the plan it has drawn up, which aims for a 2019 budget deficit of 2.4 percent.", "object": {"text": "Deputy Prime Minister", "keywords": [{"text": "Deputy Prime Minister"}], "entities": [{"type": "Person", "text": "Deputy Prime Minister Luigi Di Maio"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Italy\u2019s Deputy Prime Minister Luigi Di Maio", "keywords": [{"text": "Luigi Di Maio"}, {"text": "Deputy Prime Minister"}], "entities": [{"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}, {"type": "Person", "text": "Deputy Prime Minister Luigi Di Maio"}]}, "sentence": " Yesterday Italy\u2019s Deputy Prime Minister Luigi Di Maio insisted the country will maintain the \"big reforms\" of the plan it has drawn up, which aims for a 2019 budget deficit of 2.4 percent.", "object": {"text": "the country will maintain the \"big reforms\" of the plan it has drawn up, which aims for a 2019 budget deficit of 2.4 percent", "keywords": [{"text": "budget deficit"}, {"text": "big reforms"}, {"text": "percent"}, {"text": "country"}], "entities": [{"type": "Quantity", "text": "2.4 percent"}]}, "action": {"verb": {"text": "insist", "tense": "past"}, "text": "insisted", "normalized": "insist"}}, {"subject": {"text": "it"}, "sentence": " Yesterday Italy\u2019s Deputy Prime Minister Luigi Di Maio insisted the country will maintain the \"big reforms\" of the plan it has drawn up, which aims for a 2019 budget deficit of 2.4 percent.", "object": {"text": "the plan", "keywords": [{"text": "plan"}]}, "action": {"verb": {"text": "draw", "tense": "past"}, "text": "has drawn", "normalized": "have draw"}}, {"subject": {"text": "Any bickering between the two sides", "keywords": [{"text": "bickering"}, {"text": "sides"}]}, "sentence": " Any bickering between the two sides may continue to hurt borrowers: wrangles over Italy\u2019s budget have previously hit European financial names where it hurts, while a note from S&P Global Ratings indicated Italy\u2019s largest construction companies face high credit risks.", "object": {"text": "borrowers", "keywords": [{"text": "borrowers"}]}, "action": {"verb": {"text": "hurt", "tense": "future"}, "text": "may continue to hurt", "normalized": "may continue to hurt"}}, {"subject": {"text": "wrangles over Italy\u2019s budget", "keywords": [{"text": "Italy\u2019s budget"}], "entities": [{"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Any bickering between the two sides may continue to hurt borrowers: wrangles over Italy\u2019s budget have previously hit European financial names where it hurts, while a note from S&P Global Ratings indicated Italy\u2019s largest construction companies face high credit risks.", "object": {"text": "previously hit European financial names where it hurts", "keywords": [{"text": "European financial names"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "wrangles over Italy\u2019s budget", "keywords": [{"text": "Italy\u2019s budget"}], "entities": [{"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Any bickering between the two sides may continue to hurt borrowers: wrangles over Italy\u2019s budget have previously hit European financial names where it hurts, while a note from S&P Global Ratings indicated Italy\u2019s largest construction companies face high credit risks.", "object": {"text": "European financial names where it hurts", "keywords": [{"text": "European financial names"}]}, "action": {"verb": {"text": "hit", "tense": "past"}, "text": "hit", "normalized": "hit"}}, {"subject": {"text": "a note from S&P Global Ratings", "keywords": [{"text": "S&P Global Ratings"}, {"text": "note"}]}, "sentence": " Any bickering between the two sides may continue to hurt borrowers: wrangles over Italy\u2019s budget have previously hit European financial names where it hurts, while a note from S&P Global Ratings indicated Italy\u2019s largest construction companies face high credit risks.", "object": {"text": "Italy\u2019s largest construction companies face high credit risks", "keywords": [{"text": "high credit risks"}, {"text": "largest construction companies"}, {"text": "Italy"}], "entities": [{"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Italy, Texas", "dbpedia_resource": "http://dbpedia.org/resource/Italy,_Texas"}}]}, "action": {"verb": {"text": "indicate", "tense": "past"}, "text": "indicated", "normalized": "indicate"}}, {"subject": {"text": "the reporter", "keywords": [{"text": "reporter"}], "entities": [{"type": "JobTitle", "text": "reporter"}]}, "sentence": " To contact the reporter on this story: Emma Haslett in London at ehaslett@bloomberg.net", "object": {"text": "on this story: Emma Haslett in London at ehaslett@bloomberg.net", "keywords": [{"text": "Emma Haslett"}, {"text": "story"}, {"text": "London"}, {"text": "ehaslett"}], "entities": [{"type": "Person", "text": "Emma Haslett"}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["City"]}}, {"type": "EmailAddress", "text": "ehaslett@bloomberg.net"}]}, "action": {"verb": {"text": "contact", "tense": "future"}, "text": "To contact", "normalized": "To contact"}}, {"subject": {"text": "Tom Freke", "keywords": [{"text": "Tom Freke"}], "entities": [{"type": "Person", "text": "Tom Freke"}]}, "sentence": " To contact the editors Hannah Benjamin at hbenjamin1@bloomberg.net, Tom Freke", "object": {"text": "the editors Hannah Benjamin", "keywords": [{"text": "editors Hannah Benjamin"}], "entities": [{"type": "Person", "text": "Hannah Benjamin"}]}, "action": {"verb": {"text": "contact", "tense": "future"}, "text": "To contact", "normalized": "To contact"}}], "concepts": [{"text": "European Union", "relevance": 0.981968, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "Euro", "relevance": 0.907409, "dbpedia_resource": "http://dbpedia.org/resource/Euro"}, {"text": "Bond", "relevance": 0.888237, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "European Commission", "relevance": 0.852281, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "Westminster system", "relevance": 0.781647, "dbpedia_resource": "http://dbpedia.org/resource/Westminster_system"}, {"text": "Germany", "relevance": 0.722845, "dbpedia_resource": "http://dbpedia.org/resource/Germany"}, {"text": "Motion of no confidence", "relevance": 0.683396, "dbpedia_resource": "http://dbpedia.org/resource/Motion_of_no_confidence"}, {"text": "France", "relevance": 0.568474, "dbpedia_resource": "http://dbpedia.org/resource/France"}, {"text": "Italy", "relevance": 0.533787, "dbpedia_resource": "http://dbpedia.org/resource/Italy"}, {"text": "Risk", "relevance": 0.532384, "dbpedia_resource": "http://dbpedia.org/resource/Risk"}, {"text": "Debt", "relevance": 0.522524, "dbpedia_resource": "http://dbpedia.org/resource/Debt"}, {"text": "Israel", "relevance": 0.520582, "dbpedia_resource": "http://dbpedia.org/resource/Israel"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.51748, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "The Europeans", "relevance": 0.517136, "dbpedia_resource": "http://dbpedia.org/resource/The_Europeans_(disambiguation)"}, {"text": "European Economic Community", "relevance": 0.4964, "dbpedia_resource": "http://dbpedia.org/resource/European_Economic_Community"}, {"text": "Budget", "relevance": 0.472339, "dbpedia_resource": "http://dbpedia.org/resource/Budget"}], "categories": [{"score": 0.937606, "label": "/finance/financial news"}, {"score": 0.888347, "label": "/real estate/buying and selling homes"}, {"score": 0.886063, "label": "/finance/investing"}], "relations": [{"type": "basedIn", "sentence": "U.K. banks in particular took a hit last week as rumors swirled.", "score": 0.962417, "arguments": [{"text": "banks", "location": [370, 375], "entities": [{"type": "Organization", "text": "banks", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "U.K.", "location": [365, 369], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}]}, {"type": "agentOf", "sentence": "Yesterday Italy's Deputy Prime Minister Luigi Di Maio insisted the country will maintain the \"big reforms\" of the plan it has drawn up, which aims for a 2019 budget deficit of 2.4 percent.", "score": 0.994555, "arguments": [{"text": "Luigi Di Maio", "location": [2261, 2274], "entities": [{"type": "Person", "text": "Luigi Di Maio"}]}, {"text": "insisted", "location": [2275, 2283], "entities": [{"type": "EventCommunication", "text": "insisted"}]}]}, {"type": "affectedBy", "sentence": "Yesterday Italy's Deputy Prime Minister Luigi Di Maio insisted the country will maintain the \"big reforms\" of the plan it has drawn up, which aims for a 2019 budget deficit of 2.4 percent.", "score": 0.50535, "arguments": [{"text": "country", "location": [2288, 2295], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "insisted", "location": [2275, 2283], "entities": [{"type": "EventCommunication", "text": "insisted"}]}]}, {"type": "agentOf", "sentence": "Any bickering between the two sides may continue to hurt borrowers: wrangles over Italy's budget have previously hit European financial names where it hurts, while a note from S&P Global Ratings indicated Italy's largest construction companies face high credit risks.", "score": 0.986023, "arguments": [{"text": "S&P Global Ratings", "location": [2586, 2604], "entities": [{"type": "Organization", "text": "S&P Global Ratings", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "indicated", "location": [2605, 2614], "entities": [{"type": "EventCommunication", "text": "indicated"}]}]}, {"type": "partOf", "sentence": "Any bickering between the two sides may continue to hurt borrowers: wrangles over Italy's budget have previously hit European financial names where it hurts, while a note from S&P Global Ratings indicated Italy's largest construction companies face high credit risks.", "score": 0.765486, "arguments": [{"text": "construction companies", "location": [2631, 2653], "entities": [{"type": "Organization", "text": "construction companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Italy", "location": [2615, 2620], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Emma Haslett in London at ehaslett@bloomberg.net To contact the editors Hannah Benjamin at hbenjamin1@bloomberg.net, Tom Freke", "score": 0.415448, "arguments": [{"text": "Emma Haslett", "location": [2717, 2729], "entities": [{"type": "Person", "text": "Emma Haslett"}]}, {"text": "London", "location": [2733, 2739], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Emma Haslett in London at ehaslett@bloomberg.net To contact the editors Hannah Benjamin at hbenjamin1@bloomberg.net, Tom Freke", "score": 0.414705, "arguments": [{"text": "editors", "location": [2781, 2788], "entities": [{"type": "Person", "text": "editors"}]}, {"text": "London", "location": [2733, 2739], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Emma Haslett in London at ehaslett@bloomberg.net To contact the editors Hannah Benjamin at hbenjamin1@bloomberg.net, Tom Freke", "score": 0.959591, "arguments": [{"text": "Hannah Benjamin", "location": [2789, 2804], "entities": [{"type": "Person", "text": "Hannah Benjamin"}]}, {"text": "editors", "location": [2781, 2788], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Emma Haslett in London at ehaslett@bloomberg.net To contact the editors Hannah Benjamin at hbenjamin1@bloomberg.net, Tom Freke", "score": 0.581346, "arguments": [{"text": "Tom Freke", "location": [2834, 2843], "entities": [{"type": "Person", "text": "Tom Freke"}]}, {"text": "editors", "location": [2781, 2788], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "hasAttribute", "sentence": "To contact the reporter on this story: Emma Haslett in London at ehaslett@bloomberg.net To contact the editors Hannah Benjamin at hbenjamin1@bloomberg.net, Tom Freke", "score": 0.981312, "arguments": [{"text": "Hannah Benjamin", "location": [2789, 2804], "entities": [{"type": "Person", "text": "Hannah Benjamin"}]}, {"text": "hbenjamin1@bloomberg.net", "location": [2808, 2832], "entities": [{"type": "Age", "text": "hbenjamin1@bloomberg.net"}]}]}, {"type": "basedIn", "sentence": "... but jumbo is still where it's at U.S. surgical equipment maker Stryker Corp may be in the market with a significant-sized bond sale this week, just days after Takeda Pharmaceutical Co Ltd and Volkswagen International Finance NV became two of the year's biggest issuers, though at a price.", "score": 0.79404, "arguments": [{"text": "maker", "location": [1101, 1106], "entities": [{"type": "Organization", "text": "Stryker Corp", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "U.S.", "location": [1077, 1081], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "... but jumbo is still where it's at U.S. surgical equipment maker Stryker Corp may be in the market with a significant-sized bond sale this week, just days after Takeda Pharmaceutical Co Ltd and Volkswagen International Finance NV became two of the year's biggest issuers, though at a price.", "score": 0.966759, "arguments": [{"text": "two", "location": [1279, 1282], "entities": [{"type": "Cardinal", "text": "two"}]}, {"text": "issuers", "location": [1305, 1312], "entities": [{"type": "Person", "text": "issuers"}]}]}, {"type": "residesIn", "sentence": "If the deal goes ahead it will follow a spate of euro-denominated sales by U.S.-based borrowers: October was the first month since July in which so-called \u02bbreverse Yankees' racked up more than 5 billion euros of borrowing.", "score": 0.465482, "arguments": [{"text": "borrowers", "location": [1419, 1428], "entities": [{"type": "Person", "text": "borrowers"}]}, {"text": "U.S.", "location": [1408, 1412], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "If the deal goes ahead it will follow a spate of euro-denominated sales by U.S.-based borrowers: October was the first month since July in which so-called \u02bbreverse Yankees' racked up more than 5 billion euros of borrowing.", "score": 0.482736, "arguments": [{"text": "Yankees", "location": [1497, 1504], "entities": [{"type": "Organization", "text": "Yankees"}]}, {"text": "5 billion euros", "location": [1526, 1541], "entities": [{"type": "Money", "text": "5 billion euros", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "The other obvious prospect for this week is a sustainability bond from Co-Operative Group Ltd. Stuff happens Earnings season for Europe's high-yield issuers helped generate some negative surprises, leading to a string of sudden drops in bond prices.", "score": 0.451338, "arguments": [{"text": "issuers", "location": [1705, 1712], "entities": [{"type": "Person", "text": "issuers"}]}, {"text": "Europe", "location": [1685, 1691], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Italy isn't going away The European Commission is due to issue its opinions on member states' draft budgets on Wednesday.", "score": 0.974429, "arguments": [{"text": "member", "location": [2178, 2184], "entities": [{"type": "Person", "text": "member"}]}, {"text": "states", "location": [2185, 2191], "entities": [{"type": "EventCommunication", "text": "states"}]}]}, {"type": "timeOf", "sentence": "Italy isn't going away The European Commission is due to issue its opinions on member states' draft budgets on Wednesday.", "score": 0.745875, "arguments": [{"text": "Wednesday", "location": [2210, 2219], "entities": [{"type": "Date", "text": "Wednesday"}]}, {"text": "states", "location": [2185, 2191], "entities": [{"type": "EventCommunication", "text": "states"}]}]}, {"type": "employedBy", "sentence": "Yesterday Italy's Deputy Prime Minister Luigi Di Maio insisted the country will maintain the \"big reforms\" of the plan it has drawn up, which aims for a 2019 budget deficit of 2.4 percent.", "score": 0.75445, "arguments": [{"text": "Deputy Prime Minister", "location": [2239, 2260], "entities": [{"type": "Person", "text": "Luigi Di Maio"}]}, {"text": "Italy", "location": [2231, 2236], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "European Commission", "sentiment": {"score": -0.845726, "label": "negative"}, "relevance": 0.632143, "count": 1}, {"text": "sense of fragility", "sentiment": {"score": -0.941068, "label": "negative"}, "relevance": 0.591416, "count": 1}, {"text": "flow of bond sales", "sentiment": {"score": -0.744756, "label": "negative"}, "relevance": 0.578063, "count": 1}, {"text": "Euro credit", "sentiment": {"score": -0.706983, "label": "negative"}, "relevance": 0.571688, "count": 1}, {"text": "Economic data", "sentiment": {"score": -0.518874, "label": "negative"}, "relevance": 0.564432, "count": 1}, {"text": "Italy", "sentiment": {"score": -0.845726, "label": "negative"}, "relevance": 0.564079, "count": 1}, {"text": "week", "sentiment": {"score": -0.735523, "label": "negative"}, "relevance": 0.563291, "count": 6}, {"text": "Today", "sentiment": {"score": -0.866304, "label": "negative"}, "relevance": 0.555783, "count": 1}, {"text": "today", "sentiment": {"score": -0.856589, "label": "negative"}, "relevance": 0.555783, "count": 1}, {"text": "S&P Global Ratings", "sentiment": {"score": -0.993543, "label": "negative"}, "relevance": 0.553998, "count": 1}, {"text": "borrowers", "sentiment": {"score": -0.867063, "label": "negative"}, "relevance": 0.548626, "count": 3}, {"text": "European financial names", "sentiment": {"score": -0.993543, "label": "negative"}, "relevance": 0.547362, "count": 1}, {"text": "euros", "sentiment": {"score": -0.575786, "label": "negative"}, "relevance": 0.545967, "count": 1}, {"text": "Earnings season", "sentiment": {"score": -0.529338, "label": "negative"}, "relevance": 0.543155, "count": 1}, {"text": "Brexit endgame grinds", "sentiment": {"score": -0.893404, "label": "negative"}, "relevance": 0.537559, "count": 1}, {"text": "surgical equipment maker Stryker Corp", "sentiment": {"score": -0.575786, "label": "negative"}, "relevance": 0.536601, "count": 1}, {"text": "U.K. banks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536446, "count": 1}, {"text": "Theresa May", "sentiment": {"score": -0.866304, "label": "negative"}, "relevance": 0.536058, "count": 1}, {"text": "Brexit deal", "sentiment": {"score": -0.866304, "label": "negative"}, "relevance": 0.534145, "count": 1}, {"text": "weeks", "sentiment": {"score": -0.689697, "label": "negative"}, "relevance": 0.531773, "count": 1}, {"text": "deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531562, "count": 1}, {"text": "Such uncertainty", "sentiment": {"score": -0.777022, "label": "negative"}, "relevance": 0.531503, "count": 1}, {"text": "budget deficit", "sentiment": {"score": -0.649252, "mixed": "1", "label": "negative"}, "relevance": 0.530826, "count": 1}, {"text": "names", "sentiment": {"score": -0.911975, "label": "negative"}, "relevance": 0.530745, "count": 1}, {"text": "markets", "sentiment": {"score": -0.777022, "label": "negative"}, "relevance": 0.530495, "count": 1}, {"text": "Europe\u2019s high-yield issuers", "sentiment": {"score": -0.529338, "label": "negative"}, "relevance": 0.530243, "count": 1}, {"text": "first month", "sentiment": {"score": -0.846644, "label": "negative"}, "relevance": 0.530134, "count": 1}, {"text": "Respondents", "sentiment": {"score": -0.575786, "label": "negative"}, "relevance": 0.530088, "count": 1}, {"text": "sides", "sentiment": {"score": -0.993543, "label": "negative"}, "relevance": 0.528622, "count": 1}, {"text": "drama", "sentiment": {"score": -0.893404, "label": "negative"}, "relevance": 0.527702, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": -0.575786, "label": "negative"}, "relevance": 0.527372, "count": 1}, {"text": "issuance", "sentiment": {"score": -0.689697, "label": "negative"}, "relevance": 0.525516, "count": 1}, {"text": "U.S.", "sentiment": {"score": -0.734389, "label": "negative"}, "relevance": 0.525326, "count": 2}, {"text": "October", "sentiment": {"score": -0.846644, "label": "negative"}, "relevance": 0.525287, "count": 1}, {"text": "Investors", "sentiment": {"score": -0.911975, "label": "negative"}, "relevance": 0.524341, "count": 1}, {"text": "sales", "sentiment": {"score": -0.846644, "label": "negative"}, "relevance": 0.524308, "count": 1}, {"text": "nervousness", "sentiment": {"score": -0.941068, "label": "negative"}, "relevance": 0.523978, "count": 1}, {"text": "market tone", "sentiment": {"score": -0.893404, "label": "negative"}, "relevance": 0.523134, "count": 1}, {"text": "Italy\u2019s largest construction companies", "sentiment": {"score": -0.993543, "label": "negative"}, "relevance": 0.523002, "count": 1}, {"text": "price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522946, "count": 1}, {"text": "reverse Yankees", "sentiment": {"score": -0.846644, "label": "negative"}, "relevance": 0.522714, "count": 1}, {"text": "string of sudden drops", "sentiment": {"score": -0.786184, "label": "negative"}, "relevance": 0.522237, "count": 1}, {"text": "market", "sentiment": {"score": -0.575786, "label": "negative"}, "relevance": 0.520344, "count": 1}, {"text": "draft budgets", "sentiment": {"score": 0.561949, "label": "positive"}, "relevance": 0.520121, "count": 1}, {"text": "bond sale", "sentiment": {"score": -0.575786, "label": "negative"}, "relevance": 0.518973, "count": 1}, {"text": "Vallourec SA bond prices", "sentiment": {"score": -0.856589, "label": "negative"}, "relevance": 0.517425, "count": 1}, {"text": "year\u2019s biggest issuers", "sentiment": {"score": -0.575786, "label": "negative"}, "relevance": 0.51648, "count": 1}, {"text": "U.S. credit markets", "sentiment": {"score": -0.941068, "label": "negative"}, "relevance": 0.51613, "count": 1}, {"text": "Good morning", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516109, "count": 1}, {"text": "country", "sentiment": {"score": 0.561949, "label": "positive"}, "relevance": 0.514969, "count": 1}]}, "extracted_metadata": {"sha1": "6cdb1571d4f46fe53cca42d3df8a5241efc37836", "filename": "1542626009894.zip-bd44188a63c27b6d3b47f1703f6d3359.xml", "file_type": "json"}, "title": "What to Watch in European Credit Markets This Week", "forum_title": "News Wire"}, {"id": "17H1UyoUXVvmA0i4P2TelrqWezAU7DTW8GJyou3JzVJeF65-8cjzzpmJ6vWYs8o9", "result_metadata": {"score": 33.422707}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.916818, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Barclays", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.993224, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.944017, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.933436, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.053839, "count": 1}]}, "crawl_date": "2018-11-19T13:17:13Z", "url": "https://www.marketscreener.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-27632240/", "host": "marketscreener.com", "text": "KEY INFORMATION Identity of the person whose Barclays PLC. positions/dealings are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.765957, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.668867, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.621513, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.538754, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.520974, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.470223, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.428812, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.412546, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,105,037 1.40%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,907,286 1.50%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,379,978 1.56%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,533,923 4.22%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,576,678 4.23%", "relevance": 0.412546, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.412546, "type": "Quantity"}], "sentiment": {"document": {"score": 0.608607, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,533,923 4.22% 33,576,678 4.23% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,533,923 4.22"}, {"type": "Quantity", "text": "33,576,678 4.23"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,105,037 1.40% 12,379,978 1.56% (2) Cash-settled derivatives: 11,907,286 1.50% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,533,923 4.22% 33,576,678 4.23% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 19 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 19 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}], "concepts": [{"text": "Option", "relevance": 0.970883, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.735423, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.685537, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.607715, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.499683, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.407262, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.393599, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.376188, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.342687, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.331277, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.323509, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.31952, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.312421, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Barclays", "relevance": 0.311941, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Unit type", "relevance": 0.298352, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Japanese yen", "relevance": 0.290521, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_yen"}], "categories": [{"score": 0.859167, "label": "/real estate/buying and selling homes"}, {"score": 0.807484, "label": "/finance/financial news"}, {"score": 0.78491, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "NPV Sale 3,800 4,314.9211 JPY Ordinary NPV Sale 4,300 4,308.0162 JPY Ordinary NPV Sale 4,700 4,323.0212 JPY Ordinary NPV Sale 5,000 4,313.1800 JPY Ordinary NPV Sale 5,100 4,316.0980 JPY Ordinary NPV Sale 5,700 4,301.9122 JPY Ordinary NPV Sale 7,300 4,293.3561 JPY Ordinary NPV Sale 9,600 4,302.5520 JPY Ordinary NPV Sale 15,200 4,329.0592 JPY Ordinary NPV Sale 68,200 4,314.5586 JPY Ordinary NPV Sale 403,800 4,309.8164 JPY Ordinary NPV Sale 443,800 4,314.2559 JPY Ordinary NPV Sale 712,700 4,314.1426 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 15,500 4,356.5643 JPY Ordinary NPV SWAP Short 600 4,306.3333 JPY Ordinary NPV SWAP Short 58,100 4,293.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5387, 5388], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5390, 5397], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6361, 6367], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6378, 6385], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 19 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7287, 7293], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7301, 7305], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7733, 7739], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7747, 7760], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7368, 7392], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7360, 7365], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9879, 9903], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9871, 9876], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7527, 7532], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7546, 7573], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10038, 10043], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10057, 10084], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose Barclays PLC.", "score": 0.307984, "arguments": [{"text": "person", "location": [7809, 7815], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7822, 7834], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181119005352/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 19 November 2018 and is solely responsible for the information contained herein.", "score": 0.979718, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10250, 10283], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10284, 10293], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181119005352/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 19 November 2018 and is solely responsible for the information contained herein.", "score": 0.73776, "arguments": [{"text": "November 2018", "location": [10313, 10326], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10284, 10293], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.749722, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.653155, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.628948, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.642354, "label": "positive"}, "relevance": 0.617185, "count": 4}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.599189, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.596411, "count": 1}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.595362, "count": 12}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.593985, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.396752, "mixed": "1", "label": "positive"}, "relevance": 0.584428, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.57778, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.573855, "count": 5}, {"text": "Name of offeror", "sentiment": {"score": 0.597475, "label": "positive"}, "relevance": 0.572879, "count": 2}, {"text": "options", "sentiment": {"score": 0.769049, "label": "positive"}, "relevance": 0.571683, "count": 4}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.57037, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566331, "count": 1}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.563534, "count": 3}, {"text": "relevant Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.563171, "count": 1}, {"text": "Code", "sentiment": {"score": -0.42523, "mixed": "1", "label": "negative"}, "relevance": 0.558972, "count": 5}, {"text": "Details", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.552372, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550363, "count": 1}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.54641, "count": 1}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543276, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.540906, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.540581, "count": 1}, {"text": "sale Number of Price", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.539795, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.34423, "mixed": "1", "label": "positive"}, "relevance": 0.538132, "count": 2}, {"text": "View source version", "sentiment": {"score": -0.36111, "label": "negative"}, "relevance": 0.53715, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.536114, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.534066, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533117, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.531762, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.531762, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.531762, "count": 2}, {"text": "relation", "sentiment": {"score": 0.658494, "label": "positive"}, "relevance": 0.530826, "count": 5}, {"text": "positions", "sentiment": {"score": 0.805202, "label": "positive"}, "relevance": 0.530625, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529521, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.52877, "count": 8}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527087, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526522, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.525567, "count": 2}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.524099, "count": 2}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.524041, "count": 4}, {"text": "form", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.524011, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.542023, "label": "negative"}, "relevance": 0.524011, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523321, "count": 3}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.523301, "count": 2}, {"text": "Rule", "sentiment": {"score": -0.881961, "label": "negative"}, "relevance": 0.523233, "count": 2}, {"text": "nature of the rights", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.523204, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.522377, "count": 1}, {"text": "details", "sentiment": {"score": 0.843569, "label": "positive"}, "relevance": 0.521013, "count": 1}]}, "extracted_metadata": {"sha1": "69cf33be295882b0728edebf283b309f08f66e76", "filename": "1542633433296.zip-c5f0d24152f30a66c034737475fd8099.xml", "file_type": "json"}, "external_links": ["http://www.publicnow.com/view/F7C7AD439724CD74A55988FA79C863E269D634DB", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51901302&newsitemid=20181119005352&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=a61aaf23744b101a95f897d4d8ebb889", "https://www.businesswire.com/news/home/20181119005352/en/", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1208339", "https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51901302&newsitemid=20181119005352&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=ad28b961f64b27b9d90b03a86f2dc5c6"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "Zy2gYb7qsnXgf_KNxCm8wXkTuv9EMpB9bnpgw0kGC4v3DQLbxbJFExl0IwIm0EOd", "result_metadata": {"score": 32.1096}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.904926, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "PLC UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.960803, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.769699, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344607, "count": 1}]}, "crawl_date": "2018-11-19T13:08:30Z", "url": "https://www.businesswire.com/news/home/20181119005352/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose Barclays PLC. positions/dealings are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T12:16:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.74364, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.710548, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.57659, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.571102, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.551161, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542871, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.526098, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512758, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.46965, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.452909, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,105,037 1.40%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,907,286 1.50%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,379,978 1.56%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,533,923 4.22%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,576,678 4.23%", "relevance": 0.452909, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.452909, "type": "Quantity"}], "sentiment": {"document": {"score": 0.648254, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,533,923 4.22% 33,576,678 4.23% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,533,923 4.22"}, {"type": "Quantity", "text": "33,576,678 4.23"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,105,037 1.40% 12,379,978 1.56% (2) Cash-settled derivatives: 11,907,286 1.50% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,533,923 4.22% 33,576,678 4.23% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 19 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659596 Time of Receipt (offset from UTC): 20181119T114624+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.975086, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.737687, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.692285, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.615702, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.50349, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.409327, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.400596, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.377707, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.345951, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.331741, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.327188, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.322724, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.313419, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Unit type", "relevance": 0.300939, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.293974, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Japanese yen", "relevance": 0.292631, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_yen"}], "categories": [{"score": 0.862088, "label": "/real estate/buying and selling homes"}, {"score": 0.801478, "label": "/finance/financial news"}, {"score": 0.788349, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "agentOf", "sentence": "NPV Sale 3,800 4,314.9211 JPY Ordinary NPV Sale 4,300 4,308.0162 JPY Ordinary NPV Sale 4,700 4,323.0212 JPY Ordinary NPV Sale 5,000 4,313.1800 JPY Ordinary NPV Sale 5,100 4,316.0980 JPY Ordinary NPV Sale 5,700 4,301.9122 JPY Ordinary NPV Sale 7,300 4,293.3561 JPY Ordinary NPV Sale 9,600 4,302.5520 JPY Ordinary NPV Sale 15,200 4,329.0592 JPY Ordinary NPV Sale 68,200 4,314.5586 JPY Ordinary NPV Sale 403,800 4,309.8164 JPY Ordinary NPV Sale 443,800 4,314.2559 JPY Ordinary NPV Sale 712,700 4,314.1426 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 15,500 4,356.5643 JPY Ordinary NPV SWAP Short 600 4,306.3333 JPY Ordinary NPV SWAP Short 58,100 4,293.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5369, 5370], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5372, 5379], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6343, 6349], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6360, 6367], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 19 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7269, 7275], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7283, 7287], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7715, 7721], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7729, 7742], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7350, 7374], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7342, 7347], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9861, 9885], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9853, 9858], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7509, 7514], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7528, 7555], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10020, 10025], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10039, 10066], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose Barclays PLC.", "score": 0.307984, "arguments": [{"text": "person", "location": [7791, 7797], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7804, 7816], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659596 Time of Receipt (offset from UTC): 20181119T114624+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10166, 10169], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10145, 10152], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.753428, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.64977, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.630562, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.642354, "label": "positive"}, "relevance": 0.619112, "count": 4}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.599933, "count": 12}, {"text": "unit security securities ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.599391, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.598879, "count": 1}, {"text": "USD Ordinary NPV Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.598177, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.579023, "count": 1}, {"text": "USD ADR Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.575342, "count": 5}, {"text": "Name of offeror", "sentiment": {"score": 0.597475, "label": "positive"}, "relevance": 0.574902, "count": 2}, {"text": "Takeover Code", "sentiment": {"score": 0.583324, "label": "positive"}, "relevance": 0.574649, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573609, "count": 1}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.573583, "count": 3}, {"text": "options", "sentiment": {"score": 0.769049, "label": "positive"}, "relevance": 0.573325, "count": 4}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.571262, "count": 2}, {"text": "relevant Purchase", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.564842, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557697, "count": 1}, {"text": "Code", "sentiment": {"score": -0.289164, "mixed": "1", "label": "negative"}, "relevance": 0.554686, "count": 5}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.553307, "count": 1}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.544051, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.542377, "count": 1}, {"text": "sale Number of Price", "sentiment": {"score": 0.964001, "label": "positive"}, "relevance": 0.541976, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539704, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.538186, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.54238, "label": "positive"}, "relevance": 0.537502, "count": 2}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.536763, "count": 2}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532405, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.532277, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.532277, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.532009, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.531799, "count": 1}, {"text": "positions", "sentiment": {"score": 0.805202, "label": "positive"}, "relevance": 0.531732, "count": 2}, {"text": "relation", "sentiment": {"score": 0.663618, "label": "positive"}, "relevance": 0.53024, "count": 5}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529809, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.529529, "count": 8}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528289, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52637, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525722, "count": 1}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.524599, "count": 4}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.524533, "count": 2}, {"text": "form", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.524497, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.524497, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.523864, "count": 2}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523819, "count": 3}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.523481, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.523289, "count": 2}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.522744, "count": 1}, {"text": "details", "sentiment": {"score": 0.843569, "label": "positive"}, "relevance": 0.521391, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.520435, "count": 3}]}, "extracted_metadata": {"sha1": "c43dde0a3040dcb89a78b4935691cc4b78a989c6", "filename": "1542632910677.zip-829c1fab326793ccf144102cf8ec310d.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "UfpZDnN7JXYiIBkltri2pOUadIzh9GRrJQ8bQqFt_TUcrdJ3MIHCZUdQcFHoFxhW", "result_metadata": {"score": 31.970451}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.607673, "label": "/finance/investing/brokerages"}, {"score": 0.605701, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.597169, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.741197, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.711277, "count": 1}, {"text": "Daiwa Asset Management UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466409, "count": 1}]}, "crawl_date": "2018-11-19T11:45:38Z", "url": "https://www.businesswire.com/news/home/20181118005054/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T07:00:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.73507, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.645192, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.625582, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.606793, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.546351, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.536697, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.529796, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.527451, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.497509, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.497509, "type": "Quantity"}], "sentiment": {"document": {"score": 0.48122, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "16 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 16 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 659573 Time of Receipt (offset from UTC): 20181119T021505+0000 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.945778, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.507067, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Call option", "relevance": 0.503676, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.486225, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.448837, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.408328, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.399664, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.393056, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.372346, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.371859, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Balance sheet", "relevance": 0.367195, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.36273, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.362044, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.351963, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uniform Commercial Code", "relevance": 0.34602, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.33923, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Security", "relevance": 0.338856, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}], "categories": [{"score": 0.921781, "label": "/real estate/buying and selling homes"}, {"score": 0.83334, "label": "/finance/financial news"}, {"score": 0.707978, "label": "/finance/investing/day trading"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 659573 Time of Receipt (offset from UTC): 20181119T021505+0000 Contacts Daiwa Asset Management", "score": 0.434823, "arguments": [{"text": "UTC", "location": [5791, 5794], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [5770, 5777], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 16 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [700, 707], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [626, 663], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORD Sale 11,600 4407 JPY ORD Purchase 2,900 4407 JPY ORD Purchase 2,000 4407 JPY (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit - - - - - (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit - - - - - -", "score": 0.787954, "arguments": [{"text": "i", "location": [3272, 3273], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3275, 3282], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "- - (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) - - - - 4.", "score": 0.591687, "arguments": [{"text": "Price", "location": [3898, 3903], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3908, 3912], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4280, 4286], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4297, 4304], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 19 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5116, 5128], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5130, 5159], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 19 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5219, 5225], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5233, 5237], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5300, 5324], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5292, 5297], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5579, 5603], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5571, 5576], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5635, 5640], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5654, 5681], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.704462, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.687117, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.617846, "count": 1}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598013, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.587042, "count": 3}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57955, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.54238, "label": "positive"}, "relevance": 0.578822, "count": 2}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.575078, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.572628, "count": 1}, {"text": "Telephone number", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.568914, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567965, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.567449, "count": 3}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.562125, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560372, "count": 1}, {"text": "Details", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.553077, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.550194, "count": 1}, {"text": "natural person", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.54872, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.547784, "count": 1}, {"text": "November", "sentiment": {"score": -0.908997, "label": "negative"}, "relevance": 0.545605, "count": 2}, {"text": "Owner", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.545326, "count": 1}, {"text": "Code", "sentiment": {"score": -0.612444, "mixed": "1", "label": "negative"}, "relevance": 0.544851, "count": 3}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.5443, "count": 2}, {"text": "disclosure", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.543963, "count": 4}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.543472, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.540232, "count": 2}, {"text": "person", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.539659, "count": 4}, {"text": "Purchases", "sentiment": {"score": 0.865913, "label": "positive"}, "relevance": 0.539144, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.538854, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.704735, "label": "positive"}, "relevance": 0.538854, "count": 1}, {"text": "telephone number", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.538063, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536643, "count": 1}, {"text": "offer", "sentiment": {"score": 0.618287, "mixed": "1", "label": "positive"}, "relevance": 0.536205, "count": 3}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535203, "count": 1}, {"text": "unit ORD Sale", "sentiment": {"score": 0.865913, "label": "positive"}, "relevance": 0.534685, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.533044, "count": 3}, {"text": "Daiwa Asset Management Co. Ltd", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.532485, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53191, "count": 1}, {"text": "cash offer", "sentiment": {"score": -0.5347, "label": "negative"}, "relevance": 0.531406, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530609, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.529577, "count": 2}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.529351, "count": 2}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528806, "count": 2}, {"text": "options", "sentiment": {"score": 0.343063, "mixed": "1", "label": "positive"}, "relevance": 0.528587, "count": 4}, {"text": "understandings", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.528578, "count": 3}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528571, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.798933, "label": "negative"}, "relevance": 0.528498, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.528494, "count": 1}, {"text": "state", "sentiment": {"score": -0.5347, "label": "negative"}, "relevance": 0.527886, "count": 1}, {"text": "contact information", "sentiment": {"score": 0.822712, "label": "positive"}, "relevance": 0.526701, "count": 1}, {"text": "unit", "sentiment": {"score": 0.478033, "mixed": "1", "label": "positive"}, "relevance": 0.526087, "count": 4}]}, "extracted_metadata": {"sha1": "5bc2b6a3985c4b7e716f1a6fbffb948d6197fd06", "filename": "1542627938569.zip-3246adf5cec06de2880620240af807c1.xml", "file_type": "json"}, "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}, {"id": "eEXmm3ivpmh95Ssy9PijzpY5ue_UKovGQNRqIav9LD5hRDBqZGRE-Lu2QKdroTuK", "result_metadata": {"score": 30.120436}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.675141, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.592415, "label": "/business and industrial/shipbuilding"}, {"score": 0.57479, "label": "/business and industrial/company"}], "relations": [], "keywords": [{"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995872, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.956793, "count": 1}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.822811, "count": 1}]}, "crawl_date": "2018-11-19T10:30:45Z", "url": "http://www.4-traders.com/SHIRE-9590198/news/Shire-Form-8-3-Takeda-Pharmaceutical-Company-Ltd-27630532/", "host": "4-traders.com", "text": "., which is the legal owner of the stock (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T00:00:00+01:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adage Capital Partners", "relevance": 0.85289, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.773493, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Adage Capital Partners GP", "relevance": 0.728996, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.697305, "label": "negative"}, "text": "Short Sell", "relevance": 0.545888, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.54265, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL COMPANY LTD", "relevance": 0.540349, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dan Lehan", "relevance": 0.538852, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.51763, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "L.P.", "relevance": 0.517155, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "general partner", "relevance": 0.513669, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "executive", "relevance": 0.493489, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.491912, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.491912, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.491912, "type": "Quantity"}], "sentiment": {"document": {"score": 0.436733, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " (f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?", "action": {"verb": {"text": "disclose", "tense": "past"}, "text": "disclosed", "normalized": "disclose"}}, {"subject": {"text": "they"}, "sentence": " (f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "they"}, "sentence": " (f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?", "object": {"text": "in respect of any other party to this offer", "keywords": [{"text": "respect"}, {"text": "party"}, {"text": "offer"}]}, "action": {"verb": {"text": "disclose", "tense": "present"}, "text": "disclosing", "normalized": "disclose"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "directors' and other executive options", "keywords": [{"text": "executive options"}, {"text": "directors"}], "entities": [{"type": "JobTitle", "text": "executive"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other executive options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation", "keywords": [{"text": "consultation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Shire plc", "keywords": [{"text": "Shire plc"}], "entities": [{"type": "Company", "text": "SHIRE PLC", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " Shire plc published this content on 19 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 19 November 2018 07:13:05 UTC", "object": {"text": "05 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.976145, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.620623, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.593826, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.541907, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.490961, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.484513, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.481789, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Grammatical number", "relevance": 0.466957, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.444554, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Security", "relevance": 0.432886, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.417849, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Derivative", "relevance": 0.416472, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Futures contract", "relevance": 0.408464, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Unit type", "relevance": 0.40769, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Security", "relevance": 0.397435, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Option contract", "relevance": 0.381702, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Moneyness", "relevance": 0.371246, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.93953, "label": "/real estate/buying and selling homes"}, {"score": 0.890649, "label": "/finance/financial news"}, {"score": 0.757699, "label": "/finance/investing/day trading"}], "relations": [{"type": "partOfMany", "sentence": "KEY INFORMATION (a) Identity of the person whose positions/dealings are being disclosed: Adage Capital Partners GP, L.L.C. (Adage Capital Partners GP, L.L.C. is the general partner of Adage Capital Partners, L.P., which is the legal owner of the stock (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree TAKEDA PHARMACEUTICAL COMPANY LTD (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 16 November 2018 (", "score": 0.393394, "arguments": [{"text": "Adage Capital Partners, L.P.", "location": [367, 395], "entities": [{"type": "Organization", "text": "Adage Capital Partners, L.P.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "general partner", "location": [348, 363], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "agentOf", "sentence": "f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?", "score": 0.752641, "arguments": [{"text": "they", "location": [981, 985], "entities": [{"type": "Person", "text": "they"}]}, {"text": "disclosing", "location": [992, 1002], "entities": [{"type": "EventCommunication", "text": "disclosing"}]}]}, {"type": "timeOf", "sentence": "f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?", "score": 0.892751, "arguments": [{"text": "today", "location": [986, 991], "entities": [{"type": "Date", "text": "today"}]}, {"text": "disclosing", "location": [992, 1002], "entities": [{"type": "EventCommunication", "text": "disclosing"}]}]}, {"type": "agentOf", "sentence": "DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Short Sell 54,500 4,324.50 JPY (b) Derivatives transactions (other than options) Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.890415, "arguments": [{"text": "i", "location": [2768, 2769], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "Writing", "location": [2771, 2778], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercising Class of relevant security Product description e.g. call option Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) The currency of all prices and other monetary amounts should be stated.", "score": 0.486921, "arguments": [{"text": "Price", "location": [3340, 3345], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3350, 3354], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 16 November 2018 Contact name: Dan Lehan Telephone number: 617-867-2855 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [4833, 4839], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [4847, 4851], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [4994, 5018], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [4986, 4991], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5161, 5166], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5180, 5207], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "Adage Capital Partners GP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.787973, "count": 2}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.694865, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.630377, "count": 1}, {"text": "general partner of Adage Capital Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625221, "count": 1}, {"text": "Details of any open derivative", "sentiment": {"score": 0.438723, "label": "positive"}, "relevance": 0.606777, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0.675206, "label": "positive"}, "relevance": 0.58036, "count": 3}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580082, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.52306, "mixed": "1", "label": "positive"}, "relevance": 0.56768, "count": 2}, {"text": "Takeover Code", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.566239, "count": 1}, {"text": "Details", "sentiment": {"score": 0.916632, "label": "positive"}, "relevance": 0.564292, "count": 1}, {"text": "positions", "sentiment": {"score": 0.916632, "label": "positive"}, "relevance": 0.564053, "count": 2}, {"text": "Options", "sentiment": {"score": -0.618709, "label": "negative"}, "relevance": 0.556077, "count": 1}, {"text": "options", "sentiment": {"score": 0.479042, "mixed": "1", "label": "positive"}, "relevance": 0.556077, "count": 3}, {"text": "naming of nominee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554796, "count": 1}, {"text": "Code", "sentiment": {"score": -0.446579, "mixed": "1", "label": "negative"}, "relevance": 0.552048, "count": 4}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547919, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.916632, "label": "positive"}, "relevance": 0.547237, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.505629, "label": "positive"}, "relevance": 0.544554, "count": 2}, {"text": "agreements", "sentiment": {"score": -0.319673, "mixed": "1", "label": "negative"}, "relevance": 0.54418, "count": 2}, {"text": "relevant securities of the offeror", "sentiment": {"score": -0.618709, "label": "negative"}, "relevance": 0.542511, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.538075, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.537092, "count": 1}, {"text": "Takeover Panel", "sentiment": {"score": -0.747776, "label": "negative"}, "relevance": 0.535849, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.618709, "label": "negative"}, "relevance": 0.535567, "count": 3}, {"text": "Owner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534915, "count": 1}, {"text": "dealings", "sentiment": {"score": 0.671986, "label": "positive"}, "relevance": 0.53467, "count": 3}, {"text": "arrangements", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.532527, "count": 3}, {"text": "legal owner of the stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532444, "count": 1}, {"text": "rights", "sentiment": {"score": 0.916632, "label": "positive"}, "relevance": 0.531543, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.529496, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.529419, "count": 1}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.528708, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": -0.364484, "mixed": "1", "label": "negative"}, "relevance": 0.52747, "count": 2}, {"text": "Derivatives", "sentiment": {"score": -0.618709, "label": "negative"}, "relevance": 0.527013, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.526981, "count": 3}, {"text": "Purchases", "sentiment": {"score": 0.516511, "label": "positive"}, "relevance": 0.52457, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.747776, "label": "negative"}, "relevance": 0.523917, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.916632, "label": "positive"}, "relevance": 0.523871, "count": 2}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52347, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.52347, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.523017, "count": 1}, {"text": "INFORMATION", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.522104, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.621217, "mixed": "1", "label": "positive"}, "relevance": 0.520611, "count": 3}, {"text": "relation", "sentiment": {"score": 0.496179, "mixed": "1", "label": "positive"}, "relevance": 0.5201, "count": 3}, {"text": "Interests", "sentiment": {"score": -0.618709, "label": "negative"}, "relevance": 0.519625, "count": 1}, {"text": "Class", "sentiment": {"score": 0.599002, "label": "positive"}, "relevance": 0.518532, "count": 2}, {"text": "indemnity", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.518105, "count": 1}, {"text": "Indemnity", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.518105, "count": 1}, {"text": "SHIRE PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518081, "count": 1}, {"text": "person", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.517861, "count": 4}]}, "extracted_metadata": {"sha1": "9bd2cecc83ff4c3b4f19deb2fbf77517bc4bf0f3", "filename": "1542623445094.zip-a145b07f40f9b74ec2a0af7954e4c494.xml", "file_type": "json"}, "external_links": ["http://otp.investis.com/clients/uk/shire/rns1/regulatory-story.aspx?cid=1027&newsid=1208198", "http://www.publicnow.com/view/008F0032BD8D8CD7A9DA85E92D728860EAB35CDC"], "title": "Shire : Form 8.3 - Takeda Pharmaceutical Company Ltd", "forum_title": "F100 Stock Quote | FTSE 100 Index Stock Price () | Autre: F100 | MarketScreener"}, {"id": "qi956HFiwE2sD24A9wopaANJr9GzrFiytAh_Wo5nC_vqJgaOAAznHlPUb4Iddldd", "result_metadata": {"score": 29.321272}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.827842, "label": "negative"}, "text": "Cancer", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2 Years", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": -0.747423, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Types of cancer", "relevance": 0.852304, "dbpedia_resource": "http://dbpedia.org/resource/Types_of_cancer"}, {"text": "Chad", "relevance": 0.669373, "dbpedia_resource": "http://dbpedia.org/resource/Chad"}], "categories": [{"score": 0.996667, "label": "/health and fitness/disease/cancer"}, {"score": 0.852159, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [], "keywords": [{"text": "Drug Approvals", "sentiment": {"score": -0.747423, "label": "negative"}, "relevance": 0.994211, "count": 1}, {"text": "Common Types of Cancer", "sentiment": {"score": -0.747423, "label": "negative"}, "relevance": 0.370905, "count": 1}, {"text": "Years", "sentiment": {"score": -0.747423, "label": "negative"}, "relevance": 0.009779, "count": 1}]}, "crawl_date": "2018-11-19T06:09:43Z", "url": "https://www.biospace.com/article/drug-approvals-for-the-2-most-common-types-of-cancer-in-the-last-2-years/", "host": "biospace.com", "text": "The agency approved Takeda Pharmaceutical and ARIAD Pharmaceuticals \u2019 Alunbrig (brigatinib) in April 2018 for metastatic anaplastic lymphoma kinase (ALK)+ NSCLC that has progressed on or are intolerant to crizotinib.", "main_image_url": "https://www.biospace.com/getasset/2f68e054-2507-4036-a9c9-37f0b13e5e32/;w=625;h=350", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T00:00:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": -0.454, "label": "negative"}, "text": "metastatic breast cancer", "relevance": 0.902841, "type": "HealthCondition"}, {"count": 6, "sentiment": {"score": -0.529344, "label": "negative"}, "text": "Cancer", "relevance": 0.505546, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 12, "sentiment": {"score": -0.587261, "label": "negative"}, "text": "Food and Drug Administration", "relevance": 0.478469, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 2, "sentiment": {"score": -0.645872, "label": "negative"}, "text": "Breast Cancer", "relevance": 0.427515, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Breast cancer", "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}}, {"count": 4, "sentiment": {"score": -0.438862, "label": "negative"}, "text": "NSCLC", "relevance": 0.416785, "type": "Organization"}, {"count": 2, "sentiment": {"score": -0.647854, "label": "negative"}, "text": "metastatic disease", "relevance": 0.405621, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Metastasis", "dbpedia_resource": "http://dbpedia.org/resource/Metastasis"}}, {"count": 2, "sentiment": {"score": -0.866294, "label": "negative"}, "text": "Lung Cancer", "relevance": 0.399516, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Lung cancer", "dbpedia_resource": "http://dbpedia.org/resource/Lung_cancer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Cancer Society", "relevance": 0.345212, "type": "Organization", "disambiguation": {"subtype": ["Non-ProfitOrganisation", "PeriodicalPublisher"], "name": "American Cancer Society", "dbpedia_resource": "http://dbpedia.org/resource/American_Cancer_Society"}}, {"count": 1, "sentiment": {"score": -0.49045, "label": "negative"}, "text": "non-small cell lung cancer", "relevance": 0.332371, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Non-small-cell lung carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Non-small-cell_lung_carcinoma"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.275439, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 4, "sentiment": {"score": -0.453662, "label": "negative"}, "text": "HER2", "relevance": 0.257497, "type": "Person"}, {"count": 3, "sentiment": {"score": 0.379205, "label": "positive"}, "text": "Novartis", "relevance": 0.233435, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.230794, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.210862, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.202223, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": -0.424759, "label": "negative"}, "text": "pemetrexed", "relevance": 0.200305, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mark Terry", "relevance": 0.192674, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim", "relevance": 0.192347, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co.", "relevance": 0.192032, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": -0.424759, "label": "negative"}, "text": "carboplatin", "relevance": 0.190347, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.50883, "label": "negative"}, "text": "U.S.", "relevance": 0.187646, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.187029, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.179775, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.206015, "label": "negative"}, "text": "SCLC", "relevance": 0.169731, "type": "Organization", "disambiguation": {"subtype": [], "name": "Southern Christian Leadership Conference", "dbpedia_resource": "http://dbpedia.org/resource/Southern_Christian_Leadership_Conference"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ARIAD Pharmaceuticals", "relevance": 0.164396, "type": "Company", "disambiguation": {"subtype": [], "name": "ARIAD Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/ARIAD_Pharmaceuticals"}}, {"count": 2, "sentiment": {"score": -0.523754, "label": "negative"}, "text": "trastuzumab", "relevance": 0.164103, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan", "relevance": 0.15735, "type": "Company", "disambiguation": {"subtype": [], "name": "Mylan", "dbpedia_resource": "http://dbpedia.org/resource/Mylan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mekinist", "relevance": 0.15177, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Puma Biotechnology", "relevance": 0.151513, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pertuzumab", "relevance": 0.149037, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Verzenio", "relevance": 0.143398, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "paclitaxel", "relevance": 0.140837, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fulvestrant", "relevance": 0.139815, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2 Years", "relevance": 0.139815, "type": "Quantity"}], "sentiment": {"document": {"score": -0.768576, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "almost 601,000 people in the U.S.", "keywords": [{"text": "people"}, {"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " According to the American Cancer Society , almost 601,000 people in the U.S. died of cancer in 2017.", "object": {"text": "of cancer", "keywords": [{"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "die", "tense": "past"}, "text": "died", "normalized": "die"}}, {"subject": {"text": "The two most common types of cancer", "keywords": [{"text": "common types"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "sentence": " The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.", "object": {"text": "lung cancer and breast cancer", "keywords": [{"text": "lung cancer"}, {"text": "breast cancer"}], "entities": [{"type": "HealthCondition", "text": "Lung Cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Lung cancer", "dbpedia_resource": "http://dbpedia.org/resource/Lung_cancer"}}, {"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The two most common types of cancer are lung cancer and breast cancer", "keywords": [{"text": "lung cancer"}, {"text": "common types"}, {"text": "breast cancer"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"type": "HealthCondition", "text": "Lung Cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Lung cancer", "dbpedia_resource": "http://dbpedia.org/resource/Lung_cancer"}}, {"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "sentence": " The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.", "object": {"text": "by colorectal cancer, prostate cancer and stomach cancer", "keywords": [{"text": "colorectal cancer"}, {"text": "stomach cancer"}, {"text": "prostate cancer"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "it"}, "sentence": " In many ways, it\u2019s far more complicated than that.", "object": {"text": "far more complicated than that"}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Increasingly, biopharma companies", "keywords": [{"text": "biopharma companies"}]}, "sentence": " Increasingly, biopharma companies develop treatments for specific subpopulations of cancer.", "object": {"text": "treatments for specific subpopulations of cancer", "keywords": [{"text": "specific subpopulations"}, {"text": "treatments"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "Cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "AstraZeneca \u2019 s Tagrisso (osimertinib)", "keywords": [{"text": "AstraZeneca"}, {"text": "Tagrisso"}, {"text": "osimertinib"}], "entities": [{"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}]}, "sentence": " For example, AstraZeneca \u2019 s Tagrisso (osimertinib) was approved in April 2018 by the Food and Drug Administration (FDA) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) that have specific exon 19 deletions or exon 21 L858R mutations, which are detected by an FDA-approved test.", "object": {"text": "approved in April 2018 by the Food and Drug Administration (FDA)", "keywords": [{"text": "Drug Administration"}, {"text": "FDA"}, {"text": "Food"}], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by the Food and Drug Administration (FDA)", "keywords": [{"text": "FDA"}, {"text": "Drug Administration"}, {"text": "Food"}], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " For example, AstraZeneca \u2019 s Tagrisso (osimertinib) was approved in April 2018 by the Food and Drug Administration (FDA) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) that have specific exon 19 deletions or exon 21 L858R mutations, which are detected by an FDA-approved test.", "object": {"text": "AstraZeneca \u2019 s Tagrisso (osimertinib)", "keywords": [{"text": "AstraZeneca"}, {"text": "Tagrisso"}, {"text": "osimertinib"}], "entities": [{"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "was approved", "normalized": "be approve"}}, {"subject": {"text": "metastatic non-small cell lung cancer (NSCLC)", "keywords": [{"text": "metastatic non-small cell"}, {"text": "lung cancer"}, {"text": "NSCLC"}], "entities": [{"type": "HealthCondition", "text": "non-small cell lung cancer", "disambiguation": {"subtype": [], "name": "Non-small-cell lung carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Non-small-cell_lung_carcinoma"}}, {"type": "Organization", "text": "NSCLC"}]}, "sentence": " For example, AstraZeneca \u2019 s Tagrisso (osimertinib) was approved in April 2018 by the Food and Drug Administration (FDA) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) that have specific exon 19 deletions or exon 21 L858R mutations, which are detected by an FDA-approved test.", "object": {"text": "specific exon 19 deletions or exon 21 L858R mutations", "keywords": [{"text": "specific exon"}, {"text": "L858R mutations"}, {"text": "deletions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "by an FDA-approved test", "keywords": [{"text": "FDA-approved test"}]}, "sentence": " For example, AstraZeneca \u2019 s Tagrisso (osimertinib) was approved in April 2018 by the Food and Drug Administration (FDA) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) that have specific exon 19 deletions or exon 21 L858R mutations, which are detected by an FDA-approved test.", "object": {"text": "specific exon 19 deletions or exon 21 L858R mutations", "keywords": [{"text": "specific exon"}, {"text": "L858R mutations"}, {"text": "deletions"}]}, "action": {"verb": {"text": "detect", "tense": "past"}, "text": "are detected", "normalized": "be detect"}}, {"subject": {"text": "the cancer drugs", "keywords": [{"text": "cancer drugs"}]}, "sentence": " Let\u2019s look at some of the cancer drugs that have been approved by the FDA since the beginning of 2017 for these top 2 cancers.", "object": {"text": "approved by the FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "by the FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " Let\u2019s look at some of the cancer drugs that have been approved by the FDA since the beginning of 2017 for these top 2 cancers.", "object": {"text": "the cancer drugs", "keywords": [{"text": "cancer drugs"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "have been approved", "normalized": "have be approve"}}, {"subject": {"text": "readers", "keywords": [{"text": "readers"}]}, "sentence": " One thing that will jump out at readers is the ways in which companies are developing drugs (or at least seeking approvals) for narrower and narrower indications, and the ongoing battle among pharma companies to get their drugs approved for first-line treatment, in addition to second and third-line treatments.", "object": {"text": "the ways in which companies are developing drugs (or at least seeking approvals) for narrower and narrower indications, and the ongoing battle among pharma companies to get their drugs approved for first-line treatment, in addition to second and third-line treatments", "keywords": [{"text": "narrower indications"}, {"text": "first-line treatment"}, {"text": "pharma companies"}, {"text": "ongoing battle"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "companies", "keywords": [{"text": "companies"}]}, "sentence": " One thing that will jump out at readers is the ways in which companies are developing drugs (or at least seeking approvals) for narrower and narrower indications, and the ongoing battle among pharma companies to get their drugs approved for first-line treatment, in addition to second and third-line treatments.", "object": {"text": "approvals", "keywords": [{"text": "approvals"}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seeking", "normalized": "seek"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In March 2017, FDA approved AstraZeneca\u2019s Tagrisso (osimertinib) for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.", "object": {"text": "AstraZeneca\u2019s Tagrisso (osimertinib) for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy", "keywords": [{"text": "tyrosine kinase inhibitor"}, {"text": "metastatic epidermal growth"}, {"text": "T790M mutation-positive NSCLC"}, {"text": "factor receptor"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "The agency", "keywords": [{"text": "agency"}]}, "sentence": " The agency approved Takeda Pharmaceutical and ARIAD Pharmaceuticals \u2019 Alunbrig (brigatinib) in April 2018 for metastatic anaplastic lymphoma kinase (ALK)+ NSCLC that has progressed on or are intolerant to crizotinib.", "object": {"text": "Takeda Pharmaceutical and ARIAD Pharmaceuticals \u2019 Alunbrig (brigatinib) in April 2018 for metastatic anaplastic lymphoma kinase", "keywords": [{"text": "metastatic anaplastic lymphoma"}, {"text": "Takeda Pharmaceutical"}, {"text": "ARIAD Pharmaceuticals"}, {"text": "kinase"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "ARIAD Pharmaceuticals", "disambiguation": {"subtype": ["Organization", "Company"], "name": "ARIAD Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/ARIAD_Pharmaceuticals"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Takeda Pharmaceutical and ARIAD Pharmaceuticals \u2019 Alunbrig (brigatinib) in April 2018 for metastatic anaplastic lymphoma kinase (ALK)+ NSCLC", "keywords": [{"text": "metastatic anaplastic lymphoma"}, {"text": "Takeda Pharmaceutical"}, {"text": "ARIAD Pharmaceuticals"}, {"text": "NSCLC"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "ARIAD Pharmaceuticals", "disambiguation": {"subtype": ["Organization", "Company"], "name": "ARIAD Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/ARIAD_Pharmaceuticals"}}, {"type": "Organization", "text": "NSCLC"}]}, "sentence": " The agency approved Takeda Pharmaceutical and ARIAD Pharmaceuticals \u2019 Alunbrig (brigatinib) in April 2018 for metastatic anaplastic lymphoma kinase (ALK)+ NSCLC that has progressed on or are intolerant to crizotinib.", "object": {"text": "intolerant to crizotinib", "keywords": [{"text": "intolerant"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the agency", "keywords": [{"text": "agency"}]}, "sentence": " In May 2018, the agency granted accelerated approval to Merck & Co. \u2019s Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for patients with previously untreated metastatic non-squamous NSCLC.", "object": {"text": "accelerated approval to Merck & Co. \u2019s Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for patients with previously untreated metastatic non-squamous NSCLC", "keywords": [{"text": "metastatic non-squamous NSCLC"}, {"text": "Merck"}, {"text": "approval"}, {"text": "combination"}], "entities": [{"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Drug", "text": "pemetrexed"}, {"type": "Drug", "text": "carboplatin"}, {"type": "Organization", "text": "NSCLC"}]}, "action": {"verb": {"text": "grant", "tense": "future"}, "text": "granted", "normalized": "grant"}}, {"subject": {"text": "Merck & Co.", "keywords": [{"text": "Merck"}], "entities": [{"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " In May 2018, the agency granted accelerated approval to Merck & Co. \u2019s Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for patients with previously untreated metastatic non-squamous NSCLC.", "object": {"text": "Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for patients with previously untreated metastatic non-squamous NSCLC", "keywords": [{"text": "metastatic non-squamous NSCLC"}, {"text": "combination"}, {"text": "Keytruda"}, {"text": "pembrolizumab"}], "entities": [{"type": "Drug", "text": "pemetrexed"}, {"type": "Drug", "text": "carboplatin"}, {"type": "Organization", "text": "NSCLC"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " Also in May, FDA approved Novartis \u2019 Zykadia (ceritinib) for metastatic NSCLC whose tumors are ALK+.", "object": {"text": "Novartis \u2019 Zykadia (ceritinib)", "keywords": [{"text": "Novartis"}, {"text": "Zykadia"}, {"text": "ceritinib"}], "entities": [{"type": "Location", "text": "Novartis", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "approve", "tense": "future"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "the FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In June 2017, the FDA approved Novartis\u2019 Tafinlar (dabrafenib) and Mekinist (trametinib) in combination in metastatic NSCLC with BRAF V600E mutation detected by an FDA-approved test.", "object": {"text": "Novartis\u2019 Tafinlar (dabrafenib) and Mekinist (trametinib) in combination", "keywords": [{"text": "Novartis"}, {"text": "combination"}, {"text": "Tafinlar"}, {"text": "dabrafenib"}], "entities": [{"type": "Location", "text": "Novartis", "disambiguation": {"subtype": ["Country"]}}, {"type": "Person", "text": "Mekinist"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "by an FDA-approved test", "keywords": [{"text": "FDA-approved test"}]}, "sentence": " In June 2017, the FDA approved Novartis\u2019 Tafinlar (dabrafenib) and Mekinist (trametinib) in combination in metastatic NSCLC with BRAF V600E mutation detected by an FDA-approved test.", "object": {"text": "BRAF V600E mutation", "keywords": [{"text": "BRAF V600E mutation"}]}, "action": {"verb": {"text": "detect", "tense": "past"}, "text": "detected", "normalized": "detect"}}, {"subject": {"text": "Boehringer Ingelheim", "keywords": [{"text": "Boehringer Ingelheim"}], "entities": [{"type": "Company", "text": "Boehringer Ingelheim", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}]}, "sentence": " In January 2018, Boehringer Ingelheim \u2019s Gilotrif (afatinib) was approved for a broadened indication in first-line treatment for metastatic NSCLC whose tumors have non-resistant EGFR mutations detected by an FDA-approved test.", "object": {"text": "Gilotrif (afatinib) was approved for a broadened indication in first-line treatment for metastatic NSCLC whose tumors have non-resistant EGFR mutations detected by an FDA-approved test", "keywords": [{"text": "non-resistant EGFR mutations"}, {"text": "metastatic NSCLC"}, {"text": "first-line treatment"}, {"text": "FDA-approved test"}], "entities": [{"type": "Organization", "text": "NSCLC"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Boehringer Ingelheim \u2019s Gilotrif (afatinib)", "keywords": [{"text": "Boehringer Ingelheim"}, {"text": "Gilotrif"}], "entities": [{"type": "Company", "text": "Boehringer Ingelheim", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}]}, "sentence": " In January 2018, Boehringer Ingelheim \u2019s Gilotrif (afatinib) was approved for a broadened indication in first-line treatment for metastatic NSCLC whose tumors have non-resistant EGFR mutations detected by an FDA-approved test.", "object": {"text": "approved"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Boehringer Ingelheim \u2019s Gilotrif (afatinib)", "keywords": [{"text": "Boehringer Ingelheim"}, {"text": "Gilotrif"}], "entities": [{"type": "Company", "text": "Boehringer Ingelheim", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}]}, "sentence": " In January 2018, Boehringer Ingelheim \u2019s Gilotrif (afatinib) was approved for a broadened indication in first-line treatment for metastatic NSCLC whose tumors have non-resistant EGFR mutations detected by an FDA-approved test.", "action": {"verb": {"text": "approve", "tense": "past"}, "text": "was approved", "normalized": "be approve"}}, {"subject": {"text": "by an FDA-approved test", "keywords": [{"text": "FDA-approved test"}]}, "sentence": " In January 2018, Boehringer Ingelheim \u2019s Gilotrif (afatinib) was approved for a broadened indication in first-line treatment for metastatic NSCLC whose tumors have non-resistant EGFR mutations detected by an FDA-approved test.", "object": {"text": "non-resistant EGFR mutations", "keywords": [{"text": "non-resistant EGFR mutations"}]}, "action": {"verb": {"text": "detect", "tense": "past"}, "text": "detected", "normalized": "detect"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In April, FDA approved AstraZeneca\u2019s Tagrisso (osimertinib) for first-line treatment of metastatic NSCLC tumors with EGFR exon 19 deletions or exon 21 L858R mutations detected on a test.", "object": {"text": "AstraZeneca\u2019s Tagrisso (osimertinib) for first-line treatment of metastatic NSCLC tumors with EGFR exon 19 deletions or exon 21 L858R mutations", "keywords": [{"text": "metastatic NSCLC tumors"}, {"text": "EGFR exon"}, {"text": "first-line treatment"}, {"text": "L858R mutations"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "EGFR exon 19 deletions or exon 21 L858R mutations", "keywords": [{"text": "EGFR exon"}, {"text": "L858R mutations"}, {"text": "deletions"}]}, "sentence": " In April, FDA approved AstraZeneca\u2019s Tagrisso (osimertinib) for first-line treatment of metastatic NSCLC tumors with EGFR exon 19 deletions or exon 21 L858R mutations detected on a test.", "action": {"verb": {"text": "detect", "tense": "past"}, "text": "detected", "normalized": "detect"}}, {"subject": {"text": "Bristol-Myers Squibb", "keywords": [{"text": "Bristol-Myers Squibb"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " In August, Bristol-Myers Squibb \u2019s Opdivo (nivolumab) was approved in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.", "object": {"text": "Opdivo (nivolumab) was approved in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy", "keywords": [{"text": "metastatic small cell"}, {"text": "platinum-based chemotherapy"}, {"text": "lung cancer"}, {"text": "progression"}], "entities": [{"type": "Organization", "text": "SCLC", "disambiguation": {"subtype": ["Organization"], "name": "Southern Christian Leadership Conference", "dbpedia_resource": "http://dbpedia.org/resource/Southern_Christian_Leadership_Conference"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Bristol-Myers Squibb \u2019s Opdivo (nivolumab)", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "Opdivo"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " In August, Bristol-Myers Squibb \u2019s Opdivo (nivolumab) was approved in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.", "object": {"text": "approved in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy", "keywords": [{"text": "metastatic small cell"}, {"text": "platinum-based chemotherapy"}, {"text": "lung cancer"}, {"text": "progression"}], "entities": [{"type": "Organization", "text": "SCLC", "disambiguation": {"subtype": ["Organization"], "name": "Southern Christian Leadership Conference", "dbpedia_resource": "http://dbpedia.org/resource/Southern_Christian_Leadership_Conference"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Bristol-Myers Squibb \u2019s Opdivo (nivolumab)", "keywords": [{"text": "Bristol-Myers Squibb"}, {"text": "Opdivo"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " In August, Bristol-Myers Squibb \u2019s Opdivo (nivolumab) was approved in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.", "object": {"text": "in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy", "keywords": [{"text": "metastatic small cell"}, {"text": "platinum-based chemotherapy"}, {"text": "lung cancer"}, {"text": "progression"}], "entities": [{"type": "Organization", "text": "SCLC", "disambiguation": {"subtype": ["Organization"], "name": "Southern Christian Leadership Conference", "dbpedia_resource": "http://dbpedia.org/resource/Southern_Christian_Leadership_Conference"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "was approved", "normalized": "be approve"}}, {"subject": {"text": "Merck", "keywords": [{"text": "Merck"}], "entities": [{"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "sentence": " In August, Merck\u2019s Keytruda in combination with pemetrexed and platinum as first-line treatment was approved in patients with metastatic-nonsquamous NSCLC with no EGFR or ALK tumor aberrations.", "object": {"text": "Keytruda", "keywords": [{"text": "Keytruda"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Merck\u2019s Keytruda in combination with pemetrexed and platinum as first-line treatment", "keywords": [{"text": "first-line treatment"}, {"text": "Merck"}, {"text": "platinum"}, {"text": "combination"}], "entities": [{"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Drug", "text": "pemetrexed"}]}, "sentence": " In August, Merck\u2019s Keytruda in combination with pemetrexed and platinum as first-line treatment was approved in patients with metastatic-nonsquamous NSCLC with no EGFR or ALK tumor aberrations.", "object": {"text": "approved in patients with metastatic-nonsquamous NSCLC with no EGFR or ALK tumor aberrations", "keywords": [{"text": "ALK tumor aberrations"}, {"text": "metastatic-nonsquamous NSCLC"}, {"text": "patients"}, {"text": "EGFR"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Merck\u2019s Keytruda in combination with pemetrexed and platinum as first-line treatment", "keywords": [{"text": "first-line treatment"}, {"text": "Merck"}, {"text": "platinum"}, {"text": "combination"}], "entities": [{"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Drug", "text": "pemetrexed"}]}, "sentence": " In August, Merck\u2019s Keytruda in combination with pemetrexed and platinum as first-line treatment was approved in patients with metastatic-nonsquamous NSCLC with no EGFR or ALK tumor aberrations.", "object": {"text": "in patients", "keywords": [{"text": "patients"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "was approved", "normalized": "be approve"}}, {"subject": {"text": "the agency", "keywords": [{"text": "agency"}]}, "sentence": " In September, the agency approved Pfizer \u2019s Vizimpro (dacomitinib) for first-line treatment of NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.", "object": {"text": "Pfizer \u2019s Vizimpro (dacomitinib)", "keywords": [{"text": "Pfizer"}, {"text": "Vizimpro"}, {"text": "dacomitinib"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "Food and Drug Administration"}]}, "sentence": " And on November 2, FDA approved Pfizer\u2019s Lorbrena (lorlatinib) for patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.", "object": {"text": "Pfizer\u2019s Lorbrena", "keywords": [{"text": "Pfizer"}, {"text": "Lorbrena"}], "entities": [{"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "the agency", "keywords": [{"text": "agency"}]}, "sentence": " In March 2017, the agency approved Novartis\u2019 Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.", "object": {"text": "Novartis\u2019 Kisqali (ribociclib) in combination", "keywords": [{"text": "Novartis"}, {"text": "combination"}, {"text": "Kisqali"}, {"text": "ribociclib"}], "entities": [{"type": "Location", "text": "Novartis", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In the same month, FDA approved Pfizer\u2019s Ibrance (palbociclib) for HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.", "object": {"text": "Pfizer\u2019s Ibrance (palbociclib) for HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women", "keywords": [{"text": "metastatic breast cancer"}, {"text": "aromatase inhibitor"}, {"text": "initial endocrine-based therapy"}, {"text": "postmenopausal women"}], "entities": [{"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Person", "text": "HER2"}, {"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "HER2-", "entities": [{"type": "Person", "text": "HER2"}]}, "sentence": " In the same month, FDA approved Pfizer\u2019s Ibrance (palbociclib) for HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.", "action": {"verb": {"text": "advance", "tense": "past"}, "text": "advanced", "normalized": "advance"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In July 2017, FDA approved Puma Biotechnology \u2019s Nerlynx (neratinib) for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, which was to follow adjuvant trastuzumab-based treatment.", "object": {"text": "Puma Biotechnology \u2019s Nerlynx (neratinib) for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, which was to follow adjuvant trastuzumab-based treatment", "keywords": [{"text": "extended adjuvant treatment"}, {"text": "adjuvant trastuzumab-based treatment"}, {"text": "early-stage HER2-overexpressed/amplified breast"}, {"text": "Puma Biotechnology"}], "entities": [{"type": "Company", "text": "Puma Biotechnology"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Puma Biotechnology", "keywords": [{"text": "Puma Biotechnology"}], "entities": [{"type": "Company", "text": "Puma Biotechnology"}]}, "sentence": " In July 2017, FDA approved Puma Biotechnology \u2019s Nerlynx (neratinib) for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, which was to follow adjuvant trastuzumab-based treatment.", "object": {"text": "for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, which was to follow adjuvant trastuzumab-based treatment", "keywords": [{"text": "extended adjuvant treatment"}, {"text": "adjuvant trastuzumab-based treatment"}, {"text": "early-stage HER2-overexpressed/amplified breast"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the agency", "keywords": [{"text": "agency"}]}, "sentence": " In September 2017, the agency approved Eli Lilly and Company 's Verzenio (abemaciclib) in combination with fulvestrant for HR+, HER2- advanced or metastatic breast cancer with disease progression after endocrine therapy.", "object": {"text": "Eli Lilly and Company", "keywords": [{"text": "Eli Lilly"}, {"text": "Company"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "they"}, "sentence": " Biosimilars are basically generic versions of biologic drugs, although because they are not direct copycats, but rather \u201csimilar,\u201d they require an approval process that is similar to that of new branded drugs.", "object": {"text": "an approval process that is similar to that of new branded drugs", "keywords": [{"text": "new branded drugs"}, {"text": "approval process"}]}, "action": {"verb": {"text": "require", "tense": "present"}, "text": "require", "normalized": "require"}}, {"subject": {"text": "an approval process", "keywords": [{"text": "approval process"}]}, "sentence": " Biosimilars are basically generic versions of biologic drugs, although because they are not direct copycats, but rather \u201csimilar,\u201d they require an approval process that is similar to that of new branded drugs.", "object": {"text": "similar to that of new branded drugs", "keywords": [{"text": "new branded drugs"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "FDA", "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " In December 2017, FDA approved Mylan \u2019s Ogivri (trastuzumab-dkst) as a biosimilar to Genentech \u2019s Herceptin (trastuzumab) for patients with HER2-overexpressing breast or metastatic stomach cancer.", "object": {"text": "Mylan \u2019s Ogivri (trastuzumab-dkst)", "keywords": [{"text": "Mylan"}, {"text": "Ogivri"}], "entities": [{"type": "Company", "text": "Mylan", "disambiguation": {"subtype": [], "name": "Mylan", "dbpedia_resource": "http://dbpedia.org/resource/Mylan"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "the agency", "keywords": [{"text": "agency"}]}, "sentence": " In the same month, the agency granted Genentech\u2019s Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy as adjuvant treatment of HER2+ early breast cancer at high risk of recurrence.", "object": {"text": "Genentech\u2019s Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy as adjuvant treatment of HER2+ early breast cancer at high risk of recurrence", "keywords": [{"text": "HER2+ early breast"}, {"text": "adjuvant treatment"}, {"text": "high risk"}, {"text": "trastuzumab"}], "entities": [{"type": "Drug", "text": "pertuzumab"}, {"type": "Drug", "text": "trastuzumab"}, {"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "grant", "tense": "past"}, "text": "granted", "normalized": "grant"}}, {"subject": {"text": "AstraZeneca"}, "sentence": " In January 2018, AstraZeneca\u2019s Lymparza (olaparib) was approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "object": {"text": "Lymparza (olaparib) was approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting", "keywords": [{"text": "deleterious germline BRCA-mutated"}, {"text": "HER2- metastatic breast"}, {"text": "metastatic setting"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "AstraZeneca\u2019s Lymparza (olaparib)", "keywords": [{"text": "AstraZeneca"}, {"text": "Lymparza"}]}, "sentence": " In January 2018, AstraZeneca\u2019s Lymparza (olaparib) was approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "object": {"text": "approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting", "keywords": [{"text": "deleterious germline BRCA-mutated"}, {"text": "HER2- metastatic breast"}, {"text": "metastatic setting"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "AstraZeneca\u2019s Lymparza (olaparib)", "keywords": [{"text": "AstraZeneca"}, {"text": "Lymparza"}]}, "sentence": " In January 2018, AstraZeneca\u2019s Lymparza (olaparib) was approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "object": {"text": "with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting", "keywords": [{"text": "deleterious germline BRCA-mutated"}, {"text": "HER2- metastatic breast"}, {"text": "metastatic setting"}, {"text": "adjuvant"}], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "was approved", "normalized": "be approve"}}, {"subject": {"text": "AstraZeneca\u2019s Lymparza (olaparib)", "keywords": [{"text": "AstraZeneca"}, {"text": "Lymparza"}]}, "sentence": " In January 2018, AstraZeneca\u2019s Lymparza (olaparib) was approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "object": {"text": "deleterious germline", "keywords": [{"text": "deleterious germline"}]}, "action": {"verb": {"text": "suspect", "tense": "past"}, "text": "suspected", "normalized": "suspect"}}, {"subject": {"text": "the agency", "keywords": [{"text": "agency"}]}, "sentence": " In February 2018, the agency approved Eli Lilly\u2019s Verzenio (abemaciclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor HR+, HER2- advanced or metastatic breast cancer.", "object": {"text": "Eli Lilly\u2019s Verzenio (abemaciclib) in combination", "keywords": [{"text": "Eli Lilly"}, {"text": "combination"}, {"text": "Verzenio"}], "entities": [{"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}], "concepts": [{"text": "Cancer", "relevance": 0.955377, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Breast cancer", "relevance": 0.74279, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Metastasis", "relevance": 0.679684, "dbpedia_resource": "http://dbpedia.org/resource/Metastasis"}, {"text": "Lung cancer", "relevance": 0.562582, "dbpedia_resource": "http://dbpedia.org/resource/Lung_cancer"}, {"text": "Oncology", "relevance": 0.500758, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Epidermal growth factor receptor", "relevance": 0.45944, "dbpedia_resource": "http://dbpedia.org/resource/Epidermal_growth_factor_receptor"}, {"text": "Chemotherapy", "relevance": 0.418164, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Trastuzumab", "relevance": 0.302104, "dbpedia_resource": "http://dbpedia.org/resource/Trastuzumab"}, {"text": "Stomach cancer", "relevance": 0.295207, "dbpedia_resource": "http://dbpedia.org/resource/Stomach_cancer"}, {"text": "Estrogen", "relevance": 0.276178, "dbpedia_resource": "http://dbpedia.org/resource/Estrogen"}, {"text": "Tamoxifen", "relevance": 0.271016, "dbpedia_resource": "http://dbpedia.org/resource/Tamoxifen"}, {"text": "Prostate cancer", "relevance": 0.269121, "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}, {"text": "Non-small cell lung carcinoma", "relevance": 0.268882, "dbpedia_resource": "http://dbpedia.org/resource/Non-small_cell_lung_carcinoma"}, {"text": "American Cancer Society", "relevance": 0.258843, "dbpedia_resource": "http://dbpedia.org/resource/American_Cancer_Society"}, {"text": "Signal transduction", "relevance": 0.255908, "dbpedia_resource": "http://dbpedia.org/resource/Signal_transduction"}, {"text": "Cancer staging", "relevance": 0.254733, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Doxorubicin", "relevance": 0.230744, "dbpedia_resource": "http://dbpedia.org/resource/Doxorubicin"}, {"text": "Paclitaxel", "relevance": 0.230688, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Immune system", "relevance": 0.229186, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Pleural effusion", "relevance": 0.227475, "dbpedia_resource": "http://dbpedia.org/resource/Pleural_effusion"}, {"text": "Chemotherapy regimens", "relevance": 0.225043, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy_regimens"}, {"text": "Aromatase inhibitor", "relevance": 0.224258, "dbpedia_resource": "http://dbpedia.org/resource/Aromatase_inhibitor"}, {"text": "HER2/neu", "relevance": 0.223851, "dbpedia_resource": "http://dbpedia.org/resource/HER2/neu"}, {"text": "Epidermal growth factor", "relevance": 0.214482, "dbpedia_resource": "http://dbpedia.org/resource/Epidermal_growth_factor"}, {"text": "Growth factor", "relevance": 0.211868, "dbpedia_resource": "http://dbpedia.org/resource/Growth_factor"}, {"text": "Melanoma", "relevance": 0.203372, "dbpedia_resource": "http://dbpedia.org/resource/Melanoma"}, {"text": "BRCA2", "relevance": 0.203323, "dbpedia_resource": "http://dbpedia.org/resource/BRCA2"}, {"text": "Adenocarcinoma", "relevance": 0.202991, "dbpedia_resource": "http://dbpedia.org/resource/Adenocarcinoma"}, {"text": "Types of cancer", "relevance": 0.201724, "dbpedia_resource": "http://dbpedia.org/resource/Types_of_cancer"}, {"text": "Metastatic breast cancer", "relevance": 0.19696, "dbpedia_resource": "http://dbpedia.org/resource/Metastatic_breast_cancer"}, {"text": "Radiation therapy", "relevance": 0.182251, "dbpedia_resource": "http://dbpedia.org/resource/Radiation_therapy"}, {"text": "Eli Lilly and Company", "relevance": 0.181221, "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}, {"text": "Mesothelioma", "relevance": 0.180134, "dbpedia_resource": "http://dbpedia.org/resource/Mesothelioma"}, {"text": "Testicular cancer", "relevance": 0.178683, "dbpedia_resource": "http://dbpedia.org/resource/Testicular_cancer"}, {"text": "Small cell carcinoma", "relevance": 0.175646, "dbpedia_resource": "http://dbpedia.org/resource/Small_cell_carcinoma"}, {"text": "International Cancer Genome Consortium", "relevance": 0.175276, "dbpedia_resource": "http://dbpedia.org/resource/International_Cancer_Genome_Consortium"}, {"text": "Lymph node", "relevance": 0.174818, "dbpedia_resource": "http://dbpedia.org/resource/Lymph_node"}, {"text": "Cancer support group", "relevance": 0.172442, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_support_group"}, {"text": "Menopause", "relevance": 0.172392, "dbpedia_resource": "http://dbpedia.org/resource/Menopause"}, {"text": "Carboplatin", "relevance": 0.170563, "dbpedia_resource": "http://dbpedia.org/resource/Carboplatin"}, {"text": "Estrogen receptor", "relevance": 0.168739, "dbpedia_resource": "http://dbpedia.org/resource/Estrogen_receptor"}, {"text": "Leukemia", "relevance": 0.166934, "dbpedia_resource": "http://dbpedia.org/resource/Leukemia"}, {"text": "Receptor", "relevance": 0.165976, "dbpedia_resource": "http://dbpedia.org/resource/Receptor_(biochemistry)"}, {"text": "Brachytherapy", "relevance": 0.16465, "dbpedia_resource": "http://dbpedia.org/resource/Brachytherapy"}, {"text": "DNA", "relevance": 0.163944, "dbpedia_resource": "http://dbpedia.org/resource/DNA"}, {"text": "Epidemiology", "relevance": 0.163411, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "BRCA1", "relevance": 0.162968, "dbpedia_resource": "http://dbpedia.org/resource/BRCA1"}, {"text": "Janet Lane-Claypon", "relevance": 0.156456, "dbpedia_resource": "http://dbpedia.org/resource/Janet_Lane-Claypon"}, {"text": "Adjuvant", "relevance": 0.154516, "dbpedia_resource": "http://dbpedia.org/resource/Adjuvant"}, {"text": "Hormone", "relevance": 0.153676, "dbpedia_resource": "http://dbpedia.org/resource/Hormone"}], "categories": [{"score": 0.99809, "label": "/health and fitness/disease/cancer"}, {"score": 0.990583, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "hasAttribute", "sentence": "Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years Published: Nov 19, 2018 By Mark Terry According to the American Cancer Society , almost 601,000 people in the U.S. died of cancer in 2017.", "score": 0.444365, "arguments": [{"text": "Mark Terry", "location": [100, 110], "entities": [{"type": "Person", "text": "Mark Terry"}]}, {"text": "cancer", "location": [196, 202], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "timeOf", "sentence": "In April, FDA approved AstraZeneca's Tagrisso (osimertinib) for first-line treatment of metastatic NSCLC tumors with EGFR exon 19 deletions or exon 21 L858R mutations detected on a test.", "score": 0.731268, "arguments": [{"text": "April", "location": [2468, 2473], "entities": [{"type": "Date", "text": "April"}]}, {"text": "approved", "location": [2479, 2487], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "employedBy", "sentence": "In April, FDA approved AstraZeneca's Tagrisso (osimertinib) for first-line treatment of metastatic NSCLC tumors with EGFR exon 19 deletions or exon 21 L858R mutations detected on a test.", "score": 0.505143, "arguments": [{"text": "mutations", "location": [2622, 2631], "entities": [{"type": "Person", "text": "mutations"}]}, {"text": "L858R", "location": [2616, 2621], "entities": [{"type": "Organization", "text": "L858R"}]}]}, {"type": "partOf", "sentence": "In August, Bristol-Myers Squibb 's Opdivo (nivolumab) was approved in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.", "score": 0.8275, "arguments": [{"text": "Opdivo", "location": [2687, 2693], "entities": [{"type": "Organization", "text": "Opdivo", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Bristol-Myers Squibb", "location": [2663, 2683], "entities": [{"type": "Organization", "text": "Bristol-Myers Squibb", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "In August, Bristol-Myers Squibb 's Opdivo (nivolumab) was approved in patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.", "score": 0.954287, "arguments": [{"text": "patients", "location": [2722, 2730], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "lung cancer", "location": [2758, 2769], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "partOf", "sentence": "In September, the agency approved Pfizer 's Vizimpro (dacomitinib) for first-line treatment of NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.", "score": 0.377228, "arguments": [{"text": "agency", "location": [3080, 3086], "entities": [{"type": "Organization", "text": "American Cancer Society"}]}, {"text": "Pfizer", "location": [3096, 3102], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "productOf", "sentence": "In September, the agency approved Pfizer 's Vizimpro (dacomitinib) for first-line treatment of NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.", "score": 0.994286, "arguments": [{"text": "Vizimpro", "location": [3106, 3114], "entities": [{"type": "Product", "text": "Vizimpro"}]}, {"text": "Pfizer", "location": [3096, 3102], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "And on November 2, FDA approved Pfizer's Lorbrena (lorlatinib) for patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.", "score": 0.918659, "arguments": [{"text": "November 2", "location": [3418, 3428], "entities": [{"type": "Date", "text": "November 2"}]}, {"text": "approved", "location": [3434, 3442], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "affectedBy", "sentence": "And on November 2, FDA approved Pfizer's Lorbrena (lorlatinib) for patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.", "score": 0.48324, "arguments": [{"text": "Pfizer", "location": [3443, 3449], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "approved", "location": [3434, 3442], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "affectedBy", "sentence": "In the same month, FDA approved Pfizer's Ibrance (palbociclib) for HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.", "score": 0.479703, "arguments": [{"text": "Pfizer", "location": [4082, 4088], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "approved", "location": [4073, 4081], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "affectedBy", "sentence": "In October, FDA approved Pfizer's Talzenna (talazoparib) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER- locally advanced or metastatic breast cancer.", "score": 0.521688, "arguments": [{"text": "Pfizer", "location": [6102, 6108], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "approved", "location": [6093, 6101], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "productOf", "sentence": "And on November 2, FDA approved Pfizer's Lorbrena (lorlatinib) for patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.", "score": 0.993065, "arguments": [{"text": "Lorbrena", "location": [3452, 3460], "entities": [{"type": "Product", "text": "Lorbrena"}]}, {"text": "Pfizer", "location": [3443, 3449], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "And on November 2, FDA approved Pfizer's Lorbrena (lorlatinib) for patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.", "score": 0.493813, "arguments": [{"text": "patients", "location": [3478, 3486], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ALK+ metastatic NSCLC", "location": [3492, 3513], "entities": [{"type": "Organization", "text": "ALK+ metastatic NSCLC"}]}]}, {"type": "residesIn", "sentence": "Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years Published: Nov 19, 2018 By Mark Terry According to the American Cancer Society , almost 601,000 people in the U.S. died of cancer in 2017.", "score": 0.385955, "arguments": [{"text": "people", "location": [169, 175], "entities": [{"type": "Person", "text": "people"}]}, {"text": "U.S.", "location": [183, 187], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Breast Cancer In March 2017, the agency approved Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.", "score": 0.49023, "arguments": [{"text": "Novartis", "location": [3783, 3791], "entities": [{"type": "Person", "text": "Novartis"}]}, {"text": "women", "location": [3912, 3917], "entities": [{"type": "Person", "text": "women"}]}]}, {"type": "productOf", "sentence": "In the same month, FDA approved Pfizer's Ibrance (palbociclib) for HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.", "score": 0.993368, "arguments": [{"text": "Ibrance", "location": [4091, 4098], "entities": [{"type": "Product", "text": "Ibrance"}]}, {"text": "Pfizer", "location": [4082, 4088], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "In July 2017, FDA approved Puma Biotechnology 's Nerlynx (neratinib) for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, which was to follow adjuvant trastuzumab-based treatment.", "score": 0.85161, "arguments": [{"text": "July 2017", "location": [4271, 4280], "entities": [{"type": "Date", "text": "July 2017"}]}, {"text": "approved", "location": [4286, 4294], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "hasAttribute", "sentence": "In July 2017, FDA approved Puma Biotechnology 's Nerlynx (neratinib) for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, which was to follow adjuvant trastuzumab-based treatment.", "score": 0.684368, "arguments": [{"text": "Puma Biotechnology", "location": [4295, 4313], "entities": [{"type": "Person", "text": "Puma Biotechnology"}]}, {"text": "breast cancer", "location": [4429, 4442], "entities": [{"type": "HealthCondition", "text": "breast cancer"}]}]}, {"type": "partOf", "sentence": "In September 2017, the agency approved Eli Lilly and Company 's Verzenio (abemaciclib) in combination with fulvestrant for HR+, HER2- advanced or metastatic breast cancer with disease progression after endocrine therapy.", "score": 0.762244, "arguments": [{"text": "Verzenio", "location": [4566, 4574], "entities": [{"type": "Organization", "text": "Verzenio", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Eli Lilly and Company", "location": [4541, 4562], "entities": [{"type": "Organization", "text": "Eli Lilly and Company"}]}]}, {"type": "timeOf", "sentence": "In December 2017, FDA approved Mylan 's Ogivri (trastuzumab-dkst) as a biosimilar to Genentech 's Herceptin (trastuzumab) for patients with HER2-overexpressing breast or metastatic stomach cancer.", "score": 0.800152, "arguments": [{"text": "December 2017", "location": [4936, 4949], "entities": [{"type": "Date", "text": "December 2017"}]}, {"text": "approved", "location": [4955, 4963], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "partOfMany", "sentence": "In December 2017, FDA approved Mylan 's Ogivri (trastuzumab-dkst) as a biosimilar to Genentech 's Herceptin (trastuzumab) for patients with HER2-overexpressing breast or metastatic stomach cancer.", "score": 0.576207, "arguments": [{"text": "Mylan", "location": [4964, 4969], "entities": [{"type": "Person", "text": "Mylan"}]}, {"text": "patients", "location": [5059, 5067], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "hasAttribute", "sentence": "In December 2017, FDA approved Mylan 's Ogivri (trastuzumab-dkst) as a biosimilar to Genentech 's Herceptin (trastuzumab) for patients with HER2-overexpressing breast or metastatic stomach cancer.", "score": 0.514573, "arguments": [{"text": "Ogivri", "location": [4973, 4979], "entities": [{"type": "Person", "text": "Ogivri"}]}, {"text": "stomach cancer", "location": [5114, 5128], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "partOf", "sentence": "In December 2017, FDA approved Mylan 's Ogivri (trastuzumab-dkst) as a biosimilar to Genentech 's Herceptin (trastuzumab) for patients with HER2-overexpressing breast or metastatic stomach cancer.", "score": 0.813266, "arguments": [{"text": "Herceptin", "location": [5031, 5040], "entities": [{"type": "Organization", "text": "Herceptin", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Genentech", "location": [5018, 5027], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "In December 2017, FDA approved Mylan 's Ogivri (trastuzumab-dkst) as a biosimilar to Genentech 's Herceptin (trastuzumab) for patients with HER2-overexpressing breast or metastatic stomach cancer.", "score": 0.787713, "arguments": [{"text": "patients", "location": [5059, 5067], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stomach cancer", "location": [5114, 5128], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years Published: Nov 19, 2018 By Mark Terry According to the American Cancer Society , almost 601,000 people in the U.S. died of cancer in 2017.", "score": 0.620496, "arguments": [{"text": "people", "location": [169, 175], "entities": [{"type": "Person", "text": "people"}]}, {"text": "cancer", "location": [196, 202], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "productOf", "sentence": "In the same month, the agency granted Genentech's Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy as adjuvant treatment of HER2+ early breast cancer at high risk of recurrence.", "score": 0.994095, "arguments": [{"text": "Perjeta", "location": [5180, 5187], "entities": [{"type": "Product", "text": "Perjeta"}]}, {"text": "Genentech", "location": [5168, 5177], "entities": [{"type": "Organization", "text": "Genentech", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "In January 2018, AstraZeneca's Lymparza (olaparib) was approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "score": 0.604541, "arguments": [{"text": "Lymparza", "location": [5368, 5376], "entities": [{"type": "Person", "text": "Lymparza"}]}, {"text": "breast cancer", "location": [5495, 5508], "entities": [{"type": "HealthCondition", "text": "breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "In January 2018, AstraZeneca's Lymparza (olaparib) was approved for patients with deleterious or suspected deleterious germline BRCA-mutated HER2- metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "score": 0.371121, "arguments": [{"text": "who", "location": [5509, 5512], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "breast cancer", "location": [5495, 5508], "entities": [{"type": "HealthCondition", "text": "breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "In February 2018, the agency approved Eli Lilly's Verzenio (abemaciclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor HR+, HER2- advanced or metastatic breast cancer.", "score": 0.584062, "arguments": [{"text": "women", "location": [5779, 5784], "entities": [{"type": "Person", "text": "women"}]}, {"text": "metastatic breast cancer", "location": [5830, 5854], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "hasAttribute", "sentence": "In July 2018, Novartis' Kisqali (ribociclib) was approved in combination with an aromatase inhibitor for pre/perimenopausal women with HER+, HER2- advanced or metastatic breast cancer, as initial endocrine-based therapy.", "score": 0.47521, "arguments": [{"text": "Kisqali", "location": [5880, 5887], "entities": [{"type": "Person", "text": "Kisqali"}]}, {"text": "metastatic breast cancer", "location": [6015, 6039], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "timeOf", "sentence": "In October, FDA approved Pfizer's Talzenna (talazoparib) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER- locally advanced or metastatic breast cancer.", "score": 0.727128, "arguments": [{"text": "October", "location": [6080, 6087], "entities": [{"type": "Date", "text": "October"}]}, {"text": "approved", "location": [6093, 6101], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "productOf", "sentence": "In October, FDA approved Pfizer's Talzenna (talazoparib) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER- locally advanced or metastatic breast cancer.", "score": 0.993065, "arguments": [{"text": "Talzenna", "location": [6111, 6119], "entities": [{"type": "Product", "text": "Talzenna"}]}, {"text": "Pfizer", "location": [6102, 6108], "entities": [{"type": "Organization", "text": "Pfizer", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "In October, FDA approved Pfizer's Talzenna (talazoparib) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER- locally advanced or metastatic breast cancer.", "score": 0.783238, "arguments": [{"text": "HER", "location": [6212, 6215], "entities": [{"type": "Person", "text": "HER"}]}, {"text": "metastatic breast cancer", "location": [6237, 6261], "entities": [{"type": "HealthCondition", "text": "metastatic breast cancer"}]}]}, {"type": "agentOf", "sentence": "Lung Cancer In March 2017, FDA approved AstraZeneca's Tagrisso (osimertinib) for metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.", "score": 0.986784, "arguments": [{"text": "FDA", "location": [1265, 1268], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [1269, 1277], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "Also in May, FDA approved Novartis ' Zykadia (ceritinib) for metastatic NSCLC whose tumors are ALK+.", "score": 0.987468, "arguments": [{"text": "FDA", "location": [1967, 1970], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [1971, 1979], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "In June 2017, the FDA approved Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in combination in metastatic NSCLC with BRAF V600E mutation detected by an FDA-approved test.", "score": 0.987125, "arguments": [{"text": "FDA", "location": [2073, 2076], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [2077, 2085], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "In April, FDA approved AstraZeneca's Tagrisso (osimertinib) for first-line treatment of metastatic NSCLC tumors with EGFR exon 19 deletions or exon 21 L858R mutations detected on a test.", "score": 0.987468, "arguments": [{"text": "FDA", "location": [2475, 2478], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [2479, 2487], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "And on November 2, FDA approved Pfizer's Lorbrena (lorlatinib) for patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.", "score": 0.983605, "arguments": [{"text": "FDA", "location": [3430, 3433], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [3434, 3442], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "In the same month, FDA approved Pfizer's Ibrance (palbociclib) for HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.", "score": 0.97797, "arguments": [{"text": "FDA", "location": [4069, 4072], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [4073, 4081], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "In July 2017, FDA approved Puma Biotechnology 's Nerlynx (neratinib) for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer, which was to follow adjuvant trastuzumab-based treatment.", "score": 0.992212, "arguments": [{"text": "FDA", "location": [4282, 4285], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [4286, 4294], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "In December 2017, FDA approved Mylan 's Ogivri (trastuzumab-dkst) as a biosimilar to Genentech 's Herceptin (trastuzumab) for patients with HER2-overexpressing breast or metastatic stomach cancer.", "score": 0.987468, "arguments": [{"text": "FDA", "location": [4951, 4954], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [4955, 4963], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "agentOf", "sentence": "In October, FDA approved Pfizer's Talzenna (talazoparib) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER- locally advanced or metastatic breast cancer.", "score": 0.983605, "arguments": [{"text": "FDA", "location": [6089, 6092], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "approved", "location": [6093, 6101], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "managerOf", "sentence": "The agency approved Takeda Pharmaceutical and ARIAD Pharmaceuticals ' Alunbrig (brigatinib) in April 2018 for metastatic anaplastic lymphoma kinase (ALK)+ NSCLC that has progressed on or are intolerant to crizotinib.", "score": 0.33139, "arguments": [{"text": "Takeda Pharmaceutical", "location": [1544, 1565], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "agency", "location": [1528, 1534], "entities": [{"type": "Organization", "text": "American Cancer Society"}]}]}, {"type": "partOf", "sentence": "The agency approved Takeda Pharmaceutical and ARIAD Pharmaceuticals ' Alunbrig (brigatinib) in April 2018 for metastatic anaplastic lymphoma kinase (ALK)+ NSCLC that has progressed on or are intolerant to crizotinib.", "score": 0.80159, "arguments": [{"text": "Alunbrig", "location": [1594, 1602], "entities": [{"type": "Organization", "text": "Alunbrig", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "ARIAD Pharmaceuticals", "location": [1570, 1591], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "In May 2018, the agency granted accelerated approval to Merck & Co. 's Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for patients with previously untreated metastatic non-squamous NSCLC.", "score": 0.698152, "arguments": [{"text": "Keytruda", "location": [1812, 1820], "entities": [{"type": "Organization", "text": "Keytruda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merck & Co.", "location": [1797, 1808], "entities": [{"type": "Organization", "text": "Merck & Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "In August, Merck's Keytruda in combination with pemetrexed and platinum as first-line treatment was approved in patients with metastatic-nonsquamous NSCLC with no EGFR or ALK tumor aberrations.", "score": 0.827701, "arguments": [{"text": "Keytruda", "location": [2887, 2895], "entities": [{"type": "Organization", "text": "Keytruda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merck", "location": [2879, 2884], "entities": [{"type": "Organization", "text": "Merck & Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "In October 2018, the agency approved Merck's Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous NSCLC.", "score": 0.758307, "arguments": [{"text": "Keytruda", "location": [3276, 3284], "entities": [{"type": "Organization", "text": "Keytruda", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merck", "location": [3268, 3273], "entities": [{"type": "Organization", "text": "Merck & Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Also in May, FDA approved Novartis ' Zykadia (ceritinib) for metastatic NSCLC whose tumors are ALK+.", "score": 0.84184, "arguments": [{"text": "May", "location": [1962, 1965], "entities": [{"type": "Date", "text": "May"}]}, {"text": "approved", "location": [1971, 1979], "entities": [{"type": "EventCommunication", "text": "approved"}]}]}, {"type": "partOf", "sentence": "In January 2018, Boehringer Ingelheim 's Gilotrif (afatinib) was approved for a broadened indication in first-line treatment for metastatic NSCLC whose tumors have non-resistant EGFR mutations detected by an FDA-approved test.", "score": 0.803271, "arguments": [{"text": "Gilotrif", "location": [2279, 2287], "entities": [{"type": "Organization", "text": "Gilotrif", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Boehringer Ingelheim", "location": [2255, 2275], "entities": [{"type": "Organization", "text": "Boehringer Ingelheim", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "metastatic epidermal growth factor receptor", "sentiment": {"score": -0.619954, "label": "negative"}, "relevance": 0.63286, "count": 1}, {"text": "Common Types of Cancer", "sentiment": {"score": -0.957435, "label": "negative"}, "relevance": 0.600554, "count": 1}, {"text": "FDA", "sentiment": {"score": -0.767524, "label": "negative"}, "relevance": 0.595581, "count": 16}, {"text": "first-line treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589882, "count": 3}, {"text": "Drug Approvals", "sentiment": {"score": -0.957435, "label": "negative"}, "relevance": 0.58551, "count": 1}, {"text": "agency", "sentiment": {"score": -0.78338, "label": "negative"}, "relevance": 0.572504, "count": 8}, {"text": "breast cancer", "sentiment": {"score": -0.991581, "label": "negative"}, "relevance": 0.569118, "count": 2}, {"text": "American Cancer Society", "sentiment": {"score": -0.957435, "label": "negative"}, "relevance": 0.56828, "count": 1}, {"text": "AstraZeneca \u2019 s Tagrisso", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55285, "count": 1}, {"text": "treatments", "sentiment": {"score": 0.393914, "label": "positive"}, "relevance": 0.55139, "count": 1}, {"text": "Drug Administration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550247, "count": 1}, {"text": "metastatic anaplastic lymphoma kinase", "sentiment": {"score": -0.752259, "label": "negative"}, "relevance": 0.549773, "count": 1}, {"text": "NSCLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54658, "count": 1}, {"text": "line treatment", "sentiment": {"score": -0.876495, "label": "negative"}, "relevance": 0.54627, "count": 1}, {"text": "combination", "sentiment": {"score": -0.820499, "label": "negative"}, "relevance": 0.545601, "count": 10}, {"text": "patients", "sentiment": {"score": -0.865513, "label": "negative"}, "relevance": 0.543495, "count": 8}, {"text": "cancer", "sentiment": {"score": -0.957435, "label": "negative"}, "relevance": 0.54256, "count": 1}, {"text": "small cell lung cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540648, "count": 1}, {"text": "lung cancer", "sentiment": {"score": -0.991581, "label": "negative"}, "relevance": 0.540646, "count": 1}, {"text": "L858R mutations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537411, "count": 2}, {"text": "HER2", "sentiment": {"score": -0.857091, "label": "negative"}, "relevance": 0.536036, "count": 7}, {"text": "aromatase inhibitor", "sentiment": {"score": -0.865359, "label": "negative"}, "relevance": 0.535332, "count": 4}, {"text": "T790M mutation-positive NSCLC", "sentiment": {"score": -0.619954, "label": "negative"}, "relevance": 0.534901, "count": 1}, {"text": "biopharma companies", "sentiment": {"score": 0.393914, "label": "positive"}, "relevance": 0.534739, "count": 1}, {"text": "ongoing battle", "sentiment": {"score": -0.876495, "label": "negative"}, "relevance": 0.534055, "count": 1}, {"text": "Breast Cancer", "sentiment": {"score": -0.887905, "label": "negative"}, "relevance": 0.534006, "count": 1}, {"text": "approvals", "sentiment": {"score": -0.876495, "label": "negative"}, "relevance": 0.533582, "count": 1}, {"text": "EGFR tyrosine kinase inhibitor", "sentiment": {"score": -0.619954, "label": "negative"}, "relevance": 0.530635, "count": 1}, {"text": "EGFR", "sentiment": {"score": -0.619954, "label": "negative"}, "relevance": 0.530116, "count": 2}, {"text": "September", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52991, "count": 2}, {"text": "much progress biopharma", "sentiment": {"score": 0.782506, "label": "positive"}, "relevance": 0.528908, "count": 1}, {"text": "companies", "sentiment": {"score": -0.876495, "label": "negative"}, "relevance": 0.528676, "count": 1}, {"text": "exon", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528673, "count": 3}, {"text": "specific exon", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528321, "count": 1}, {"text": "thing", "sentiment": {"score": -0.876495, "label": "negative"}, "relevance": 0.528288, "count": 1}, {"text": "March", "sentiment": {"score": -0.76681, "label": "negative"}, "relevance": 0.526736, "count": 2}, {"text": "Novartis \u2019 Zykadia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526434, "count": 1}, {"text": "metastatic breast cancer", "sentiment": {"score": -0.863897, "label": "negative"}, "relevance": 0.526084, "count": 7}, {"text": "approval process", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52587, "count": 1}, {"text": "narrower indications", "sentiment": {"score": -0.876495, "label": "negative"}, "relevance": 0.525762, "count": 1}, {"text": "April", "sentiment": {"score": -0.752259, "label": "negative"}, "relevance": 0.52571, "count": 3}, {"text": "generic versions of biologic drugs", "sentiment": {"score": -0.758379, "label": "negative"}, "relevance": 0.525239, "count": 1}, {"text": "October", "sentiment": {"score": -0.807185, "label": "negative"}, "relevance": 0.524971, "count": 2}, {"text": "metastatic NSCLC", "sentiment": {"score": -0.92844, "label": "negative"}, "relevance": 0.524284, "count": 4}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.752259, "label": "negative"}, "relevance": 0.524194, "count": 1}, {"text": "Pfizer \u2019s Vizimpro", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523708, "count": 1}, {"text": "drugs", "sentiment": {"score": -0.876495, "label": "negative"}, "relevance": 0.523685, "count": 3}, {"text": "disease", "sentiment": {"score": -0.844832, "label": "negative"}, "relevance": 0.523284, "count": 3}, {"text": "colorectal cancer", "sentiment": {"score": -0.991581, "label": "negative"}, "relevance": 0.522882, "count": 1}, {"text": "reminder", "sentiment": {"score": 0.782506, "label": "positive"}, "relevance": 0.522469, "count": 1}]}, "extracted_metadata": {"sha1": "54b37420c58e84c853f87fce401f1cc42bceb54d", "filename": "1542607783204.zip-fc4781e0f9a8a226ad26bbbf8af42e7d.xml", "file_type": "json"}, "external_links": ["https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm", "https://www.msn.com/en-us/health/medical/the-20-most-common-types-of-cancer/ss-BBJvekc?ocid=spartanntp#image=1"], "title": "Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years", "forum_title": "New FDA Drug & Device Approvals | BioSpace"}, {"id": "dtFgv46nKQnNQwGTI_weiRNEotrwiJ3yqX94WXTNP9O_Sc95Bp8uGCBA9aTXKmRW", "result_metadata": {"score": 28.869179}, "author": "Trent Williams", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.495347, "label": "negative"}, "text": "Zacks Investment Research", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Insurance", "relevance": 0.837714, "dbpedia_resource": "http://dbpedia.org/resource/Insurance"}], "categories": [{"score": 0.9988, "label": "/finance/investing"}, {"score": 0.9988, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "memberOf", "sentence": "Ovid Therapeutics (OVID) Rating Lowered to Hold at Zacks Investment Research", "score": 0.269462, "arguments": [{"text": "Ovid Therapeutics", "location": [0, 17], "entities": [{"type": "Person", "text": "Ovid Therapeutics"}]}, {"text": "OVID", "location": [19, 23], "entities": [{"type": "Organization", "text": "OVID"}]}]}], "keywords": [{"text": "Ovid Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999985, "count": 1}, {"text": "OVID", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.739113, "count": 1}, {"text": "Rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.663134, "count": 1}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.003029, "count": 1}]}, "crawl_date": "2018-11-18T17:18:35Z", "url": "https://www.com-unik.info/2018/11/18/ovid-therapeutics-ovid-rating-lowered-to-hold-at-zacks-investment-research.html", "host": "com-unik.info", "text": "It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "main_image_url": "https://www.marketbeat.com/logos/ovid-therapeutics-inc-logo.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-18T16:17:00Z", "enriched_text": {"entities": [{"count": 17, "sentiment": {"score": -0.0395027, "label": "negative"}, "text": "Ovid Therapeutics Inc.", "relevance": 0.950237, "type": "Company"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "OVID", "relevance": 0.416261, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Get Ovid Therapeutics", "relevance": 0.353899, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics Company", "relevance": 0.35157, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics Daily", "relevance": 0.298538, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ovid Therapeutics", "relevance": 0.292751, "type": "PrintMedia"}, {"count": 2, "sentiment": {"score": -0.324064, "label": "negative"}, "text": "Zacks Investment Research", "relevance": 0.143874, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.607986, "label": "negative"}, "text": "Angelman syndrome", "relevance": 0.132499, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acadian Asset Management LLC", "relevance": 0.119789, "type": "Company", "disambiguation": {"subtype": [], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}, {"count": 1, "sentiment": {"score": -0.433046, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.114395, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.396221, "label": "positive"}, "text": "Zacks", "relevance": 0.112917, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.700724, "label": "negative"}, "text": "Fragile X syndrome", "relevance": 0.112906, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}, {"count": 2, "sentiment": {"score": -0.42003, "label": "negative"}, "text": "United States", "relevance": 0.101299, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Trent Williams", "relevance": 0.0993578, "type": "Person", "disambiguation": {"subtype": ["FootballPlayer"], "name": "Trent Williams", "dbpedia_resource": "http://dbpedia.org/resource/Trent_Williams"}}, {"count": 2, "sentiment": {"score": -0.335943, "label": "negative"}, "text": "JPMorgan Chase & Co.", "relevance": 0.0973631, "type": "Company", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}, {"count": 1, "sentiment": {"score": 0.493628, "label": "positive"}, "text": "Piper Jaffray Companies", "relevance": 0.0945937, "type": "Company", "disambiguation": {"subtype": [], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.085349, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.0836408, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cantor Fitzgerald", "relevance": 0.0814155, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ValuEngine", "relevance": 0.0811219, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.206115, "label": "positive"}, "text": "BidaskClub", "relevance": 0.0771576, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Millennium Management LLC", "relevance": 0.0770065, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dimensional Fund Advisors LP", "relevance": 0.0749375, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MarketBeat.com", "relevance": 0.0686068, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "12-month", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$113.16 million", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$132,000", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$154,000", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$233,000", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$420,000", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$444,000", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$12.44", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$17.58", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$20.00", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "109.8%", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "165.4%", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "31.09%", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "482.8%", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.07", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.08", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.53", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.60", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.16", "relevance": 0.0686068, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.59", "relevance": 0.0686068, "type": "Quantity"}], "sentiment": {"document": {"score": -0.296075, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "by Trent Williams", "keywords": [{"text": "Trent Williams"}], "entities": [{"type": "Person", "text": "Trent Williams", "disambiguation": {"subtype": ["FootballPlayer"], "name": "Trent Williams", "dbpedia_resource": "http://dbpedia.org/resource/Trent_Williams"}}]}, "sentence": "Posted by Trent Williams on Nov 18th, 2018 // No Comments", "object": {"text": "// No Comments", "keywords": [{"text": "Comments"}]}, "action": {"verb": {"text": "Posted", "tense": "past"}, "text": "Posted", "normalized": "Posted"}}, {"subject": {"text": "by Zacks Investment Research from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research note issued to investors on Friday", "keywords": [{"text": "Zacks Investment Research"}, {"text": "research note"}, {"text": "Friday"}, {"text": "investors"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "sentence": " Ovid Therapeutics (NASDAQ:OVID) was downgraded by Zacks Investment Research from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research note issued to investors on Friday.", "object": {"text": "OVID)"}, "action": {"verb": {"text": "downgrade", "tense": "past"}, "text": "was downgraded", "normalized": "be downgrade"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Ovid Therapeutics (NASDAQ:OVID) was downgraded by Zacks Investment Research from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research note issued to investors on Friday.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " According to Zacks, \u201cOvid Therapeutics Inc. is a biopharmaceutical company.", "object": {"text": "a biopharmaceutical company", "keywords": [{"text": "biopharmaceutical company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "product pipeline", "keywords": [{"text": "product pipeline"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The company\u2019s product pipeline", "keywords": [{"text": "product pipeline"}, {"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome", "keywords": [{"text": "Angelman syndrome"}, {"text": "Fragile X syndrome"}, {"text": "development"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Angelman syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"type": "HealthCondition", "text": "Fragile X syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consists", "normalized": "consist"}}, {"subject": {"text": "The company\u2019s product pipeline consists of OV101,", "keywords": [{"text": "product pipeline"}, {"text": "company"}]}, "sentence": " The company\u2019s product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome.", "object": {"text": "in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome", "keywords": [{"text": "Angelman syndrome"}, {"text": "Fragile X syndrome"}, {"text": "development"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Angelman syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Angelman syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Angelman_syndrome"}}, {"type": "HealthCondition", "text": "Fragile X syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor", "Disease"], "name": "Fragile X syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Fragile_X_syndrome"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "object": {"text": "in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies", "keywords": [{"text": "rare epileptic encephalopathies"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "collaboration"}, {"text": "Limited"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "It"}, "sentence": " It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "object": {"text": "OV935", "keywords": [{"text": "OV935"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics Inc. is based in New York, United States.", "object": {"text": "based in New York, United States", "keywords": [{"text": "New York"}, {"text": "United States"}], "entities": [{"type": "Location", "text": "New York", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Ovid Therapeutics Inc.", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics Inc. is based in New York, United States.", "action": {"verb": {"text": "base", "tense": "past"}, "text": "is based", "normalized": "be base"}}, {"subject": {"text": "OVID", "entities": [{"type": "Organization", "text": "OVID"}]}, "sentence": " OVID has been the subject of a number of other reports.", "object": {"text": "been the subject of a number of other reports", "keywords": [{"text": "subject"}, {"text": "number"}, {"text": "reports"}], "entities": [{"type": "Organization", "text": "OVID"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $20.00 price objective on shares of Ovid Therapeutics and gave the company a \u201cbuy\u201d rating in a research report on Sunday, August 12th.", "object": {"text": "a $20.00 price objective", "keywords": [{"text": "price objective"}], "entities": [{"type": "Quantity", "text": "$20.00"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $20.00 price objective on shares of Ovid Therapeutics and gave the company a \u201cbuy\u201d rating in a research report on Sunday, August 12th.", "object": {"text": "a \u201cbuy\u201d rating in a research report", "keywords": [{"text": "research report"}, {"text": "buy"}, {"text": "rating"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "gave", "normalized": "give"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}], "entities": [{"type": "Company", "text": "ValuEngine"}]}, "sentence": " ValuEngine cut shares of Ovid Therapeutics from a \u201chold\u201d rating to a \u201csell\u201d rating in a research report on Tuesday, August 14th.", "object": {"text": "shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " ValuEngine cut shares of Ovid Therapeutics from a \u201chold\u201d rating to a \u201csell\u201d rating in a research report on Tuesday, August 14th.", "object": {"text": "to a \u201csell\u201d rating in a research report on Tuesday, August 14th", "keywords": [{"text": "research report"}, {"text": "Tuesday"}, {"text": "sell"}, {"text": "rating"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Cantor Fitzgerald", "keywords": [{"text": "Cantor Fitzgerald"}], "entities": [{"type": "Person", "text": "Cantor Fitzgerald"}]}, "sentence": " Cantor Fitzgerald assumed coverage on shares of Ovid Therapeutics in a research report on Wednesday.", "object": {"text": "coverage on shares of Ovid Therapeutics in a research report on Wednesday", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "research report"}, {"text": "Wednesday"}, {"text": "coverage"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "assume", "tense": "past"}, "text": "assumed", "normalized": "assume"}}, {"subject": {"text": "They"}, "sentence": " They set an \u201coverweight\u201d rating on the stock.", "object": {"text": "an \u201coverweight\u201d rating on the stock", "keywords": [{"text": "overweight"}, {"text": "rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "BidaskClub", "keywords": [{"text": "BidaskClub"}], "entities": [{"type": "Company", "text": "BidaskClub"}]}, "sentence": " Finally, BidaskClub cut shares of Ovid Therapeutics from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research report on Friday, July 27th.", "object": {"text": "shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Finally, BidaskClub cut shares of Ovid Therapeutics from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research report on Friday, July 27th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Three equities research analysts", "keywords": [{"text": "equities research analysts"}]}, "sentence": " Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "rate", "tense": "past"}, "text": "have rated", "normalized": "have rate"}}, {"subject": {"text": "four"}, "sentence": " Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock.", "object": {"text": "issued a buy rating to the stock", "keywords": [{"text": "buy rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "four"}, "sentence": " Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock.", "object": {"text": "a buy rating to the stock", "keywords": [{"text": "buy rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "have issued", "normalized": "have issue"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has an average rating of \u201cBuy\u201d and a consensus price target of $17.58.", "object": {"text": "an average rating of \u201cBuy\u201d and a consensus price target of $17.58", "keywords": [{"text": "consensus price target"}, {"text": "average rating"}], "entities": [{"type": "Quantity", "text": "$17.58"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "OVID", "entities": [{"type": "Organization", "text": "OVID"}]}, "sentence": " NASDAQ:OVID traded up $0.08 on Friday, reaching $4.59.", "action": {"verb": {"text": "trade", "tense": "past"}, "text": "traded", "normalized": "trade"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock had a trading volume of 23,911 shares, compared to its average volume of 44,779.", "object": {"text": "a trading volume of 23,911 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "a trading volume of 23,911 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "sentence": " The stock had a trading volume of 23,911 shares, compared to its average volume of 44,779.", "object": {"text": "to its average volume of 44,779", "keywords": [{"text": "average volume"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market cap of $113.16 million, a P/E ratio of -1.37 and a beta of 1.15.", "object": {"text": "a market cap of $113.16 million, a P/E ratio of -1.37 and a beta of 1.15", "keywords": [{"text": "market cap"}, {"text": "P/E ratio"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$113.16 million"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "sentence": " Ovid Therapeutics has a 12-month low of $4.16 and a 12-month high of $12.44.", "object": {"text": "a 12-month low of $4.16 and a 12-month high of $12.44", "keywords": [{"text": "12-month high"}], "entities": [{"type": "Quantity", "text": "12-month"}, {"type": "Quantity", "text": "$12.44"}, {"type": "Quantity", "text": "$4.16"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "its quarterly earnings data", "keywords": [{"text": "quarterly earnings data"}]}, "sentence": " Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Thursday, November 8th.", "action": {"verb": {"text": "post", "tense": "past"}, "text": "posted", "normalized": "post"}}, {"subject": {"text": "analysts", "keywords": [{"text": "analysts"}]}, "sentence": " On average, analysts predict that Ovid Therapeutics will post -2.1 earnings per share for the current year.", "object": {"text": "that Ovid Therapeutics will post -2.1 earnings per share for the current year", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "predict", "tense": "present"}, "text": "predict", "normalized": "predict"}}, {"subject": {"text": "Several hedge funds", "keywords": [{"text": "hedge funds"}], "entities": []}, "sentence": " Several hedge funds have recently modified their holdings of OVID.", "object": {"text": "recently modified their holdings of OVID", "keywords": [{"text": "OVID"}, {"text": "holdings"}], "entities": [{"type": "Organization", "text": "OVID"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Several hedge funds", "keywords": [{"text": "hedge funds"}], "entities": []}, "sentence": " Several hedge funds have recently modified their holdings of OVID.", "object": {"text": "their holdings of OVID", "keywords": [{"text": "OVID"}, {"text": "holdings"}], "entities": [{"type": "Organization", "text": "OVID"}]}, "action": {"verb": {"text": "modify", "tense": "past"}, "text": "modified", "normalized": "modify"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System lifted its position in shares of Ovid Therapeutics by 109.8% during the first quarter.", "object": {"text": "its position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter.", "object": {"text": "18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$132,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter.", "object": {"text": "stock worth $132,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$132,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "California State Teachers Retirement System", "keywords": [{"text": "State Teachers Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}]}, "sentence": " California State Teachers Retirement System now owns 18,676 shares of the company\u2019s stock worth $132,000 after purchasing an additional 9,776 shares during the last quarter.", "object": {"text": "an additional 9,776 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC lifted its position in shares of Ovid Therapeutics by 165.4% during the second quarter.", "object": {"text": "its position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the last quarter.", "object": {"text": "19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$154,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the last quarter.", "object": {"text": "stock worth $154,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$154,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Acadian Asset Management LLC", "keywords": [{"text": "Acadian Asset Management"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Acadian Asset Management LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Acadian Asset Management", "dbpedia_resource": "http://dbpedia.org/resource/Acadian_Asset_Management"}}]}, "sentence": " Acadian Asset Management LLC now owns 19,729 shares of the company\u2019s stock worth $154,000 after purchasing an additional 12,294 shares during the last quarter.", "object": {"text": "an additional 12,294 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. lifted its position in shares of Ovid Therapeutics by 482.8% during the first quarter.", "object": {"text": "its position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. now owns 33,006 shares of the company\u2019s stock worth $233,000 after purchasing an additional 27,343 shares during the last quarter.", "object": {"text": "33,006 shares of the company\u2019s stock worth $233,000 after purchasing an additional 27,343 shares during the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$233,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " JPMorgan Chase & Co. now owns 33,006 shares of the company\u2019s stock worth $233,000 after purchasing an additional 27,343 shares during the last quarter.", "object": {"text": "stock worth $233,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$233,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "JPMorgan Chase & Co.", "keywords": [{"text": "JPMorgan Chase"}], "entities": [{"type": "Company", "text": "JPMorgan Chase & Co.", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}]}, "sentence": " JPMorgan Chase & Co. now owns 33,006 shares of the company\u2019s stock worth $233,000 after purchasing an additional 27,343 shares during the last quarter.", "object": {"text": "an additional 27,343 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Millennium Management LLC", "keywords": [{"text": "Millennium Management LLC"}], "entities": [{"type": "Company", "text": "Millennium Management LLC"}]}, "sentence": " Millennium Management LLC bought a new position in shares of Ovid Therapeutics during the first quarter worth about $420,000.", "object": {"text": "a new position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "new position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "buy", "tense": "past"}, "text": "bought", "normalized": "buy"}}, {"subject": {"text": "Dimensional Fund Advisors LP", "keywords": [{"text": "Dimensional Fund Advisors"}, {"text": "LP"}], "entities": [{"type": "Company", "text": "Dimensional Fund Advisors LP"}]}, "sentence": " Finally, Dimensional Fund Advisors LP bought a new position in shares of Ovid Therapeutics during the third quarter worth about $444,000. 31.09% of the stock is currently owned by institutional investors and hedge funds.", "object": {"text": "a new position in shares of Ovid Therapeutics", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "new position"}, {"text": "shares"}], "entities": [{"type": "PrintMedia", "text": "Ovid Therapeutics Inc."}]}, "action": {"verb": {"text": "buy", "tense": "past"}, "text": "bought", "normalized": "buy"}}, {"subject": {"text": "the third quarter worth about $444,000. 31.09% of the stock", "keywords": [{"text": "quarter worth"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$444,000"}, {"type": "Quantity", "text": "31.09"}]}, "sentence": " Finally, Dimensional Fund Advisors LP bought a new position in shares of Ovid Therapeutics during the third quarter worth about $444,000. 31.09% of the stock is currently owned by institutional investors and hedge funds.", "object": {"text": "currently owned by institutional investors and hedge funds", "keywords": [{"text": "institutional investors"}, {"text": "funds"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by institutional investors and hedge funds", "keywords": [{"text": "institutional investors"}, {"text": "funds"}], "entities": []}, "sentence": " Finally, Dimensional Fund Advisors LP bought a new position in shares of Ovid Therapeutics during the third quarter worth about $444,000. 31.09% of the stock is currently owned by institutional investors and hedge funds.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "owned", "normalized": "own"}}, {"subject": {"text": "Ovid Therapeutics Inc, a biopharmaceutical company,", "keywords": [{"text": "Ovid Therapeutics"}, {"text": "biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Ovid Therapeutics Inc"}]}, "sentence": " Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.", "object": {"text": "impactful medicines for patients and families", "keywords": [{"text": "impactful medicines"}, {"text": "patients"}, {"text": "families"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}], "concepts": [{"text": "Neurological disorders", "relevance": 0.91988, "dbpedia_resource": "http://dbpedia.org/resource/Neurological_disorders"}, {"text": "Syndromes", "relevance": 0.86261, "dbpedia_resource": "http://dbpedia.org/resource/Syndromes"}, {"text": "Financial services", "relevance": 0.835256, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services"}, {"text": "Clinical trial", "relevance": 0.79447, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Stock market", "relevance": 0.786509, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "JPMorgan Chase", "relevance": 0.767797, "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}, {"text": "Stock", "relevance": 0.72493, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.710013, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Piper Jaffray", "relevance": 0.691932, "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}, {"text": "Share", "relevance": 0.614169, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}], "categories": [{"score": 0.799419, "label": "/finance/investing"}, {"score": 0.799419, "label": "/finance/investing/beginning investing"}, {"score": 0.716839, "label": "/health and fitness/disease/autism and pdd"}], "relations": [{"type": "agentOf", "sentence": "Posted by Trent Williams on Nov 18th, 2018 // No Comments Ovid Therapeutics (NASDAQ:OVID) was downgraded by Zacks Investment Research from a \"buy\" rating to a \"hold\" rating in a research note issued to investors on Friday.", "score": 0.946019, "arguments": [{"text": "Trent Williams", "location": [10, 24], "entities": [{"type": "Person", "text": "Trent Williams"}]}, {"text": "Posted", "location": [0, 6], "entities": [{"type": "EventCommunication", "text": "Posted"}]}]}, {"type": "partOf", "sentence": "California State Teachers Retirement System lifted its position in shares of Ovid Therapeutics by 109.8% during the first quarter.", "score": 0.452236, "arguments": [{"text": "its", "location": [2372, 2375], "entities": [{"type": "Organization", "text": "State Teachers Retirement System"}]}, {"text": "Ovid Therapeutics", "location": [2398, 2415], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}]}, {"type": "agentOf", "sentence": "Millennium Management LLC bought a new position in shares of Ovid Therapeutics during the first quarter worth about $420,000.", "score": 0.925148, "arguments": [{"text": "Millennium Management LLC", "location": [3163, 3188], "entities": [{"type": "Organization", "text": "Millennium Management LLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "bought", "location": [3189, 3195], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "affectedBy", "sentence": "Millennium Management LLC bought a new position in shares of Ovid Therapeutics during the first quarter worth about $420,000.", "score": 0.595042, "arguments": [{"text": "Ovid Therapeutics", "location": [3224, 3241], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}, {"text": "bought", "location": [3189, 3195], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "affectedBy", "sentence": "Finally, Dimensional Fund Advisors LP bought a new position in shares of Ovid Therapeutics during the third quarter worth about $444,000.", "score": 0.595042, "arguments": [{"text": "Ovid Therapeutics", "location": [3362, 3379], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}, {"text": "bought", "location": [3327, 3333], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "agentOf", "sentence": "Finally, Dimensional Fund Advisors LP bought a new position in shares of Ovid Therapeutics during the third quarter worth about $444,000.", "score": 0.926248, "arguments": [{"text": "Dimensional Fund Advisors LP", "location": [3298, 3326], "entities": [{"type": "Organization", "text": "Dimensional Fund Advisors LP", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "bought", "location": [3327, 3333], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "hasAttribute", "sentence": "Ovid Therapeutics Company Profile Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.", "score": 0.584058, "arguments": [{"text": "families", "location": [3642, 3650], "entities": [{"type": "Person", "text": "families"}]}, {"text": "neurological disorders", "location": [3656, 3678], "entities": [{"type": "HealthCondition", "text": "neurological disorders"}]}]}, {"type": "partOfMany", "sentence": "The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.", "score": 0.458802, "arguments": [{"text": "I", "location": [3840, 3841], "entities": [{"type": "Person", "text": "I"}]}, {"text": "adolescents", "location": [3861, 3872], "entities": [{"type": "Person", "text": "adolescents"}]}]}, {"type": "partOf", "sentence": "Get a free copy of the Zacks research report on Ovid Therapeutics (OVID) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter . \u00ab", "score": 0.555841, "arguments": [{"text": "Ovid Therapeutics", "location": [3967, 3984], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}, {"text": "Zacks", "location": [3942, 3947], "entities": [{"type": "Organization", "text": "Zacks Investment Research", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Get a free copy of the Zacks research report on Ovid Therapeutics (OVID) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter . \u00ab", "score": 0.722813, "arguments": [{"text": "OVID", "location": [3986, 3990], "entities": [{"type": "Person", "text": "OVID"}]}, {"text": "Ovid Therapeutics", "location": [3967, 3984], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}]}, {"type": "partOf", "sentence": "Get a free copy of the Zacks research report on Ovid Therapeutics (OVID) For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter . \u00ab", "score": 0.526306, "arguments": [{"text": "Zacks.com Receive News & Ratings", "location": [4076, 4108], "entities": [{"type": "Organization", "text": "Zacks.com Receive News & Ratings"}]}, {"text": "Ovid Therapeutics Daily", "location": [4113, 4136], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}]}, {"type": "timeOf", "sentence": "Posted by Trent Williams on Nov 18th, 2018 // No Comments Ovid Therapeutics (NASDAQ:OVID) was downgraded by Zacks Investment Research from a \"buy\" rating to a \"hold\" rating in a research note issued to investors on Friday.", "score": 0.923896, "arguments": [{"text": "Nov 18th, 2018", "location": [28, 42], "entities": [{"type": "Date", "text": "Nov 18th, 2018"}]}, {"text": "Posted", "location": [0, 6], "entities": [{"type": "EventCommunication", "text": "Posted"}]}]}, {"type": "partOf", "sentence": "Posted by Trent Williams on Nov 18th, 2018 // No Comments Ovid Therapeutics (NASDAQ:OVID) was downgraded by Zacks Investment Research from a \"buy\" rating to a \"hold\" rating in a research note issued to investors on Friday.", "score": 0.317966, "arguments": [{"text": "Zacks Investment Research", "location": [108, 133], "entities": [{"type": "Organization", "text": "Zacks Investment Research", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Ovid Therapeutics", "location": [58, 75], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}]}, {"type": "hasAttribute", "sentence": "It engaged in developing therapies for patients with rare neurological disorders.", "score": 0.892415, "arguments": [{"text": "patients", "location": [338, 346], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neurological disorders", "location": [357, 379], "entities": [{"type": "HealthCondition", "text": "neurological disorders"}]}]}, {"type": "participantIn", "sentence": "It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.", "score": 0.915883, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [593, 630], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "collaboration", "location": [574, 587], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "basedIn", "sentence": "Ovid Therapeutics Inc. is based in New York, United States.", "score": 0.935425, "arguments": [{"text": "Ovid Therapeutics Inc.", "location": [685, 707], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}, {"text": "New York", "location": [720, 728], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}]}, {"type": "partOf", "sentence": "Finally, BidaskClub cut shares of Ovid Therapeutics from a \"buy\" rating to a \"hold\" rating in a research report on Friday, July 27th.", "score": 0.406135, "arguments": [{"text": "Ovid Therapeutics", "location": [1308, 1325], "entities": [{"type": "Organization", "text": "Ovid Therapeutics Company Profile\nOvid Therapeutics Inc"}]}, {"text": "BidaskClub", "location": [1283, 1293], "entities": [{"type": "Organization", "text": "State Teachers Retirement System"}]}]}, {"type": "agentOf", "sentence": "The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.07.", "score": 0.993814, "arguments": [{"text": "company", "location": [2026, 2033], "entities": [{"type": "Organization", "text": "State Teachers Retirement System"}]}, {"text": "reported", "location": [2034, 2042], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "partOfMany", "sentence": "Several hedge funds have recently modified their holdings of OVID.", "score": 0.590813, "arguments": [{"text": "OVID", "location": [2315, 2319], "entities": [{"type": "Person", "text": "OVID"}]}, {"text": "their", "location": [2297, 2302], "entities": [{"type": "Person", "text": "their"}]}]}], "keywords": [{"text": "Ovid Therapeutics Inc.", "sentiment": {"score": -0.595398, "label": "negative"}, "relevance": 0.799045, "count": 2}, {"text": "biopharmaceutical company", "sentiment": {"score": -0.571438, "label": "negative"}, "relevance": 0.718748, "count": 2}, {"text": "shares of Ovid Therapeutics", "sentiment": {"score": 0.621652, "mixed": "1", "label": "positive"}, "relevance": 0.698484, "count": 8}, {"text": "OVID", "sentiment": {"score": -0.269318, "mixed": "1", "label": "negative"}, "relevance": 0.664295, "count": 5}, {"text": "Zacks Investment Research", "sentiment": {"score": 0.554818, "mixed": "1", "label": "positive"}, "relevance": 0.619892, "count": 2}, {"text": "JPMorgan Chase", "sentiment": {"score": -0.579592, "label": "negative"}, "relevance": 0.607772, "count": 2}, {"text": "ValuEngine cut shares of Ovid Therapeutics", "sentiment": {"score": -0.620198, "label": "negative"}, "relevance": 0.607438, "count": 1}, {"text": "Ovid Therapeutics alerts", "sentiment": {"score": -0.595398, "label": "negative"}, "relevance": 0.60283, "count": 1}, {"text": "Acadian Asset Management LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.600004, "count": 2}, {"text": "company\u2019s product pipeline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598699, "count": 1}, {"text": "Cantor Fitzgerald", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576512, "count": 1}, {"text": "stock", "sentiment": {"score": 0.306804, "mixed": "1", "label": "positive"}, "relevance": 0.567509, "count": 9}, {"text": "United States", "sentiment": {"score": -0.585914, "label": "negative"}, "relevance": 0.566824, "count": 2}, {"text": "average rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561046, "count": 1}, {"text": "hedge funds", "sentiment": {"score": -0.571438, "label": "negative"}, "relevance": 0.560783, "count": 2}, {"text": "California State Teachers Retirement System", "sentiment": {"score": -0.263316, "label": "negative"}, "relevance": 0.557885, "count": 2}, {"text": "company", "sentiment": {"score": 0.328077, "mixed": "1", "label": "positive"}, "relevance": 0.556228, "count": 4}, {"text": "Piper Jaffray Companies", "sentiment": {"score": 0.788165, "label": "positive"}, "relevance": 0.55463, "count": 1}, {"text": "research report", "sentiment": {"score": 0.288764, "mixed": "1", "label": "positive"}, "relevance": 0.554121, "count": 4}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550142, "count": 1}, {"text": "shares", "sentiment": {"score": 0.311564, "mixed": "1", "label": "positive"}, "relevance": 0.547272, "count": 4}, {"text": "email address", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.544778, "count": 1}, {"text": "clinical trial", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.544492, "count": 2}, {"text": "position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543126, "count": 3}, {"text": "related companies", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.540836, "count": 1}, {"text": "share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539429, "count": 2}, {"text": "equities research analysts", "sentiment": {"score": 0.500223, "label": "positive"}, "relevance": 0.536598, "count": 1}, {"text": "NASDAQ", "sentiment": {"score": -0.544965, "label": "negative"}, "relevance": 0.533918, "count": 3}, {"text": "hold rating", "sentiment": {"score": 0.500223, "label": "positive"}, "relevance": 0.530395, "count": 1}, {"text": "com Receive News", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.529167, "count": 1}, {"text": "institutional investors", "sentiment": {"score": 0.390217, "mixed": "1", "label": "positive"}, "relevance": 0.527182, "count": 1}, {"text": "analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527111, "count": 1}, {"text": "Fragile X syndrome", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525884, "count": 1}, {"text": "Co.", "sentiment": {"score": -0.579592, "label": "negative"}, "relevance": 0.52332, "count": 2}, {"text": "earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521723, "count": 2}, {"text": "OV101", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.521398, "count": 2}, {"text": "Ratings", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.52012, "count": 1}, {"text": "angelman syndrome", "sentiment": {"score": -0.289765, "mixed": "1", "label": "negative"}, "relevance": 0.519989, "count": 2}, {"text": "research note", "sentiment": {"score": -0.544965, "label": "negative"}, "relevance": 0.519285, "count": 1}, {"text": "Phase", "sentiment": {"score": -0.576249, "label": "negative"}, "relevance": 0.518052, "count": 2}, {"text": "collaboration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516136, "count": 1}, {"text": "current year", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515645, "count": 1}, {"text": "information", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.515598, "count": 1}, {"text": "quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514126, "count": 1}, {"text": "subject of a number of other reports", "sentiment": {"score": 0, "mixed": "1", "label": "neutral"}, "relevance": 0.513941, "count": 1}, {"text": "neurological disorders", "sentiment": {"score": -0.574368, "label": "negative"}, "relevance": 0.513829, "count": 1}, {"text": "patients", "sentiment": {"score": -0.574727, "label": "negative"}, "relevance": 0.513526, "count": 2}, {"text": "coverage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513166, "count": 1}, {"text": "second quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512757, "count": 1}, {"text": "fragile X syndrome", "sentiment": {"score": 0.860188, "label": "positive"}, "relevance": 0.511978, "count": 1}]}, "extracted_metadata": {"sha1": "662177b141e60f97559ee58ce5de8356f1d65293", "filename": "1542561515797.zip-c3338ed01511ab46ea8148913492515b.xml", "file_type": "json"}, "external_links": ["https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=OVID", "http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=OVID", "http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "https://www.marketbeat.com/newsletter/default.aspx", "https://www.marketbeat.com/stocks/NASDAQ/OVID/price-target/"], "title": "Ovid Therapeutics (OVID) Rating Lowered to Hold at Zacks Investment Research", "forum_title": "Community Financial News"}, {"id": "8wO0NzZJAkQplVdS8ZaixkcEHqyFlyVGfTjaSXZVxS_tkqSOHNwoNhWNraXuTFuh", "result_metadata": {"score": 25.648785}, "author": "neha", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.602987, "label": "negative"}, "text": "Tokyo", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["City"]}}], "sentiment": {"document": {"score": -0.594976, "label": "negative"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 1, "label": "/finance/investing/stocks"}], "relations": [], "keywords": [{"text": "Tokyo", "sentiment": {"score": -0.594976, "label": "negative"}, "relevance": 0.997761, "count": 1}, {"text": "uncertainty", "sentiment": {"score": -0.594976, "label": "negative"}, "relevance": 0.815614, "count": 1}]}, "crawl_date": "2018-11-18T15:32:21Z", "url": "https://www.siasat.com/news/tokyo-stocks-open-lower-amid-uncertainty-1434384/", "host": "siasat.com", "text": "In Tokyo, Tokyo Electron was down 2.06 percent at 14,730 yen and Takeda Pharmaceutical was down 2.34 percent at 4,304 yen but market heavyweight Fast Retailing, the Uniqlo casual wear operator, was up 0.20 percent at 59,430 yen.", "main_image_url": "https://www.siasat.com/wp-content/uploads/2018/08/SENSEX_ANI.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-18T15:14:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.770631, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": -0.0934698, "label": "negative"}, "text": "Tokyo", "relevance": 0.6908, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo Electron", "relevance": 0.508729, "type": "Company", "disambiguation": {"subtype": [], "name": "Tokyo Electron", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Electron"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.484615, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.426457, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.471943, "label": "negative"}, "text": "US", "relevance": 0.410498, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AFP", "relevance": 0.397556, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Okasan Online Securities", "relevance": 0.395598, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.258778, "label": "positive"}, "text": "Fast Retailing", "relevance": 0.381405, "type": "Company", "disambiguation": {"subtype": [], "name": "Fast Retailing", "dbpedia_resource": "http://dbpedia.org/resource/Fast_Retailing"}}, {"count": 1, "sentiment": {"score": -0.573685, "label": "negative"}, "text": "Brexit", "relevance": 0.357455, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.08 percent", "relevance": 0.357455, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.18 percent", "relevance": 0.357455, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.20 percent", "relevance": 0.357455, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.06 percent", "relevance": 0.357455, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.34 percent", "relevance": 0.357455, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.8 percent", "relevance": 0.357455, "type": "Quantity"}], "sentiment": {"document": {"score": -0.788646, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Tokyo stocks", "keywords": [{"text": "Tokyo stocks"}], "entities": [{"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["AdministrativeDivision", "JapanesePrefecture", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Tokyo", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}}]}, "sentence": " Japan: Tokyo stocks opened lower on Friday in uncertain trade as investors sought fresh clues after US shares surged out of the red.", "action": {"verb": {"text": "open", "tense": "past"}, "text": "opened", "normalized": "open"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " Japan: Tokyo stocks opened lower on Friday in uncertain trade as investors sought fresh clues after US shares surged out of the red.", "object": {"text": "fresh clues", "keywords": [{"text": "fresh clues"}]}, "action": {"verb": {"text": "seek", "tense": "past"}, "text": "sought", "normalized": "seek"}}, {"subject": {"text": "The benchmark Nikkei 225 index", "keywords": [{"text": "benchmark Nikkei"}, {"text": "index"}], "entities": []}, "sentence": " The benchmark Nikkei 225 index was down 0.18 percent or 39.45 points at 21,764.17 in early trade, while the broader Topix index was down 0.08 percent or 1.34 points at 1,637.63.", "object": {"text": "down 0.18 percent or 39.45 points at 21,764.17 in early trade", "keywords": [{"text": "early trade"}, {"text": "percent"}, {"text": "points"}], "entities": [{"type": "Quantity", "text": "0.18 percent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "the broader Topix index", "keywords": [{"text": "broader Topix index"}]}, "sentence": " The benchmark Nikkei 225 index was down 0.18 percent or 39.45 points at 21,764.17 in early trade, while the broader Topix index was down 0.08 percent or 1.34 points at 1,637.63.", "object": {"text": "down 0.08 percent or 1.34 points at 1,637.63", "keywords": [{"text": "percent"}, {"text": "points"}], "entities": [{"type": "Quantity", "text": "0.08 percent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "both indexes", "keywords": [{"text": "indexes"}]}, "sentence": " But both indexes soon edged into positive territory.", "action": {"verb": {"text": "edge", "tense": "past"}, "text": "edged", "normalized": "edge"}}, {"subject": {"text": "Japanese shares", "keywords": [{"text": "Japanese shares"}]}, "sentence": " \u201cJapanese shares may see some buying following a rally in New York, but it is hard to predict a direction during later trade,\u201d Okasan Online Securities said in a commentary.", "object": {"text": "some buying", "keywords": [{"text": "buying"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "may see", "normalized": "may see"}}, {"subject": {"text": "some buying", "keywords": [{"text": "buying"}]}, "sentence": " \u201cJapanese shares may see some buying following a rally in New York, but it is hard to predict a direction during later trade,\u201d Okasan Online Securities said in a commentary.", "object": {"text": "a rally in New York", "keywords": [{"text": "rally"}, {"text": "New York"}], "entities": [{"type": "Location", "text": "New York", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "follow", "tense": "future"}, "text": "following", "normalized": "follow"}}, {"subject": {"text": "Okasan Online Securities", "keywords": [{"text": "Okasan Online Securities"}], "entities": [{"type": "Company", "text": "Okasan Online Securities"}]}, "sentence": " \u201cJapanese shares may see some buying following a rally in New York, but it is hard to predict a direction during later trade,\u201d Okasan Online Securities said in a commentary.", "object": {"text": "Japanese shares may see some buying following a rally in New York, but it is hard to predict a direction during later trade", "keywords": [{"text": "later trade"}, {"text": "Japanese shares"}, {"text": "New York"}, {"text": "rally"}], "entities": [{"type": "Location", "text": "New York", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Short-term investors", "keywords": [{"text": "Short-term investors"}]}, "sentence": " \u201cShort-term investors may dominate the market and prices may show some volatile movement,\u201d it added.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "may dominate", "normalized": "may dominate"}}, {"subject": {"text": "it"}, "sentence": " \u201cShort-term investors may dominate the market and prices may show some volatile movement,\u201d it added.", "object": {"text": "Short-term investors may dominate the market and prices may show some volatile movement", "keywords": [{"text": "Short-term investors"}, {"text": "volatile movement"}, {"text": "market"}, {"text": "prices"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "added", "normalized": "add"}}, {"subject": {"text": "Investors", "keywords": [{"text": "Investors"}]}, "sentence": " Investors are cautious due partly to uncertainty over Brexit, and simmering trade tensions, analysts said.", "object": {"text": "cautious due partly to uncertainty over Brexit", "keywords": [{"text": "uncertainty"}, {"text": "Brexit"}], "entities": [{"type": "Company", "text": "Brexit"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Investors", "keywords": [{"text": "Investors"}]}, "sentence": " Investors are cautious due partly to uncertainty over Brexit, and simmering trade tensions, analysts said.", "object": {"text": "trade tensions", "keywords": [{"text": "trade tensions"}]}, "action": {"verb": {"text": "simmer", "tense": "present"}, "text": "simmering", "normalized": "simmer"}}, {"subject": {"text": "analysts", "keywords": [{"text": "analysts"}]}, "sentence": " Investors are cautious due partly to uncertainty over Brexit, and simmering trade tensions, analysts said.", "object": {"text": "Investors are cautious due partly to uncertainty over Brexit, and simmering trade tensions", "keywords": [{"text": "trade tensions"}, {"text": "uncertainty"}, {"text": "Investors"}, {"text": "Brexit"}], "entities": [{"type": "Company", "text": "Brexit"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The dollar", "keywords": [{"text": "dollar"}]}, "sentence": " The dollar fetched 113.54 yen in early Asian trade, against 113.64 yen in New York.", "action": {"verb": {"text": "fetch", "tense": "past"}, "text": "fetched", "normalized": "fetch"}}, {"subject": {"text": "Tokyo Electron", "keywords": [{"text": "Tokyo Electron"}], "entities": [{"type": "Company", "text": "Tokyo Electron", "disambiguation": {"subtype": [], "name": "Tokyo Electron", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Electron"}}]}, "sentence": " In Tokyo, Tokyo Electron was down 2.06 percent at 14,730 yen and Takeda Pharmaceutical was down 2.34 percent at 4,304 yen but market heavyweight Fast Retailing, the Uniqlo casual wear operator, was up 0.20 percent at 59,430 yen.", "object": {"text": "2.06 percent at 14,730 yen", "keywords": [{"text": "yen"}, {"text": "percent"}], "entities": [{"type": "Quantity", "text": "2.06 percent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "14,730 yen and Takeda Pharmaceutical", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "yen"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " In Tokyo, Tokyo Electron was down 2.06 percent at 14,730 yen and Takeda Pharmaceutical was down 2.34 percent at 4,304 yen but market heavyweight Fast Retailing, the Uniqlo casual wear operator, was up 0.20 percent at 59,430 yen.", "object": {"text": "down 2.34 percent at 4,304 yen", "keywords": [{"text": "yen"}, {"text": "percent"}], "entities": [{"type": "Quantity", "text": "2.34 percent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "market heavyweight Fast Retailing, the Uniqlo casual wear operator,", "keywords": [{"text": "heavyweight Fast Retailing"}, {"text": "casual wear operator"}, {"text": "market"}, {"text": "Uniqlo"}], "entities": [{"type": "Company", "text": "Fast Retailing", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Fast Retailing", "dbpedia_resource": "http://dbpedia.org/resource/Fast_Retailing"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " In Tokyo, Tokyo Electron was down 2.06 percent at 14,730 yen and Takeda Pharmaceutical was down 2.34 percent at 4,304 yen but market heavyweight Fast Retailing, the Uniqlo casual wear operator, was up 0.20 percent at 59,430 yen.", "object": {"text": "0.20 percent at 59,430 yen", "keywords": [{"text": "yen"}, {"text": "percent"}], "entities": [{"type": "Quantity", "text": "0.20 percent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "the benchmark Dow", "keywords": [{"text": "benchmark Dow"}], "entities": []}, "sentence": " In New York, the benchmark Dow rose 0.8 percent, swinging 500 points from the low point of the day to close at 25,290.39.", "object": {"text": "0.8 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "0.8 percent"}]}, "action": {"verb": {"text": "rise", "tense": "past"}, "text": "rose", "normalized": "rise"}}], "concepts": [{"text": "Japan", "relevance": 0.972785, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "Nikkei 225", "relevance": 0.897656, "dbpedia_resource": "http://dbpedia.org/resource/Nikkei_225"}, {"text": "Tokyo Stock Exchange", "relevance": 0.833268, "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}, {"text": "Japanese asset price bubble", "relevance": 0.62587, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_asset_price_bubble"}, {"text": "Stock market index", "relevance": 0.625036, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market_index"}, {"text": "Topix", "relevance": 0.623869, "dbpedia_resource": "http://dbpedia.org/resource/Topix"}, {"text": "Trade", "relevance": 0.602198, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "New York City", "relevance": 0.577454, "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}, {"text": "Stock", "relevance": 0.548958, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Risk", "relevance": 0.527845, "dbpedia_resource": "http://dbpedia.org/resource/Risk"}, {"text": "Economics", "relevance": 0.524043, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Market", "relevance": 0.512346, "dbpedia_resource": "http://dbpedia.org/resource/Market"}, {"text": "Silk Road", "relevance": 0.500744, "dbpedia_resource": "http://dbpedia.org/resource/Silk_Road"}, {"text": "Tokyo", "relevance": 0.482053, "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.472719, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uncertainty", "relevance": 0.471062, "dbpedia_resource": "http://dbpedia.org/resource/Uncertainty"}, {"text": "Index", "relevance": 0.470999, "dbpedia_resource": "http://dbpedia.org/resource/Index"}, {"text": "Japanese diaspora", "relevance": 0.45927, "dbpedia_resource": "http://dbpedia.org/resource/Japanese_diaspora"}, {"text": "Casual", "relevance": 0.458803, "dbpedia_resource": "http://dbpedia.org/resource/Casual"}, {"text": "Dollar", "relevance": 0.45791, "dbpedia_resource": "http://dbpedia.org/resource/Dollar"}], "categories": [{"score": 0.936266, "label": "/finance/investing/stocks"}, {"score": 0.918753, "label": "/finance/investing/beginning investing"}, {"score": 0.888898, "label": "/finance/investing/day trading"}], "relations": [{"type": "residesIn", "sentence": "Click for full image Photo: ANI Japan: Tokyo stocks opened lower on Friday in uncertain trade as investors sought fresh clues after US shares surged out of the red.", "score": 0.520527, "arguments": [{"text": "ANI", "location": [28, 31], "entities": [{"type": "Person", "text": "ANI"}]}, {"text": "Japan", "location": [32, 37], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "\"Japanese shares may see some buying following a rally in New York, but it is hard to predict a direction during later trade,\" Okasan Online Securities said in a commentary.", "score": 0.974328, "arguments": [{"text": "Okasan Online Securities", "location": [523, 547], "entities": [{"type": "Organization", "text": "Okasan Online Securities", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "said", "location": [548, 552], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Investors are cautious due partly to uncertainty over Brexit, and simmering trade tensions, analysts said.", "score": 0.976445, "arguments": [{"text": "analysts", "location": [763, 771], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "said", "location": [772, 776], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "locatedAt", "sentence": "In Tokyo, Tokyo Electron was down 2.06 percent at 14,730 yen and Takeda Pharmaceutical was down 2.34 percent at 4,304 yen but market heavyweight Fast Retailing, the Uniqlo casual wear operator, was up 0.20 percent at 59,430 yen.", "score": 0.983698, "arguments": [{"text": "Tokyo", "location": [865, 870], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo"}]}, {"text": "Tokyo Electron", "location": [872, 886], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo Electron"}]}]}], "keywords": [{"text": "Tokyo stocks", "sentiment": {"score": -0.728612, "label": "negative"}, "relevance": 0.790179, "count": 1}, {"text": "Tokyo", "sentiment": {"score": -0.527801, "label": "negative"}, "relevance": 0.698008, "count": 1}, {"text": "uncertain trade", "sentiment": {"score": -0.728612, "label": "negative"}, "relevance": 0.67618, "count": 1}, {"text": "New York", "sentiment": {"score": -0.763763, "label": "negative"}, "relevance": 0.67208, "count": 3}, {"text": "Short-term investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.628034, "count": 1}, {"text": "investors", "sentiment": {"score": -0.728612, "label": "negative"}, "relevance": 0.627477, "count": 1}, {"text": "yen", "sentiment": {"score": -0.692772, "label": "negative"}, "relevance": 0.612001, "count": 5}, {"text": "Japanese shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.600781, "count": 1}, {"text": "Investors", "sentiment": {"score": -0.881695, "label": "negative"}, "relevance": 0.586037, "count": 1}, {"text": "early trade", "sentiment": {"score": -0.808779, "label": "negative"}, "relevance": 0.584795, "count": 1}, {"text": "dollar", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577164, "count": 1}, {"text": "benchmark Nikkei", "sentiment": {"score": -0.808779, "label": "negative"}, "relevance": 0.575, "count": 1}, {"text": "index", "sentiment": {"score": -0.808779, "label": "negative"}, "relevance": 0.564897, "count": 1}, {"text": "points", "sentiment": {"score": -0.854728, "label": "negative"}, "relevance": 0.558332, "count": 3}, {"text": "Tokyo Electron", "sentiment": {"score": -0.527801, "label": "negative"}, "relevance": 0.554808, "count": 1}, {"text": "market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55392, "count": 1}, {"text": "rally", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544678, "count": 1}, {"text": "indexes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543401, "count": 1}, {"text": "low point of the day", "sentiment": {"score": -0.930877, "label": "negative"}, "relevance": 0.535669, "count": 1}, {"text": "market heavyweight Fast Retailing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532668, "count": 1}, {"text": "direction", "sentiment": {"score": -0.763681, "label": "negative"}, "relevance": 0.529861, "count": 1}, {"text": "uncertainty", "sentiment": {"score": -0.881695, "label": "negative"}, "relevance": 0.529672, "count": 1}, {"text": "US", "sentiment": {"score": -0.728612, "label": "negative"}, "relevance": 0.527755, "count": 1}, {"text": "Brexit", "sentiment": {"score": -0.881695, "label": "negative"}, "relevance": 0.52655, "count": 1}, {"text": "prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522646, "count": 1}, {"text": "Source", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519388, "count": 1}, {"text": "benchmark Dow rose", "sentiment": {"score": -0.930877, "label": "negative"}, "relevance": 0.517354, "count": 1}, {"text": "early Asian trade", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515568, "count": 1}, {"text": "analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511834, "count": 1}, {"text": "commentary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510484, "count": 1}, {"text": "AFP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510484, "count": 1}, {"text": "broader Topix index", "sentiment": {"score": -0.808779, "label": "negative"}, "relevance": 0.509774, "count": 1}, {"text": "later trade", "sentiment": {"score": -0.763681, "label": "negative"}, "relevance": 0.502934, "count": 1}, {"text": "fresh clues", "sentiment": {"score": -0.728612, "label": "negative"}, "relevance": 0.501768, "count": 1}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.527801, "label": "negative"}, "relevance": 0.496072, "count": 1}, {"text": "casual wear operator", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485172, "count": 1}, {"text": "trade tensions", "sentiment": {"score": -0.881695, "label": "negative"}, "relevance": 0.471506, "count": 1}, {"text": "full image Photo", "sentiment": {"score": -0.728612, "label": "negative"}, "relevance": 0.461589, "count": 1}, {"text": "Okasan Online Securities", "sentiment": {"score": -0.763681, "label": "negative"}, "relevance": 0.459897, "count": 1}, {"text": "Friday", "sentiment": {"score": -0.728612, "label": "negative"}, "relevance": 0.454448, "count": 1}, {"text": "buying", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.449431, "count": 1}, {"text": "volatile movement", "sentiment": {"score": -0.881695, "label": "negative"}, "relevance": 0.439536, "count": 1}, {"text": "positive territory", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433786, "count": 1}, {"text": "Uniqlo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43021, "count": 1}]}, "extracted_metadata": {"sha1": "6c630c9aaa4b532ae7281dfb9df5eaa8d9682897", "filename": "1542555141507.zip-6f742e8e3bc06a8719a190915bb6bb0d.xml", "file_type": "json"}, "title": "Tokyo stocks open lower amid uncertainty", "forum_title": "The Siasat Daily"}, {"id": "PrADbca6-3tOVhjdNEkyn_HligoZXuevo1-IZqHhjIneTCqcqFQO19Jd8mf6D_4r", "result_metadata": {"score": 24.87915}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.576212, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.555341, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.536987, "label": "/travel/tourist facilities"}], "relations": [], "keywords": [{"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998597, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.972078, "count": 1}, {"text": "SHIRE PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.916301, "count": 1}, {"text": "RI", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.874487, "count": 1}, {"text": "EPT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.148737, "count": 1}]}, "crawl_date": "2018-11-19T11:21:36Z", "url": "http://www.4-traders.com/SHIRE-9590198/news/Shire-Form-8-5-EPT-RI-SHIRE-PLC-27631739/", "host": "4-traders.com", "text": "Yes - Takeda Pharmaceutical Company Limited 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-19T00:00:00+01:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0.609667, "label": "positive"}, "text": "PRINCIPAL", "relevance": 0.77802, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.774447, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.57131, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "GBP", "relevance": 0.518986, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.430748, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.36972, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.577097, "label": "positive"}, "text": "Morgan Stanley & Co", "relevance": 0.364979, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LLC", "relevance": 0.358254, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Craig Horsley", "relevance": 0.3382, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.305031, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.305031, "type": "EmailAddress"}], "sentiment": {"document": {"score": 0.403713, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC", "keywords": [{"text": "PUBLIC"}]}, "sentence": " PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY", "object": {"text": "DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY", "keywords": [{"text": "EXEMPT PRINCIPAL TRADER"}, {"text": "INTERMEDIARY STATUS"}, {"text": "CLIENT-SERVING CAPACITY"}, {"text": "DISCLOSURE"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}]}, "action": {"verb": {"text": "DEALING", "tense": "present"}, "text": "DEALING", "normalized": "DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "the EPT", "keywords": [{"text": "EPT"}]}, "sentence": " (e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?", "action": {"verb": {"text": "disclose", "tense": "past"}, "text": "disclosed", "normalized": "disclose"}}, {"subject": {"text": "it"}, "sentence": " (e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?", "object": {"text": "today disclosing", "keywords": [{"text": "disclosing"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " (e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?", "object": {"text": "to this offer", "keywords": [{"text": "offer"}]}, "action": {"verb": {"text": "disclose", "tense": "present"}, "text": "disclosing", "normalized": "disclose"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "formal or informal, relating to relevant securities", "keywords": [{"text": "relevant securities"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer", "keywords": [{"text": "exempt principal trader"}, {"text": "disclosure"}, {"text": "person"}, {"text": "party"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}]}, "action": {"verb": {"text": "refrain", "tense": "present"}, "text": "to deal or refrain", "normalized": "to deal or refrain"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "principal trader", "keywords": [{"text": "principal trader"}], "entities": [{"type": "JobTitle", "text": "PRINCIPAL"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:", "object": {"text": "the disclosure and any other person relating to", "keywords": [{"text": "disclosure"}, {"text": "person"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation", "keywords": [{"text": "consultation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Shire plc", "keywords": [{"text": "Shire plc"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " Shire plc published this content on 19 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 19 November 2018 11:03:05 UTC", "object": {"text": "05 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.960899, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.536075, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.502861, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.457079, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.45588, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "United States dollar", "relevance": 0.446007, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.439622, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Put option", "relevance": 0.429795, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock exchange", "relevance": 0.408464, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Stock market", "relevance": 0.399229, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Stock", "relevance": 0.382589, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Pound sterling", "relevance": 0.382477, "dbpedia_resource": "http://dbpedia.org/resource/Pound_sterling"}, {"text": "Unit type", "relevance": 0.373178, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Bond", "relevance": 0.368042, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Security", "relevance": 0.36268, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Grammatical number", "relevance": 0.353871, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Derivative", "relevance": 0.349741, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Arrangement", "relevance": 0.346587, "dbpedia_resource": "http://dbpedia.org/resource/Arrangement"}, {"text": "Moneyness", "relevance": 0.339633, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Euro", "relevance": 0.339584, "dbpedia_resource": "http://dbpedia.org/resource/Euro"}, {"text": "Option contract", "relevance": 0.33819, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "United Kingdom company law", "relevance": 0.338104, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom_company_law"}], "categories": [{"score": 0.930597, "label": "/real estate/buying and selling homes"}, {"score": 0.862518, "label": "/finance/financial news"}, {"score": 0.798704, "label": "/finance/investing/day trading"}], "relations": [{"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchases/sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received ADR PURCHASES 218,728 176.8200 USD 174.8000 USD ADR SALES 217,448 176.7800 USD 175.0000 USD 5p ordinary PURCHASES 34,632 45.7344 GBP 45.6905 GBP 5p ordinary SALES 34,632 45.7303 GBP 45.6905 GBP (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit N/A N/A N/A N/A N/A (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.771309, "arguments": [{"text": "i", "location": [1754, 1755], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [1757, 1764], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state 'none' None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii)", "score": 0.361749, "arguments": [{"text": "person", "location": [3152, 3158], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [3169, 3176], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "agentOf", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state 'none' None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii)", "score": 0.258089, "arguments": [{"text": "party", "location": [3184, 3189], "entities": [{"type": "Organization", "text": "party", "disambiguation": {"subtype": ["Political"]}}]}, {"text": "concert", "location": [3169, 3176], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state 'none' None Date of disclosure: 19 NOVEMBER 2018 Contact name: Craig Horsley Telephone number: +44(141) 245 7736 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.738349, "arguments": [{"text": "Rule 8", "location": [3939, 3945], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [3953, 3957], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [4100, 4124], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [4092, 4097], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [4267, 4272], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [4286, 4313], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "PUBLIC DEALING DISCLOSURE", "sentiment": {"score": -0.890732, "label": "negative"}, "relevance": 0.667444, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.628894, "count": 2}, {"text": "Takeover Code", "sentiment": {"score": -0.890732, "label": "negative"}, "relevance": 0.626014, "count": 1}, {"text": "EXEMPT PRINCIPAL TRADER", "sentiment": {"score": -0.453178, "mixed": "1", "label": "negative"}, "relevance": 0.608774, "count": 2}, {"text": "Name of exempt principal trader", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590408, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.641722, "label": "positive"}, "relevance": 0.586692, "count": 2}, {"text": "Code", "sentiment": {"score": -0.348337, "mixed": "1", "label": "negative"}, "relevance": 0.582425, "count": 4}, {"text": "Takeover Panel", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.579378, "count": 1}, {"text": "DEALINGS", "sentiment": {"score": 0.641722, "label": "positive"}, "relevance": 0.570575, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564703, "count": 1}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.563628, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.559074, "count": 3}, {"text": "Morgan Stanley", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555459, "count": 1}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": -0.531215, "label": "negative"}, "relevance": 0.55411, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.553511, "count": 1}, {"text": "Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549227, "count": 1}, {"text": "dealings", "sentiment": {"score": 0.641929, "label": "positive"}, "relevance": 0.547225, "count": 3}, {"text": "Highest price", "sentiment": {"score": 0.661784, "label": "positive"}, "relevance": 0.547065, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0.642121, "label": "positive"}, "relevance": 0.543314, "count": 2}, {"text": "additional class of relevant security", "sentiment": {"score": 0.641722, "label": "positive"}, "relevance": 0.542284, "count": 2}, {"text": "Lowest price", "sentiment": {"score": 0.661784, "label": "positive"}, "relevance": 0.53918, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.537688, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.641722, "label": "positive"}, "relevance": 0.536907, "count": 2}, {"text": "arrangements", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.535934, "count": 3}, {"text": "Rule", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.535896, "count": 1}, {"text": "unit", "sentiment": {"score": 0.655573, "label": "positive"}, "relevance": 0.533366, "count": 3}, {"text": "INFORMATION", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.532244, "count": 1}, {"text": "Class", "sentiment": {"score": 0.642121, "label": "positive"}, "relevance": 0.531355, "count": 1}, {"text": "option", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.531157, "count": 2}, {"text": "options", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.531157, "count": 2}, {"text": "relation", "sentiment": {"score": -0.531215, "label": "negative"}, "relevance": 0.530908, "count": 2}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530881, "count": 1}, {"text": "FORM", "sentiment": {"score": -0.890732, "label": "negative"}, "relevance": 0.530881, "count": 1}, {"text": "Regulatory Information Service", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.530128, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.529442, "count": 3}, {"text": "option arrangement", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.529191, "count": 1}, {"text": "indemnity", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.527066, "count": 1}, {"text": "Indemnity", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.527066, "count": 1}, {"text": "party", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.525474, "count": 3}, {"text": "consultation", "sentiment": {"score": -0.531215, "label": "negative"}, "relevance": 0.525256, "count": 1}, {"text": "Agreements", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.525152, "count": 1}, {"text": "offer", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.523076, "count": 4}, {"text": "today", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522625, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.661784, "label": "positive"}, "relevance": 0.522503, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521869, "count": 1}, {"text": "Stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518331, "count": 1}, {"text": "Public disclosures", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.518149, "count": 1}, {"text": "arrangement", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.51799, "count": 1}, {"text": "Name of the party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517615, "count": 1}, {"text": "inducement", "sentiment": {"score": 0.790339, "label": "positive"}, "relevance": 0.517605, "count": 1}]}, "extracted_metadata": {"sha1": "76d401445fe334feb42f39b264213886abe78941", "filename": "1542626496069.zip-da107b28a2f9f2baafcb7e6ba55f57eb.xml", "file_type": "json"}, "external_links": ["http://otp.investis.com/clients/uk/shire/rns1/regulatory-story.aspx?cid=1027&newsid=1208284", "http://www.publicnow.com/view/8066CAB9F8B31ED05195F2AE23570DEC5F3E812F"], "title": "Shire : Form 8.5 (EPT/RI) - SHIRE PLC", "forum_title": "Markets : News - Marketscreener.com"}]}